The role of EphB6 and ephrinbs in blood pressure regulation by Wu, Zenghui
  
 
Université de Montréal 
 
 
THE ROLE OF EPHB6 AND EPHRINBS IN 
BLOOD PRESSURE REGULATION 
 
 
par 
Zenghui Wu 
 
 
Département de Sciences Biomédicales 
Faculté de Médecine 
 
 
 
Thèse présentée  à la faculté des études supérieures 
en vue de l’obtention du grade de 
Philosophiae Doctor (Ph.D.) 
en sciences biomédicales 
 
 
 
Décembre  2012 
 
 
 
© Zenghui wu, 2012  
  
 
Université de Montréal 
Faculté des études supérieures 
Cette thèse intitulée: 
<<THE ROLE OF EPHB6 AND EPHRINBS IN BLOOD PRESSURE REGULATION>> 
Présentée par: 
 
Zenghui Wu 
a été évaluée par un jury composé des personnes suivantes: 
Dr Edward Bradley 
……………………………… 
Président du jury 
 
Dr Jiangping Wu 
……………………………… 
Directeur de recherche 
 
Dr Hongyu Luo 
……………………………… 
Directeur de recherche 
 
Dr Jonathan Ledoux 
……………………………… 
Membre du jury  
 
Dr Serge Lemay 
……………………………… 
Examinateur externe 
 
Dr Marie-Josée Hébert 
……………………………… 
Repésentante de la doyenne  
 i 
Résumé 
L’hypertension artérielle est le facteur de risque le plus important dans les maladies 
cardiovasculaires (MCV) et les accidents vasculaires cérébraux (AVC). L’hypertension 
artérielle essentielle est une maladie complexe, multifactorielle et polygénique. Même si on a 
identifié de nombreux facteurs de risque de l’hypertension artérielle, on ne comprend pas encore 
clairement les mécanismes qui la régissent. 
Les kinases hépatocytes produisant l’érythropoïétine (Eph) constituent la plus grande famille 
des récepteurs tyrosine kinase qui se lient à des ligands de surface cellulaire appelés éphrines 
sur les cellules avoisinantes. On sait que les interactions de Eph et des éphrines sont essentielles 
aussi bien dans les processus de développement que dans le fonctionnement des organes et des 
tissus adultes. Cependant on n’a pas encore étudié la relation entre  Eph/éphrines et 
l’hypertension artérielle. 
Nous avons créé des modèles de souris knockout (K.O.) Ephb6-/-, Efnb1-/- et Efnb3-/- pour cette 
étude. Dans le modèle EphB6-/-, nous avons observé que les souris K.O. Ephb6 castrées, mais 
pas les femelles, ainsi que les souris mâles non castrées présentaient une tension artérielle élevée 
(TA) par rapport à leurs homologues de type sauvage (TS). Ceci suggère que Ephb6 doit agir 
de concert avec l’hormone sexuelle mâle pour réguler la TA. Les petites artères des mâles castrés 
Ephb6-/- présentaient une augmentation de la contractilité, une activation de RhoA et une 
phosphorylation constitutive de la chaîne légère de la myosine (CLM) lorsque comparées à 
celles de leurs homologues TS. Ces deux derniers résultats indiquent que la phosphorylation de 
CLM et de RhoA passe par la voie de signalisation de Ephb6 dans les cellules du muscle lisse 
de la paroi vasculaire (CMLV). Nous avons démontré que la réticulation de Efnbs mais non 
celle de Ephb6 aboutit à une réduction de la contractilité des CMLV. Ceci montre que l’effet de 
Ephb6 passe par la signalisation inversée à travers  Efnb. 
Dans le modèle Efnb1-/- conditionnel spécifique au muscle lisse, nous n’avons observé aucune 
différence entre Efnb1-/- et les souris de TS concernant la mesure de la TA dans des conditions 
normales. Cependant, la TA des souris K.O. Efnb1 lors d’un stress d’immobilisation est 
supérieure à celle des souris de TS. Dans les petites artères des souris K.O. Efnb1, le 
rétrécissement et la phosphorylation de CLM étaient élevés. In vitro, la contractilité et 
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l’activation RhoA de la CMLV des souris TS étaient augmentées quand leur Efnb1 était réticulé. 
Ces résultats corroborent ceux des souris KO Ephb6 et prouvent que l’effet de Ephb6 dans le 
contrôle de la TA se produit au moins par l’intermédiaire d’un de ses ligands Efnb1 dans les 
CMLV. 
Dans le modèle Efnb3-/-, on a observé une augmentation de la TA et du rétrécissement des 
vaisseaux chez les femelles Efnb3-/-, mais non chez les mâles; l’échographie a aussi révélé une 
résistance accrue au débit sanguin des souris K.O. femelles. Cependant la mutation de Efnb3 ne 
modifie pas la phosphorylation de la CLM ou l’activation de RhoA in vivo. Dans l’expérience 
in vitro, les CMLV des souris femelles Efnb3-/- ont présenté une augmentation de la contractilité 
mais pas celle des souris mâles Efnb3-/-. La réticulation des CMLV chez les mâles ou les 
femelles de TS avec solide anti-Efnb3 Ab peut réduire leur contractilité. 
Notre étude est la première à évaluer le rôle de Eph/éphrines dans la régulation de la TA. Elle 
montre que les signalisations Eph/éphrines sont impliquées dans le contrôle de la TA. La 
signalisation inverse est principalement responsable du phénotype élevé de la TA.  Bien que les 
Efnb1, Efnb3 appartiennent à la même famille, leur fonction et leur efficacité dans la régulation 
de la TA pourraient être différentes. La découverte de Eph/Efnb nous permet d’explorer plus 
avant les mécanismes qui gouvernent la TA. 
 
Mots-clés : Eph; Efnb; hypertension; cellule du muscle lisse vasculaire; tension artérielle 
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Abstract 
Hypertension is the most important risk factor for the cardiovascular diseases (CVD) and 
strokes. The essential hypertension is a complex, multifactorial and polygenic disease. Although 
many hypertension risk factors have been identified, the comprehensive understanding of 
mechanisms remains elusive. 
Erythropoietin-producing hepatocyte kinases (Ephs) are the largest family of receptor tyrosine 
kinases, which bind to cell surface ligands called ephrins on neighboring cells. Eph and ephrin 
interactions are known to be essential in developmental processes, as well as in functions of 
adult organs and tissues. However the relationship between Ephs/ephrins and hypertension has 
not been studied. 
Ephb6-/-, Efnb1-/- and Efnb3-/-knockout mice models were established for this study. In the 
EphB6-/- model, we observed that the castrated Ephb6 KO mice but not female or uncastrated 
male mice presented heightened blood pressure (BP) compared to the wild type (WT) 
counterparts. This suggests that Ephb6 needs to act in concert with sex hormone to regulate 
blood pressure. Small arteries from castrated Ephb6-/- males showed increased contractility, 
RhoA activation and constitutive myosin light chain (MLC) phosphorylation compared to their 
WT counterparts. The latter two findings indicate that RhoA and MLC phosphorylation are in 
the signaling pathway of Ephb6 in vascular smooth muscle cell (VSMC). We demonstrated that, 
crosslinking of Efnbs but not Ephb6 resulted in reduced VSMC contractility. This indicates that 
the effect of Ephb6 is via reverse signaling through Efnbs. 
In smooth muscle-specific conditional Efnb1-/- model, no difference was observed between 
Efnb1-/- and WT mice in BP measurement under a normal condition. However, the BP of Efnb1 
KO mice during immobilization stress were higher than that of WT mice. In the small arteries 
from Efnb1 KO mice, the constriction and MLC phosphorylation were elevated. In vitro, the 
contractility and RhoA activation of WT VSMC were augmented when their Efnb1 was 
crosslinked. These results corroborate the findings from Ephb6 KO mice, and prove that the 
effect of Ephb6 in BP control is at least via one of its ligand Efnb1 in VSMC. 
In the Efnb3-/- model the heightened BP and increased vessel constriction were observed in 
Efnb3-/-females but not males; the echography also revealed the increased blood flow resistance 
of female KO mice. However the mutation of Efnb3 doesn’t alter the MLC phosphorylation or 
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RhoA activation in vivo. In in vitro experiment, VSMCs from Efnb3-/- female mice showed 
increased contractility but did not Efnb3-/- male mice. Crosslinking of VSMCs from WT males 
or females with solid anti-Efnb3 Ab can reduce their contractility. 
Our study is the first to assess the role of Eph/ephrins in BP regulation. Eph/ephrins signalings 
are involved in the regulation of BP. The reverse signaling is mainly responsible for the elevated 
BP phenotype. Although the Efnb1, Efnb3 belongs to the same family, their function and 
effectiveness in the regulation of BP might be different. The discovery of Eph/Efnbs allows us 
to further explore the mechanism in BP. 
 
Keywords: Eph; Efnb; hypertension; vascular smooth muscle cell; blood pressure 
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I. INTRODUCTION  
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Part I 
Structure and function of Eph/ephrin family members 
Receptor tyrosine kinases (RTKs) are trans-membrane glycoproteins 1, 2, which are the key 
components of signaling pathways involved in cell proliferation3, differentiation, migration 
and metabolism 4, 5. The activation of RTKs is due to the binding of their cognate ligands, 
by which they transduce the extracellular signal to cytoplasm through auto-
phosphorylation process. The receptor tyrosine kinases are widely spread among different 
organs, and are involved in different kinds of cellular processes. More than 90 tyrosine 
kinase genes have been identified in human genome. 58 are cell surface receptors, which 
are divided into 20 subfamilies 6, 7.  
The Eph receptors are the largest family of receptor tyrosine kinases8, which are 
successfully isolated from the cDNA of erythropoietin-producing hepatocellular carcinoma 
cell line9. Since then, the Eph receptors have been identified in affecting the physiological 
and pathological processes in many cell types and organs10, such as axon guidance, 
angiogenesis, tissue border formation, cell adhesion and cell migration 11-14. As the Eph 
receptor-interacting proteins15, ephrins also involve in many aspects of cell survival, 
differentiation, proliferation, and migration16. 
The initial subdivision of Ephs into EphA and EphB classes was based on similarities in 
extracellular sequences8, and a corresponding binding preference to either the 
glycosylphosphatidylinositol anchored ephrin-A ligands or the three transmembrane 
ephrin-B ligands. Eph-ephrin interactions are promiscuous, but EphA members 
preferentially bind to ephrinAs, and EphBs bind to ephrinBs.  
There are 16 members of Eph receptors identified in mammals17. EphA1-EphA10 bind to 
5 ephrinAs; EphB1-EphB6 bind to 3 ephrinBs. As stated above, ten EphA (EphA1-A10) 
members promiscuously interact with 5 A-ephrins (EfnA1-A5) and six different EphBs 
(EphB1-B6) promiscuously interact with 3 B-ephrins (EfnbB1-B3). However, EphB2 can 
also bind to ephrinA5, and EphA4 binds to ephrinB2 18. 
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Figure 1 the family of Eph/ephrin proteins 
1.1 Structure and signaling mechanism of Eph/ephrins 
Like all RTKs, Eph receptors are type I trans-membrane protein. The functional domains 
can be divided into extracellular and intracellular region. The extracellular region contains 
ligand-binding globular domain of a highly conserved N-terminal sequence, which is both 
necessary and sufficient for ligand recognition and binding. The binding domain is 
followed by a cysteine-rich region and two fibronectin type III repeats19, which might be 
involved in receptor-receptor dimerization interactions or other proteins such as the NMDA 
receptors. 
The cytoplasmic part of Eph receptors can be divided into four functional units: the 
juxtamembrane domain containing two conserved tyrosine residues; a classical protein 
tyrosine kinase domain, a serile α-motif (SAM) and a PDZ-domain-binding motif. The 
resolved structure of SAM domain (around 70 amino acids) indicates that Eph receptor 
could form dimers and oligomers. The PDZ-binding motif is located in the carboxy-
terminal with 4-5 amino acid residues, which contains a consensus binding sequence that 
includes a hydrophobic residue (usually valine or isoleucine).  
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As ligands of Eph receptors, ephrins are membrane-anchored proteins or transmembrane 
proteins. EphrinAs have an extracellular Eph receptor-binding domain; and they directly 
attach to the cell surface without the intracellular tail. EphrinBs are transmembrane 
proteins. The extracellular Eph receptor-binding domain is located at its N-terminus, and 
about 3 amino-acid PDZ-binding motifs are at the carboxy terminus. 
 
Figure 2 structure of Eph/ephrin proteins 20 
As Ephs and ephrins are membrane proteins, they can only interact within short distance. 
Eph receptors are activated once they are bound by clustered ephrins on membrane between 
two neighboring cells, which express Ephs and ephrins respectively. 
The first step in the formation of an Eph/ephrin “signaling cluster” is the monovalent 
interaction between Eph and ephrin in juxtaposed cell surface, which occurs with 
nanomolar affinity21. The Eph/ephrin complexes can progressively aggregate into larger 
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clusters, the size of which depend on the densities of Eph receptors and ephrins on the cell 
surface21.  
The significant characteristics of Eph/ephrin signaling pathway is bi-directionality 22. The 
forward signals depend on Eph kinase activity in receptor-expressing cell, in which 
Eph/ephrin complex induces the initiation of Eph signaling through auto-phosphorylation, 
such as phosphorylation of juxtamembrane domain and downstream target proteins 23. The 
reverse signal depends on Src family kinases in eprhin-expressing cells 22.  
Several years of studies have revealed that Ephs/ephrins have many effects on different 
aspects of cell activities and broad roles in normal physiology and in pathogenesis: such as 
angiogenesis 24, the development of neurons 25, cardiovascular development 26, 27 and 
tumorigenesis 28 et al.  
1.2 Ephs/ephrins in nervous system  
In the literature, many papers show that Eph/ephrin signaling plays an essential role during 
the process of synapse formation and neuronal plasticity29. It is known that Ephs are 
expressed in developing and mature nervous system, with classic functions of mediating 
axon guidance and target recognition30. 
The roles of Eph receptors in spine morphogenesis have been widely studied. As small 
protrusions, the dendritic spines are located on the surface of dendrite, which receive the 
excitatory synapses and are responsible for synaptic transmission and long-term memory. 
N-methyl-D-aspartate (NMDA)-type glutamate receptors are essential for activity-
dependent synaptic plasticity31 and memory formation32.  
Eph forward signaling has effects on spine and synapse formation31. It is known that 
dynamic formation and retraction of spines is one of features underlying synaptic plasticity 
and possibly long-term memory 33. 
Eph receptors expressed on dendrites are activated by ephrins, which are expressed on 
axons or astrocytes and regulate spine and synapse formation. Eph/ephrin complex 
participates in activity-induced long-term changes in synaptic strength34.  
In hippocampus, several Ephs have been localized to dendrites and spines33, 34. The 
experiment of null mutant mice has clearly indicated a functionally redundant requirement 
of three EphB receptors in dendritic spine morphogenesis33. For example EphB2-deficient 
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mice show modestly reduced hippocampal long-term potentiation. In this model, EphB2 
receptors associate with NMDA receptors at synaptic sites and play a role in 
synaptogenesis. Eph/ephrin complex induces the clustering of NMDA receptors and 
promotes morphogenesis of dendritic spines; in the meantime forward signaling can 
stabilize clustering of NMDAR to further enhance NMDAR-dependent Ca2+ flux 35. 
Although normal hippocampus synapse morphology still exists, the deletion of EphB2 
drastically impairs long-lasting LTP and leads to extinguish LTD and depotentiation 33.  
EphB2 interacts with Syndecan-2 of trans-membrane heparin sulfate proteoglycan to 
induce mature spine morphology in mouse brain 36. EphB2 also plays an important role in 
the regulation of AMPAR, which mediates most fast excitatory synaptic transmission 37. 
Under the stimulation of ephrinB, the EphB2 co-clusters with Glu2 and Glu3 subunits of 
AMPAR, mediates the interaction between AMPAR binding protein and PKC-intracting 
protein 1 (PICK1) or GRIP1 through PDZ motif 38. 
As mentioned before, EphB2 controls AMPA-type glutamate receptor localization through 
PDZ binding domain interactions and triggers presynaptic differentiation via its ephrin 
binding domain. However, not all the EphBs exhibit equal effects during the spine and 
synapse formation. Triple null mutation of EphB1-3 leads to synapse number reduction; 
double mutants (EphB1/EphB2, EphB1/EphB3, EphB2/EphB3) show obvious defects in 
spine formation; however, the EphB1/EphB2 mutant leads severe defects than other 
mutants in spine formation 39. The re-expression of EphB2 is sufficient to rescue phenotype 
and support normal function of spine in EphB2-/- mice. 
In cultured hippocampal neurons, EphB receptors regulate spine morphology by 
modulating the activity of Rho family GTPases. This process involves the activation of 
focal adhesion kinase (FAK) 40, Src, Grb2 and paxillin, among which FAK is a non-
receptor tyrosine kinase that is widely expressed in different cells and is typically activated 
after assembly of integrin-mediated focal adhesions. Spine morphogenesis is shown to 
depend on signaling of kalinrin/Rac1 and intersectin/Cdc42/N-WASP to promote 
filamentous actin formation 41. EphA binds and activates ephexin, which is a member of 
Dbl family of exchange factors that activate RhoA and suppress Cdc42 42. In the 
meanwhile, the EphBs appear to be linked to GEFs, such as the kalinrin and intersectin, 
with exchange activity towards Rac1 and Cdc42 respectively. 
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EphrinBs are also essential in regulation of neuronal migration and plasticity in brain 
during the process of neuronal migration and proper functional maintenance. The secreted 
glycoprotein reelin (RELN) guides migration of neurons by binding to two lipoprotein 
receptors, the very-low density lipoprotein receptor (VLDLR) and apolipoprotein E 
receptor 2 (ApoER2). Loss of reelin function in humans results in a severe developmental 
disorder lissencephaly and other neurological disorders such as Alzheimer’s disease and 
schizophrenia43. Compound mouse mutants (Reln+/-/EphrinB3-/- , Reln+/- /EphrinB2-/-) and 
triple EphrinB1, B2, B3 knockout mice show neuronal migration defects. Clustering of 
ephrinBs recruit and phosphorylate Dab1, which is necessary for the activation of Reelin 
signaling 44. Therefore, the lack of EphrinBs in neurons causes interruption between Reelin 
and Dab1, leading to a reduced phosphorylation of Dab1 then neuronal migration defects. 
In humans, mutations in ephrinB1 lead to the craniofrontonasal syndrome (CFNS) by 
disturbing the crest/mesoderm boundary formation 45. CFNS is an X-linked developmental 
disorder that different gender shows the different phenotypes: females have frontonasal 
dysplasia and cornal craniosynostosis (fusion of the coronal sutures); in males, 
hypertenlorism is the only typical manifestation. PDZ-dependent reverse ephrinB1 
signaling is also critical for the formation of a major commissural axon tract and the corpus 
callosum46. The miR-124 of an abundant brain microRNA (miRNA) acts as a 
posttranscriptional effector to regulate ephrinB1 reverse signaling47 in development of 
neural tube48. 
Plasticity is essential for maintaining memory and learning. AMPA receptors, which are 
the main transducers of rapid excitatory transmission in the brain, are pivotal in this 
process. EphrinB2 signaling is critical for the stabilization of AMPA receptors on cellular 
membrane. The lack of ephrinB2 enhances internalization of AMPA receptors on cell 
membrane and reduces synaptic transmission 49.  
EphrinB3 regulates the morphogenesis of postsynaptic compartment by transducing the 
tyrosine phosphorylation/SH2-dependent and PDZ-dependent reverse signaling 50. It is 
reported that ephrinB3-/- mice exhibit peculiar hopping gaits, which are correlated to the 
loss of unilateral motor control. As a midline repulsive barrier, EphrinB3 prevents 
corticospinal tract axons from re-crossing once they enter the spinal gray matter51. 
EphrinB3 also induces axon pruning by binding the sytoplasmic SH2/SH3 adaptor protein 
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Grb4, which functions as a molecular bridge to connect activated tyrosine-phosphorylated 
intracellular domain of ephrinB3 with Dock180, Rac/Cdc 42, and PAK52. 
1.3 Ephs/ephrins in immune system 
Ephs and ephrins are widely expressed in lymphoid organs53-55 as well as lymphocytes 56. 
Study shows that Eph/Ephrin signaling is essential for thymus migration during the 
organogenesis and lymphocyte maturation 57, 58. Thymus organogenesis requires 
coordinated interactions of multiple cell types, such as neural crest (NC) cells, 
mesenchymal cells and thymic epithelial cells 59. EphB2-/-, EphB3-/-, EphB2-/-/EphB3-/- 
mice show significantly decreased thymic cellularity compared to WT mice 60  
The formation, separation, and subsequent migration are critical for the development of 
thymus59. EphrinB2 plays an important role in correct position of thymus on NC-derived 
cells. The conditional mutation of ephrinB2 in the NC-derived cell leads to abnormal 
anatomical location of thymus 57. However, deletion of ephrinB2 doesn’t disturb separation 
of thymus. EphA4 also influences the development of thymus through alternations of 
epithelial network development. The EphA4-/- mice show smaller thymuses compared to 
wild-type controls 54. 
The migration of lymphoid progenitors from fetal liver or bone marrow (BM) into thymic 
parenchyma is the first step of intrathymic T cell development, and following steps are 
essential for immature thymocytes, which develop their proper function through distinct 
thymic epithelial environment 61. EphB2 regulates the response of BM progenitors to 
extracellular matrix (ECM) ligand and chemokine. Deletion of EphB2 in BM progenitors 
exhibits a decreased migratory response to ECM ligands and chemokines (CXCL12, 
CXCL21, and CXCL25) 62. EphA1, EphA4 regulate the migration of CD4+ T lymphocyte 
and induce tyrosine phosphorylation of PYK2, which associates with Src family kinase 
members 63, 64.  
Binding of ephrinA1 and EphA receptors stimulates migration on CD4+and CD8+ T cell 65, 
66. However, ephrinA1 induced migration is mainly found in CD45RO+ memory subset 
cells 67. Stimulation of Eph receptors leads to migration involving activation of Lck, Pyk2, 
PI3K, Vav1 and Rho GTPase in CD8+ CCR7 T cells 67.  
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T cell receptor (TCR), located on the cell surface with a highly diverse repertoire of αβ 
chains, is responsible for recognizing antigens and bounding to major histocompatibility 
complex (MHC) molecules68. This recognition process is crucial for T cell differentiation 
and maturation 68. Studies have shown that Eph receptors modulate responses mediated by 
TCR 69. Under suboptimal condition, EphB6 cross-linked with EphB6 Ab leads to drastic 
T cell proliferation; EphB6+ T cell has stronger response to anti-CD3 and anti-CD28 
activation than EphB6- T cell. EphB6 is aggregated and co-localized with TCR to enhance 
the following response through the activation of p38 MAPK signaling pathway69, 70. 
EphrinB1 and ephrinB2 are involved in thymocyte development and peripheral T cell 
differentiation 71, 72. EphB3/EphB6 induced reverse signaling of ephrinB1/ephrinB2 
strongly suppresses Fas-induced apoptosis in Malignant T lymphocytes, in which the 
activation is associated with promotion of Akt activation and the inhibition of the Fas 
receptor-initiated caspase proteolytic cascade 73. EphrinB1/B2 also interacts with IL 7Rα 
to promote the IL7-indeuced internalization in T cell 74, 75. 
EphA receptors inhibit TCR-induced (anti-CD3) apoptosis of CD4+CD8+ thymocytes in 
culture and selection process in vivo 76. The immobilized EphB2-Fc and EfnB1-Fc fusion 
protein, at certain concentration can modulate anti-CD3 Ab induced apoptosis of 
CD4+CD8+ thymocytes 58. 
Eph/ephrin signaling is also involved in the regulation of B cell77. EphA4 and EphA7 are 
expressed on B cells 77. The activated human B lymphocytes express ephrinA4 78. 
EphrinB3 specifically binds to B lymphocytes in blood through the sulphated cell surface 
receptor 79, in which the binding of ephrinB3 and B cell induces migration of IgD- memory 
B cell subpopulation 79. 
1.4 Ephs/ephrins in bone homeostasis 
Bone homeostasis is strictly controlled by proper cellular communication between 
osteoclasts and osteoblasts 80, 81 and balance of bone formation and resorption 82, 83. The 
mutation of ephrinB1 in mice leads to severe defects, including the neural crest cell (NCC)-
derived tissues, incomplete body wall closure, and abnormal skeletal patterning and 
embryonic lethality 84. 
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The bone formation and resorption is regulated by the EphB4/ephrinB2 bidirectional 
signaling pathway85. The osteoclasts express ephrinB2 and osteoblasts express the EphB4 
respectively. Reverse signaling of ephrinB2 leads to the suppression of osteoclast 
differentiation by inhibiting the osteoclastogenic c-Fos-NFATc1 cascade, while the EphB4 
forward signaling stimulates osteogenic differentiation 86. Osteoclast precursors87 express 
EphA2/ephrinA2, which is induced by receptor activator of NF-κB ligand (RANKL) 88, 89. 
EphA2/ephrinA2 up-regulates RhoA in osteoclast precursors to suppress osteoblast 
differentiation89.  
1.5 Eph/ephrin signaling in cancer 
Numerous studies implicate the role of Eph/ephrin signaling in cancer progression and 
neovascularization such as cancer cell migration and invasion, in which Eph/ephrins were 
thought to play an oncogenic role 3, 90, 91. In recent years, the aberrant expression of Eph 
and ephrin genes has been identified in a wide range of human tumors 92 such as colorectal 
cancers (CRCs), lung cancer, myeloid cancer, breast carcinoma cells 93and prostate cancer 
et al 94.  
CRC is one of the most common cancers in the world. Strong relationship is observed 
between Ephs/ephrins and CRC. The mRNA level of EphA1 and EphA2 are highly 
elevated in CRC cell lines95 and down-regulated EphA1 expression in colorectal cancer is 
correlated with poor survival 96 indicating that down regulation of EphA1 correlates with 
invasion and metastasis in colorectal carcinomas 97. 
Human gastric cancer has strong relationship with expression level of EphA4. The 
overexpression of EphA4 are observed in 55 tumor specimen 98, which correlates with 
overexpression of FGFR1. Patients with EphA4-positive cancers have significantly lower 
survival rate than the patients with EphA4-negative cancers 98. 
EphA4/ephrinA signaling also regulates cancer cell proliferation in pancreatic ductal 
adenocarcinoma (PDAC) carcinogenesis and development. Suppressing expression of 
EphA4/ephrinA3 drastically attenuates PDAC cell viability. Conversely, overexpression 
of EphA4 increases growth rate in PDAC cells 99. 
EphB/ephrinBs have been reported to promote mesenchymal-epithelial transition (MET), 
which is a critical mechanism for acquisition of malignant phenotypes by epithelial cell100, 
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101. Interaction of EphB3/ephrinBs promotes MET through inactivation of CrkL-Rac1 
signaling pathway: Overexpression of EphB3 inactivates both CrkL and Rac1; the 
knockdown of EphB3 activates CrkL by decreasing its phosphorylation. In CRCs, the 
expression level of EphB3 is decreased. Overexpression of EphB3 results in tumor 
suppression in HT29 CRC cell line 102. 
However, opposite results are also observed in other cancer cell line, such as non-small-
cell lung cancer (NSCLC). In NSCLC cells, expression level of EphB3 is elevated 
comparing normal cells; the tyrosine phosphorylation of EphB3 is reduced; the migration 
is inhibited under the stimulation of ephrinB1-Fc/ephrinB2-Fc; the silencing of EphB3 
shows suppression of tumor growth and metastasis in vivo 73, 103. The possible signaling 
pathway is that the activation of EphB3 forms the protein complex of RACK1, PP2A and 
Akt to inhibit cell migration; Silencing of EphB3 disassociates complex of AKT and 
RACK1, leading to cell migration103. 
 
Figure 3 the signaling pathway of EphB3 /ephrinB1 in cell migration103 
EphB4/ephrinB2 signaling has been linked to breast cancer. The breast cancer cells grow 
faster in EphB4ΔC-EGFP mouse xenograft model, where EphB4 kinase dominant negative 
form is overexpressed in recipients 104. Through the reverse signaling way, ephrinB2 
increases blood content in tumor by enhancing the angiogenesis. EphB4 is expressed in 
human breast cancer; however its function is unclear. EphB4 induces migration of tumor 
cells and promotes tumor growth/survival. On the contrary, EphB4 also activates an 
antioncogenic Abl-Crk pathway in MDA-MB-435c breast cancer cells. EphB4 enhances 
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the phosphorylation of Crk on Tyr221 to inhibit breast cancer cell of viability, proliferation, 
motility, invasion and down-regulation of pro-invasive matrix metalloprotease (MMP-
2)105.  
In prostate cancer, ephrinB2 induces migration of Pc-3 prostate cancer cells and activates 
their Cdc42 by regulating the contact inhibition of locomotion (CIL), a process of stopping 
the continual locomotion of a cell in the same direction after collision with another cell 106. 
Through the Eph-Rho-ROCK pathway, Pc-3 prostate cancer cells switch from restrained 
state to invasive state107. 
EphA2/ephrinA1 interaction also promotes tumor growth and metastasis of breast cancer 
cells 108. In a tumor xenografts mouse model with the MDA-MB-435 human breast cancer 
cells or KS1767 human Kaposi’s sarcoma cells, EphA2 shows continuous tyrosine 
phosphorylation throughout tumor vasculature 109. EphB2 is also important for the growth, 
migration and invasiveness in colon cancer cell. As the target gene of Wnt signaling 
pathway, EphB2 is related to early stage of colorectal cancer110. 
1.6 Eph/ephrin in cardiovascular system  
1.6.1 Eph/ephrin in angiogenesis  
In vertebrate circulatory system, most of arteries and veins are formed in early stage of 
embryonic development 111. The remodeling and formation of vessels, through 
angiogenesis or the outgrowth of the new sprouts, perform complex cascade processes, in 
which Eph/ephrins are extensively involved 53, 112. 
Angiogenesis is a highly orchestrated process that plays an essential role in physiological 
and pathophysiological development. Through angiogenesis, the pre-existing vessels 
sprout new vessels to complete the vascular formation and remodeling. EphB4/ephrinB2 
is the first pair of genes which are found differentially expressed in arterial and venous 
endothelium113. According to the literature, EphB4/ephrinB2 plays an important role in 
embryonic vessel development and vascular remodeling 114. EphB4 marks venous 
endothelial cells and its ligand ephrinB2 marks arterial endothelial cells 115. Disruption of 
EphB4 or miss-expression of ephrinB2 results in intersomitic veins growing abnormally 
into the adjacent somatic tissue116.  
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Vascular endothelial growth factor (VEGF) signaling plays a crucial role in development 
and remodeling of blood vessels during embryogenesis117. VEGF is also involved in 
pathogenic angiogenesis, such as the recruitment and maintenance of tumor vasculature118. 
It is reported that VEGF can induce the expression of ephrinA1 in endothelial cells and 
subsequently activate EphA receptor signaling to promote angiogenesis through a 
juxtacrine mechanism. The soluble EphA2-Fc receptors inhibit VEGF-mediated 
endothelial cell survival, migration, sprouting, and assembly in vitro; however, it has no 
effect on FGF-induced angiogenesis 119.  
Vascular endothelial growth factor receptor (VEGFR), the ligand of VEGF, is a receptor 
tyrosine kinase and a key regulator in blood vessel growth and homeostasis117. It is 
produced by endothelial, hematopoietic, and stromal cells. The VEGFR can be classified 
as three main subtypes, VEGFR-1, -2, and -3 120.  
EphrinB2 regulates the internalization and signaling activity of VEGFR2. Through PDZ 
domain, ephrinB2 regulates VEGFR2 trafficking and controls endothelial tip-cell-
mediated vessel sprouting121. EphrinB2 also regulates internalization of VEGFR3 in 
cultured lymphatic endothelial cells 122. However, the mutation of ephrinB2 only affects 
VEGFR but shows no effect on other angiogenic regulator receptors such as fibroblast 
growth factor receptors 123. Normal development of lymphatic vasculature needs the 
ephrinB2, in which PDZ motif plays the essential role124, 125. EphrinB2 regulates the 
remodeling of lymphatic vasculature through the interaction of PDZ-binding motif and 
PDZ-RGS3 and Dvl2 124, 125. 
Slit/roundabout (Robo) proteins with three different members have emerged as key 
regulators of vascular remodeling and homeostasis126. The cooperation between Slit2 and 
ephrinA1 regulates a balance between angiogenesis and angiostasis. Slit2 stimulates 
angiogenesis through mRORC2-dependent activation of Akt and Rac GTPase. EphrinA1 
down-regulates the activation of Slit2 and inhibits angiogenesis 127. EphrinB2 induces 
migration of endothelial cells by induction of Akt phosphorylation through the 
phosphorylatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature 
128. The dominant negative form of EphA2 inhibits capillary tube-like formation in human 
umbilical vein endothelial cells 109. EphA2 also promotes tight junction formation and 
impairs angiogenesis in brain endothelial cells 129. 
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1.6.2 Eph/ephrins in VSMCs 
Eph/ephrin participates in the regulation of migration, spreading, contraction and 
attachment in VSMCs 130. EphrinA1 inhibits the activated Rac1 of Rac/PAK pathway to 
impair VSMC migration 131. EphrinB2 is involved in the spreading, migration 132 and 
attachment 133 of VSMC. During the blood-vessel-wall formation process, interaction of 
ephrinB2 and Crk-p130 (CAS) is required for directional migration and cell-matrix 
association in VSMC 53. Mice of ehprinB2 tissue-specific mutation in epithelium show 
vascular defects in skin, lung and gastrointestinal tract53.  
EphA4 increases the activated RhoA via Vsm-RhoGEF to regulate VSMC contractility134. 
The EphB6 activated reverse signaling pathway regulates VSMC contractility through 
RhoA-ROCK-MLCP signaling pathway135, 136. In EphB6 knockout mice model, EphB6 
knockout female and castrated male VSMCs show increased phosphorylated MLC and 
contractility135 and castrated male KO mice show elevated BP. 
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Part II 
Blood pressure regulation and hypertension 
Cardiovascular disease (CVD) is the lead cause of death worldwide, responsible for 30% 
of all death137. Increased blood pressure is the most-important risk factor for CVD. It is 
demonstrated that persistent hypertension is involved in stroke, ischemic heart diseases, 
kidney failure, and metabolic syndrome 138. 
Hypertension is a medical condition, in which the blood pressure is chronically elevated 
According to “Reports of the joint national committee on prevention, detection, evaluation 
and treatment”, the diagnosis of hypertension in adults will be made when the average of 
2 or more diastolic BP measurements on at least 2 subsequent visits is over 90mmHg or 
when the average of multiple systolic BP readings on 2 or more subsequent visits is 
consistently over 140mmHg. Isolated systolic hypertension is defined as systolic BP 
>140mmHg and diastolic BP<90mmHg 139, 15% to 30% of adult population as well as 
more than half of elderly population suffer from high blood pressure in most countries.  
Normally, hypertension can be classified into two categories: the secondary hypertension 
and essential hypertension139. The secondary hypertension indicates that the elevated BP is 
a result of other conditions, such as reno-vascular disease 140, renal failure, 
pheochromocytoma, aldosteronism, et al. On the contrary, essential hypertension, also 
called idiopathic hypertension, accounting for 95% of all cases of hypertension, indicates 
that no specific medical cause is responsible for the elevated BP. Until now, the etiological 
of essential hypertension is still unclear. Genetic variations, gene malfunction, and disease 
conditions may be involved in essential hypertension, such as obesity and insulin 
resistance. Certain physiological status and life styles also involve in essential 
hypertension, such as high alcohol intake, high salt uptake, aging and stress139. 
2.1 The physiology of vascular smooth muscle  
In vasculature, small arteries and arterioles are main contributors to blood flow resistance 
in circulation141.Small arteries are composed of three layers: tunica adventitia, tunica media 
and tunica intima. The outer and inner layers are composed of mainly connective tissues 
and endothelial cells respectively; tunica media is composed of smooth muscle cells 142. 
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Two opposite effects tightly control homeostasis of VSMC tone: generation of force 
(contraction) and release of force (relaxation) 143, in which circulating neurotransmitters, 
hormones, and endothelium-1derived factors are involved.  
Contraction and relaxation of smooth muscle cells are regulated by the phosphorylation 
and de-phosphorylation of myosin light chain (MLC20), which is controlled by myosin light 
chain kinase (MLCK) 144, 145 and myosin light chain phosphatase (MLCP) 146 separately. 
Upon stimulating of smooth muscle cell, Ca2+ is transiently elevated in the cytoplasm 
through extracellular fluid Ca2+ and intracellular stores. Ca2+ combines calmodulin to form 
the Ca2+/calmodulin complex, which binds and provokes MLCK to phosphorylate MLC20 
at Ser 19 and Thr18 147. The activation of myosin ATPase promotes interaction of actin 
and myosin then leading to muscle contraction. 
De-phosphorylated MLC20 is responsible for vessel relaxation, which is regulated by 
MLCP. MLCP is a heterotrimer, consisting of a catalytic subunit PP1cδ, a 20kDa subunit 
(M20) and Myosin-targeting subunit (MYPT1)
148, 149. MLCP dephosphorylates MLC20 and 
induces VSMC relaxation. 
2.2 Duality phenotypes of VSMC (contractile and synthetic phenotypes) 
Under physiological condition, VSMC keep the quiescent “contractile” phenotype state 
and maintain appropriate vessel tone150. However VSMC shifts “contractile” to “synthetic” 
phenotypes 151 in response to certain circumstances such as stretch, injury, atherosclerosis 
and inflammation, in which VSMC enhances migration, proliferation and secretion but 
suppresses contraction 151. VSMC of synthetic phenotype changes morphology from 
“spindle” to “rhomboid” shape (Figure 4) and decreases expression level of contractile 
marker proteins (Figure 5), such as α-smooth muscle actin, smooth muscle myosin heavy 
chain, smoothelin-A/B152. 
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Figure 4 the morphology of VSMC in different phenotypes152 
 
 
Figure 5 the expression level of contractile and synthetic protein marker152 
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2.3 The renin-angiotensin-aldosterone system (RAAS) 
The RAAS is essential in physiological and pathophysiological processes of cardiovascular 
system, and involved in the renal or non-renal complications of hypertension. 
Traditionally, RAAS plays the function of regulating renal sodium and water excretion 153, 
and body sodium-fluid balance154. With further understating of RAAS, its function is also 
recognized in endocrine systems and multiple hormonal systems, such as endocrine, 
paracrine and intracrine 155.  
2.4 Angiotensin II in RAAS  
Angiotensin II (Ang II), produced from the liver, is the active component of renin-
angiotensin system (RAS)156. Ang II is the key effector to maintain systemic blood pressure 
through various mechanisms in cardiovascular and renal systems157. In classic RAAS, 
circulating renal-derived renin cleaves hepatic-derived angiotensinogen to form the deca-
peptide angiotensin I (Ang I), which is converted by angiotensin-converting enzyme (ACE) 
to the Ang II. Besides the renin enzymetic pathway, Ang I and Ang II also can be produced 
through a nonrenin enzymetic pathway. For example the tonin and cathepsin convert 
angiotensinogen to Ang I then Trypsin, cathepsin and chymase convert Ang I to Ang II 158.  
As the cleavage product of Ang I, Ang II has potent effects on RAAS system. Ang II 
elevates blood pressure and retains salt and water in body. Ang II induces the secretion of 
aldosterone from zona glomerulosa of adrenal gland cortex. Ang II also stimulates 
vasoconstriction through AT1R-mediated activation of RhoA/Rho kinase-dependent 
myosin light chain (MLC) phosphorylation. 
There are two subtypes of Ang II receptors, AT1 and AT2
159. Both of them belong to the 
super-family of G-protein-coupled receptors (GPCRs). AT1 receptor is expressed 
ubiquitously and involved in most of the biological functions of Ang II, such as 
vasoconstriction, cardiac contractility, renal tubular sodium re-absorption, cell 
proliferation, vascular and cardiac hypertrophy, inflammatory responses, and oxidative 
stress160. In rodents, the AT1 can be classified into two isoforms, AT1a and AT1b. The AT1a 
is main activator of many signaling pathways in vascular smooth muscle cells. AT1R 
presents a basal activity in VSMC and may bind to GPCR kinases and β-arrestins. GPCR 
kinases can desensitize AT1R through a phosphorylation process. The AT1R-associated 
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protein (ATRAP) binds to AT1R and negatively regulates its signaling pathway. Inositol 
triphosphate (IP3) is the fast signaling factor in response to Ang II, leading to contraction 
of VSMCs 161, in which IP3 induces intracellular stores to release calcium and increases 
intracellular calcium concentration. AT1R is also involved in the inflammation process
162. 
AT1R activates the NADPH oxidase, which generates superoxide anions and activates NF-
κB in response to the induction of expression of pro-inflammatory molecules VCAM-1, 
MCP-1 and IL-6 163. 
AT2R promotes different signaling pathway and works opposite to that of AT1R 
164. AT2R 
is only highly expressed in fetal tissues164. Its expression dramatically decreases after birth 
and is restricted to a few organs mainly in cardiovascular system165. However, the AT2R is 
re-expressed in adult after cardiac and vascular injury. AT2R binds to AT2R-interacting 
protein-1 (ATIP1) to relax vascular smooth muscle cells through NO/cGMP signaling 
pathway 166.  
Pro-renin receptor (PRR) 167 can be classified into three different molecular forms: a full-
length integral TM protein (transmembrane), a soluble PRR, existing in plasma and urine, 
and a truncated form 168. The activation of PRR triggers the phosphorylation of mitogen-
activated protein kinases (MAPKs), the intracellular signaling of extracellular signal 
regulated kinase 1/2 (ERK1/2) 169, up-regulation of cyclo-oxygenase 2 (COX2) and the 
activation of p38 MAPK/hsp27 170. PRR also regulates the Wnt/β-catenin signaling 
pathway of cell proliferation, migration and polarity171. 
 
Figure 6 the Angiotensin system165 
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2.5 Aldosterone in RAAS 
Numerous studies have shown that aldosterone, a steroid hormone, is widely involved in 
physiological and pathological processes in blood pressure regulation 172.  
As downstream molecule of Ang II in RAAS, aldosterone is produced by the outer-section 
of adrenal cortex in adrenal gland in response to Ang II and affects renal distal tubules and 
collecting ducts of nephron173. Besides regulating salt homeostasis, aldosterone is now 
considered as a key factor of performing profibrotic and proinflammatory effects in 
cardiovascular diseases and metabolic diseases, such as hypertension, insulin resistance 
and dyslipidemia et al 174. Elevated level of aldosterone in patients with heart failure is 
related to a high risk of mortality175.  
The mineralocorticoid receptor (MR), receptor of aldosterone, has two ligands, aldosterone 
and cortisol 176. MR is widely expressed on extra-renal tissues such as cardiomyocytes 177, 
178, endothelial cells 179, 180 and VSMCs 181, 182. Through MR, aldosterone performs actions 
in renal distal convoluted tubules for fluid and electrolyte balance. The MR blockers 
(apironolactone and eplerenone) restrain action of aldosterone at the level of the receptor 
and effectively suppress blood pressure 173.  
2.5.1 Aldosterone and endothelial cells 
Endothelial cells are critical for vessel homeostasis 183. Aldosterone is broadly involved in 
physiological and pathophysiological process of endothelial cells. Aldosterone induces the 
early stage swelling and stiffness of endothelial cells by stimulating the epithelial sodium 
channel (ENAC) 184-186, ENAC decreases production of nitric oxide by down regulating 
endothelial nitric oxide synthase (eNOS) in endothelial cell 187, 188. Aldosterone also 
inhibits morphogenesis and angiogenesis of endothelial through down-regulating vascular 
endothelial growth factor receptor-2 (VEGFR-2) expression189.  
2.5.2 Aldosterone and vascular smooth muscle cells 
Aldosterone has been shown to induce vascular damage, proliferation 190. There are two 
ways to regulate VSMC by aldosterone. One is through MR, the other is through another 
proteins such as GPR30191. 
Aldosterone mediates VSMC apoptosis by activating intermediate signaling pathways 
including PI3 kinase, ERK, GPR30 191 and MR 192. Aldosterone influences migration and 
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proliferation of VSMCs through IGF-I signaling pathway, which enhances the VSMC 
proliferation under the stimulation of αVβ3 integrin 193, 194. Aldosterone modulates 12-/15-
lipoxygenase (LO) atherogenesis in VSMC. VSMCs, treated with aldosterone, show 
elevated hydroxyeicosatetraenoic acid level and mRNA expression of platelet type 12-LO. 
In rat VSMC, uniaxial cyclic stretch (CS) promotes aldosterone synthesis and cytochrome 
p450 aldosterone synthase (CYP11B2) through ERK1/2 phosphorylation signaling 195. 
2.6 Calcium in VSMCs 
Plenty of ion channels are expressed in the plasma membrane of VSMCs, which form the 
walls of resistance arteries and regulate vascular tone196. Four types of K+ channels 197, 198, 
Ca2+ channel199 and two Cl- channels200 are expressed on the membrane of VSMC. Ca2+ is 
the key factor to trigger VSMC contraction196, 201. Four Ca2+ channels are shown as follows: 
the voltage-gated Ca2+ channels, receptor-operated Ca2+, the store-operated Ca2+ channels 
(SOC) and the Ca2+ permeable nonselective cation channels 202. 
Voltage-gated Ca2+ channel is essential for influx of extracellular Ca2+ in vascular smooth 
muscles203. The channel is regulated by the membrane potential 204. Under physiological 
conditions, the channel is activated by depolarization and shut off by hyper polarization205. 
Voltage-gated Ca2+ channels can be classified into five different types, L-type, P-type, N-
type, R-type and T-type channels. Through two basic modes of low-activity and high-
activity of Ca2+ sparklets199, 206, 207, L-type Ca2+ channel primarily mediates Ca2+ influx in 
VSMC among five type channels 208. 
The store-operated Ca2+ channels, being ATP and bradykinin sensitive, are highly selective 
for calcium 209. Store-operated Ca2+ channels are activated when intracellular calcium 
stores are empty 210. Store-operated Ca2+ channels are involved not only in the cell 
contraction but also proliferation211 and apoptosis 212. In smooth muscle cells, IP3-mediated 
Ca2+ release induces the mitogen or growth factor depletion of the sarcoplasmic reticulum 
(SR) 213 and results in the subsequent activation of transient receptor potential (TRP) cation 
channels that triggers Ca2+ entry into the cell. Platelet-derived growth factor (PDGF), an 
indicator in the development of pulmonary hypertension, enhances the store-operated Ca2+ 
entry by up-regulating STIM1/Orai1 through activation of Akt/mTOR211. 
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2.7 NO and NOS in the cardiovascular system 
Nitric oxide (NO) is a gaseous molecule, which has broad functions in cardiovascular 
system214. NO works as a cofactor to interact with many molecules, such as NADPH, FMN, 
FAD, Calmodulin, Heme and tetrahydrobiopterin (BH4) to fulfill its functions. As a key 
signaling messenger, NO inhibits platelet aggregation and vascular smooth muscle 
proliferation to maintain vascular integrity. As an endothelium-derived relaxation factor, 
NO inhibits L-type Ca2+ channels and promotes Ca2+ re-uptake of SR to induce 
vasodilation in VSMC 215. 
NO is produced by nitric oxide synthase (NOS). There are three distinct isoforms of NOS: 
inducible NOS (NOS-II), neuronal NOS (NOS-I) and endothelial NOS (NOS-III). NOS-
III and NOS-I are constitutively produced by cardiomyocytes and NOS-II is induced under 
certain stress conditions216. Three isoforms are found in cardiac myocytes, VSMCs and 
vascular endothelial cells. Besides these three isoforms of NOS, there is a constitutively 
active NOS in mitochondria, which is the mtNOS 217, 218. 
One of the most important functions for NO is to activate the soluble guanylate cyclase 
(sGC) signaling pathway via a complex interplay between NO and sGC of heme /non-heme 
sites 219. sGC, a heterodimer with α and β subunits acts as the biosensor of NO and leads 
to the production of intracellular cyclic guanosine 3’, 5’-monophosphate (cGMP), which 
is a ubiquitous intracellular secondary messenger, mediating VSMC proliferation, 
differentiation, cell growth, apoptosis, cellular mobility and contractility 220. In vasculature, 
NO up-regulates cGMP production, activates NO-dependent relaxation of vascular smooth 
muscles and leads to vasodilation 221. As a neurotransmitter in the autonomic nervous 
system, NO plays a role in the gastrointestinal tract, urinary tract, and mediates the smooth 
muscle relaxation of these tissues by increasing cGMP production. 
NO can also be a modulator of oxidative stress in cells 222, where the NO interacts with 
superoxide (O2
-) to form peroxynitrite (ONOO-). Large amounts of NO can directly inhibit 
mitochondrial complexes I, IV and activate poly-ADP-ribose polymerase (PARP) 223, lead 
to the depletion of cellular energy stores. 
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2.8 G proteins in the regulation of VSMCs 
Guanine nucleotide regulatory proteins (G proteins) are a family of guanosine triphosphate 
(GTP)-binding proteins that play a key regulatory role as transducers in a variety of signal 
transduction systems. G proteins are heterotrimetric proteins, composed of three distinct 
subunits: α, β, γ 224. 
Different sets of G proteins couple with their receptors to regulate the vasoconstriction 
through the phosphorylation of MLC via Ca2+/MLCK- or Rho/ROCK-mediated signaling 
pathways. A typical example is regulation of VSMCs through Gq-G11 and G12-G13
225, 226. 
Gq/11 plays the role of maintaining basal tone in VSMC. Gq family induces the activation 
of β isoforms of phospholipase C (PLC) and forms inositol-1, 4, 5-trisphosphate, which 
leads to MLC20 phosphorylation through elevated Ca
2+ concentration and complex of Ca2+ 
and calmodulin in the cytosol227. As one of RhoA-specific GEFs, P63RhoGEF selectively 
couples Gq/11to activation of RhoA in blood vessel to regulate Ca
2+ sensitization 228. 
The injection of G12/13-expressing plasmids induces VSMC contraction within 3 hours, in 
which the signaling pathway might go through the Rho/ROCK pathway 226. In salt-induced 
hypertension mice, G12/13 activates RhoA/ROCK signaling pathway through Leukemia-
associated Rho guanine nucleotide exchange factor (LARG) to regulate VSMC 
contractility 225. 
2.9 The Rho/ROCK signaling pathway in VSMCs 
Rho and Rac are two members of the Ras-related superfamily of small GTPases, which 
have diverse functions in eukaryotic cells, such as assembly of actin cytoskeleton 229, cell 
polarity and cell migration 230. GTPases are molecule switchers controlling complex 
cellular processes 231, 232. There is a cycle of Rho/Rac between two conformational states: 
they bind to GTP, they are in active state; they hydrolyze GTP to GDP and bind to it, they 
are in inactive state. The guanine nucleotide exchanger factors (GEFs) can switch GDP-
bound Rho/Rac from inactive state to active GTP-bound state. The guanosine nucleotide 
dissociation inhibitors (GDI) work as inhibitors to maintain small GTPases in off-state and 
GTPase activating proteins (GAP) enhance GTP hydrolysis 233. 
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Figure 7 the signaling pathway of Rho family 233 
Rho GTPases control signaling transduction pathways that link cell surface receptors to a 
variety of intracellular processes. There are evidences showing that Rho/Rho kinase 
signaling plays important physiological and pathological roles in cardiovascular system234, 
235. The Rho family proteins are classified into five subfamilies: Rho, Cdc42, Rac, Rnd and 
RhoBTB subfamilies 236. More than 20 genes encoding Rho-like small GTPase proteins 
with a GTPase domain have been found in human229. 
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Figure 8 the distribution of Rho family 229 
In VSMC, Rho not only directly interacts with MLC kinase which phosphorylates the 
regulatory MLC, but inhibits MLC phosphatase as well 237. Cdc42, Rac1 and RhoA are the 
most studied family members of Rho GTPase. They are well known as regulators of actin 
cytoskeleton, cell contractility, cell polarity, gene expression, microtubule dynamics and 
vesicular trafficking 238, 239. It is reported that recombinant RhoA increases Ca2+ sensitivity 
in permeable through the activation of ROCK, which inhibits MLCP and extends 
phosphorylation of MLC20 
240 . 
As specific ROCK inhibitor, Y-27632, can consistently suppresses the function of p160 
ROCK, resulting in reduced Ca2+ sensitization in smooth muscle cells. It can thus reduce 
blood pressure in rat hypertensive model, in which p160 ROCK plays the role in formation 
of stress fibers in smooth muscle cell 235. 
2.10 Hormones in the cardiovascular system 
Catecholamines, produced by the medulla of the adrenal glands and postganglionic fibers 
of sympathetic nervous system are molecules, which include adrenaline, dopamine and 
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noradrenaline. Studies have shown that catecholamine bind to plasma proteins in 
bloodstream in response to stress 241. The different sympathetic reactivity is associated with 
elevated cardiovascular responses and plasma catecholamine 242. Increased catecholamine 
levels contribute to the elevated blood pressure in TRPM4-deficient and Ephb6-deficient 
mice 135, 243. 
Endogenous estrogens are important blood pressure regulation molecules 244; however the 
mechanism is still unclear245. Normally estrogens are thought as a vasodilator to reduce 
vascular tone in various arteries 246, 247. Estrogens act via three different estrogen receptors 
(ERs) affecting both gene transcription and the rapid signaling pathways in a complex 
interplay. ERs can be classified into estrogen receptor α (ER α) 248, the estrogen receptor β 
(ERβ) and the GPR30.  
ERs are ligand-activated transcription factors. Once binding to the estrogen, ERs change 
the conformation of their protein structure, which triggers their dissociation from 90-kDa 
heat shock protein to allow dimerization of receptors. The dimerized receptors then interact 
with estrogen response element (ERE), a specific regulatory DNA sequence present in the 
promoter region of target genes. As the transcriptional regulators, ERα and ERβ mediate 
vasodilation 249. Through ERβ, the estrogen rescues severe pulmonary hypertension in a 
rat model 250; on the other hand, ERβ-deficient mice show sustained systolic and diastolic 
hypertension 244. Estrogen also interacts with G protein on cell membrane. 17β-estradiol 
has been shown to modulate the process of vasodilation through the phosphatidylinositol 
3-kinase-Akt pathway 251.  
The G protein-coupled estrogen receptor 1 (GEPR), a cell membrane protein formally 
named GPR30, is widely expressed in the brain, heart, bone and vasculature 252. Several 
studies shown GPR30 is related to the expression of Bcl-2 253, cAMP generation 254, 
calcium mobilization 255 and PI3k activation 256. In kidney, GPR30 is highly expressed in 
renal tubules and renal epithelial cells 257. In Gper-/- mouse model, the male Gper-/- mice 
show the left ventricular dilatation and an elevation of diastolic pressure258, 259. 
Testosterone, the main male sex steroid hormone, has been implicated in cardiovascular 
risks, such as increased arterial BP, left ventricular hypertrophy and myocardial 
infarction260, 261.  
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Testosterone regulates vascular remodeling by inducing VSMC migration through 
NADPH Oxidaseand c-Src pathways, in which testosterone promotes NADPH Oxidase 
expression and c-Src activation 262. However testosterone also promotes vessel relaxation 
by activating NO production in endothelial cells 263 as well as suppressing of vascular 
smooth muscle L type voltage-gated Ca2+ channels 264. In diabete rat model, testosterone 
showes the suppression of activated RhoA and mRNA level of ROCK1265. 
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Conclusion and remarks 
Our group pioneered the research on the biological functions of Eph/ephrins. Previous 
Eph/Efn studies are focused on the function in systems such as the central nervous system, 
immune system and cancer development. We investigated its roles in VSMC function and 
blood pressure regulation and the signaling pathways involved, by employing several Eph 
and ephrin gene knockout mouse models. Our results revealed the pivotal function of Eph 
and ephrin in blood pressure regulation. Details of our investigation are provided in the 
following 3 articles. 
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Summary: in this paper we showed the elevated blood pressure in Ephb6-/-mice. The 
phosphorylation of MLC was also increased in knockout mice. The level of catecholamine 
was changed before and after castration in knockout mice. It was revealed that the Ephb6 
forward signaling and sex hormones were involving in the regulation of blood pressure and 
the function of vascular smooth muscle cells. 
 
Dr Hongyu Luo and Zenghui Wu performed the experiments and analyzed the data except 
the blood pressure measurement and vessel constriction. Dr Hongyu Luo made the EphB6 
KO mice, in collaboration with Mark Cameron, she conducted microarray analysis which 
identified EphB6-regulated gene with a function in BP control. She also performed 
aldosterone level check in sera; Drs. Johanne Tremblay, Junzheng Peng and Julie Lavoie 
measured the blood pressure in vivo and analyzed the data; Dr Eric Thorin did the 
experiments of vessel constriction in vitro. Dr. Shijie Qi performed castration and 
ovariectomy and took care of animal husbandry. Drs. Stoyanova and Cloutier performed 
ultrasonic analysis of the cardiovascular system. Dr. Hu conducted histological analysis. 
Dr. Tao Wu initiated the VSMC culture protocol. Dr Jiangping Wu and Dr Hongyu Luo 
directed the experimental design and data analysis.  
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Abstract 
Background: Eph kinases constitute the largest receptor tyrosine kinase family and there is 
no knowledge about their function in blood pressure regulation. Results: Ephb6 regulates 
vascular smooth muscle cell contraction and its knockout resulted in increased blood 
pressure in castrated male mice. Conclusion: Ephb6 and its ligands can regulate vessel tone 
and blood pressure. Significance: We have identified a new group of molecules capable of 
regulating blood pressure. Eph kinases constitute the largest receptor tyrosine kinase 
family, and their ligands, ephrins (Efns), are also cell surface molecules. Our study is the 
first to assess the role of Ephb6 in blood pressure (BP) regulation. We observed that EphB6 
and all 3 of their Efnb ligands were expressed on vascular smooth muscle cells (VSMC) in 
mice. We discovered that small arteries from castrated Ephb6 gene knockout (KO) males 
showed increased contractility, RhoA activation and constitutive myosin light chain 
phosphorylation ex vivo compared to their wild type (WT) counterparts. Consistent with 
this finding, castrated Ephb6 KO mice presented heightened BP compared to castrated WT 
controls. In vitro experiments in VSMC revealed that crosslinking Efnbs but not Ephb6 
resulted in reduced VSMC contractions, suggesting that reverse signaling through Efnbs 
was responsible for the observed BP phenotype. The reverse singaling was mediated by an 
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adaptor protein Grip1. Additional experiments demonstrated decreased 24-h urine 
catecholamines in male Ephb6 KO mice, probably as a compensatory feedback mechanism 
to keep their BP in the normal range. After castration, however, such compensation was 
abolished in Ephb6 KO mice and was likely the reason why BP increased overtly in these 
animals. It suggests that Ephb6 has a target in the nervous/endocrine system in addition to 
VSMC, regulating a testosterone-dependent catecholamine compensatory mechanism. Our 
study discloses that Ephs and Efns, in concert with testosterone, play a critical role in 
regulating small artery contractility and BP. 
Primary hypertension represents a high blood pressure (BP) condition that is not induced 
by other diseases. About 90 to 95% of hypertension cases fall into this category. As a result 
of numerous studies, some risk genes contributing to primary hypertension have been 
identified, such as genes related to the renin-angiotensin-aldosterone system1, the 
sympatho-adrenal system2, endothelial hormones3,4 and sex steroids5-7, to name a few. 
However, the etiology of primary hypertension remains incompletely understood.  
Ephs, the largest family of receptor tyrosine kinases, comprise about 25% of known 
receptor tyrosine kinases8. The ligands of Ephs, ephrins (Efns), are also cell surface 
molecules8 and can transduce signals into cells9 in a phenomenon called reverse signaling. 
Interactions among Ephs and Efns are promiscuous. One Eph can interface with multiple 
Efns and vice versa. In general, EphA members interact preferentially with EfnA members, 
and EphB members with EfnB members10-12. Such interactions suggest that these 
molecules are so vital to biological systems that heavy redundancy is obligatory. 
Various Eph and Efn members are expressed in various tissues and organs. They are 
important not only in embryonic development but also in physiological and 
pathophysiological conditions in adults. Most reported functions of Ephs occur in the 
central nervous system10,11. They are essential in the development of neuronal connections, 
circuit plasticity and repair. Some Ephs and Efns, expressed in endothelial cells, are vital 
in angiogenesis during normal embryonic development as well as in tumorigenesis12,13. 
This and other studies have reported that Ephs and Efns, particularly their B family 
members, as well as some A family members, are expressed in thymocytes and T cells; 
they are capable of modulating T-cell responses and survival14. It has been shown that 
Ephs/Efns are involved in intestinal epithelium self-renewal15, urorectal development16, 
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pancreatic α-cell insulin secretion17, bone development, maintenance and repair18, 19, 
regulation of red blood cell production in response to hypoxia20, clotting21, glomerular 
filtration22 and ionic homeostasis of vestibular endolymph fluid in the inner ear23.  
Efnb2 and Efna1 are expressed in vascular smooth muscle cells (VSMC)24-27. Conditional 
knockout (KO) of Efnb2 in pericytes and VSMC with a platelet-derived growth factor 
receptor β promoter leads to perinatal lethality24. VSMC with Efnb2 deletion manifest 
compromised migration24. Ogita et al. showed that in long-term cultures of rat and human 
VSMC, Efna1 triggered Epha4 signaling and actin stress fiber assembly28, but whether 
such signaling elicited changes in VSMC contractility was not investigated. Therefore, Eph 
and Efn function in VSMC contractility and BP regulation has not been studied to date.  
Our earlier DNA microarray analysis of Ephb6 KO mouse thymocytes indicated that the 
expression of some genes regulating BP seems to be altered. Based on this clue, we 
hypothesized that Ephb6 KO mice might have abnormal BP. This hypothesis was the focus 
of our study. 
Materials and Methods 
EphB6 KO mice 
EphB6 KO mice were generated in our laboratory, as described previously29. They have 
been backcrossed to the C57BL/6 background for more than 10 generations. Age- and 
gender-matched wild type (WT) littermates or C57BL/6 mice were used as controls and 
are referred to as WT mice.  
We also generated transgenic (Tg) mice with human β-actin promoter-driven expression 
of a truncated Ephb6 (aa 1-667), whose intracellular domain was deleted, with a plasmid 
construct pAC-Ephb6∆, as illustrated in Supplemental Fig. 1. The Tg mice were 
backcrossed to the C57BL/6 background for 10 generations and then crossed with Ephb6 
KO. The resulting mice, called Ephb6∆/KO mice, expressed tailless Ephb6 on the cell 
surface. Again, age- and gender-matched WT littermates or C57BL/6 mice were used as 
controls and are referred to as WT mice.  
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
Ephn6, Efnb1, Efnb2, Efnb3, Dishevelled, PDZ-RGS3 and Grip1 mRNA levels were 
measured by RT-qPCR. Total RNA from VSMC or mesenteric artery endothelial cells was 
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extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) and then reverse-transcribed with 
Superscript II™ reverse-transcriptase (Invitrogen). The primers utilized in RT-qPCR and 
the fragment sizes amplified are listed in Supplemental Table I.  PCR conditions for the 
reactions were as follows: 2 min at 50oC, 2 min at 95oC, followed by 20-25 cycles of 10 s 
at 94oC, 20 s at 58oC and 20 s at 72oC. β-actin mRNA levels served as internal controls, 
and the data were expressed as signal ratios of test gene mRNA/β-actin mRNA. 
VSMC isolation 
Mouse VSMCs were isolated, as described by Golovina and Blaustein30, with 
modifications. The aorta and mesenteric arteries, including their secondary branches, were 
digested with collagenase type II (347 U/ml) (Worthington Biochemical Corporation, 
Lakewood, NJ, USA). These vessels were washed twice, and the adventitia and 
endothelium were removed with fine forceps and sterile cotton-tipped applicators. They 
were further digested with both collagenase type II (347 U/ml) and elastase type IV (6 
U/ml) (Sigma-Aldrich Corporation, St. Louis, MO, USA). The dissociated cells were 
cultured at 37oC in Dulbecco’s modified Eagle’s medium (Wisent, St-Bruno, Quebec, 
Canada) supplemented with 15% fetal bovine serum for 4 to 5 days before experimentation. 
In the studies of sex hormones, VSMC were cultured in 15% stripped fetal bovine serum 
(serum reacted with active charcoal for 24 h to remove bovine sex hormones).  
Immunofluorescence microscopy 
VSMC cultured for 4-5 days were fixed with paraformaldehyde (4%) for 15 min. The cells 
were blocked with 10% goat immunoglobulin G (IgG) in phosphate-buffered saline for 20 
min and then incubated with various first antibodies (Abs, 2 µg/ml): goat anti-mouse 
Efnb1, Efnb1, Efnb3 and Ephb6 Abs (R&D Systems, Minneapolis, MN, USA). The cells 
were reacted overnight at 4 oC with rhodamine-conjugated donkey anti-goat Ab (0.15 
µg/ml, Jackson ImmunoResearch Laboratories, West Grove, PA, USA). For intracellular 
α-actin staining, the cells were permeabilized with permeabilization buffer (BD 
Biosciences, San Jose, CA, USA) for 20 min at 4oC, and then incubated with mouse anti-
human α-actin monoclonal antibodies (mAbs, 2 µg/ml, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) followed by FITC-conjugated goat anti-mouse IgG (0.2 µg/ml, Bethyl 
Laboratories, Montgomery, TX, USA). The stained cells were examined under a Zeiss 
microscope. 
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Ex vivo vessel constriction 
Vessel constriction was studied ex vivo as described previously31. Mesenteric artery 
segments (2 mm in length) of third-order branches (exterior diameter 125 to 150 µm) were 
stripped off endothelium and mounted on 20-µm tungsten wires in small vessel myographs, 
stretched to optimal tension and maintained in physiological saline solution (PSS: NaCl, 
130 mM; KCl, 4.7 mM; KH2PO4, 1.18 mM; MgSO4, 1.17 mM; NaHCO3, 1.17 mM; CaCl2, 
1.6 mM; EDTA, 0.023 mM; glucose, 10 mM; aerated with 12% O2/5% CO2/83% N2; pH 
7.4) at 37°C. After a 40-min stabilization period, arterial segments were challenged with 
40-mM KCl PSS (KCl was substituted for an equivalent concentration of NaCl). Single 
cumulative concentration-response curves to the α1-adrenergic receptor agonist 
phenylephrine (PE, 1 nM to 100 µM, Sigma, St. Louis, MO, USA) were charted. At the 
end of the protocol, maximal tension (Emax) was determined by changing the PSS to a 
solution containing 127 mM KCl. The data are expressed as percentages of Emax. 
Student’s t tests were performed to compare concentration-response curves.  
Immunoblotting of myosin light chain (MLC) phosphorylation 
The aorta and mesenteric arteries of WT and KO mice were isolated, washed twice with 
Ca++-free Hank’s buffered salt solution (HBSS) buffer, and then frozen in liquid nitrogen 
until they were used. The vessels were homogenized for 1 min at room temperature in 0.4 
ml radio-immunoprecipitation assay buffer, which contained Pho-stop and Protease 
Inhibitor Cocktail (Roche Applied Science, Laval, QC, Canada). The samples were spun 
at 12,000 rpm for 15 min at 4oC, and the supernatants were collected. Twenty micrograms 
of proteins per sample were resolved in 12% SDS-PAGE. Proteins from the gel were 
transferred to PVDF membranes (Invitrogen), which were incubated in blocking buffer 
containing 5% (w/v) skimmed milk (for MLC, 5% BSA was used in the blocking buffer) 
for 1 h at room temperature, and then hybridized overnight at 4oC with mouse anti-mouse 
phospho-MLC mAb or rabbit anti-mouse total MLC Ab (both from Cell Signaling 
Technology, Danvers, MA, USA). The Abs were used at the manufacturer’s recommended 
dilutions or at 1:1,000. The membranes were washed 3 times and reacted with 
corresponding second Abs, i.e., horseradish peroxidise-conjugated sheep anti-mouse IgG 
Ab (GE Healthcare, Baie D’Urfe, Quebec, Canada), or horseradish peroxidise-conjugated 
rabbit anti-goat IgG Ab (R&D Systems), for 90 min. The signals were detected with 
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SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, 
USA).  
BP measurements by radiotelemetry 
The mice were anesthetized with isoflurane and implanted surgically with TA11PA-C10 
radiotelemetry sensors (Data Sciences International, St. Paul, MN, USA) in the left carotid 
artery for direct measurement of arterial pressure (AP) and heart rate (HR), as described 
previously32. Seven days were allowed for recovery before measurement. For castrated 
mice, the measurement was conducted 21 days after surgery. In some experiments, male 
mice were castrated one week after transmitter implantation; three weeks after the 
castration, mice were administered with estrogen (240mg) daily subcutaneously for 7 day. 
Their BP and HR were measured by telemetry during the last 3 days of estrogen 
administration.  
Arterial pressure and HR in conscious, free-moving mice were then recorded continuously 
for 3 days with the Dataquest acquisition 3.1 system (Data Sciences International). 
Individual 10-s waveforms of systolic pressure (SP), diastolic pressure (DP), mean arterial 
pressure (MAP) and HR were sampled every 2 min throughout the monitoring period. The 
raw data were processed with the Dataquest A.R.T-Analysis program32 and presented as 
means ± SE. Statistically significant differences between the experimental groups were 
evaluated by unpaired t test and repeated-measures ANOVA with Statview. P<0.05 values 
were considered to be statistically significant. 
Measurement of VSMC contractility 
Cultured primary VSMC were washed once with HBSS and cultured in the same solution. 
They were placed under a Zeiss microscope with environmental controls (37oC and 5% 
CO2).  The cells were stimulated with PE (20 µM), unless otherwise indicated, and 
photographed continuously for 15 min at a rate of 1 picture per min. Fifteen or more cells 
were selected randomly, and their length was measured at each time point with Zeiss 
Axiovision software. Percentage contraction was calculated as follows: 
% contraction = (cell length at time 0 – cell length at time X) / cell length at time 0.  
Student’s t test was performed to assess statistically significant differences. 
Small interfering RNA (siRNA) transfection 
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siRNAs of Disheveled, PDZ-RGS3 and Grip1 as well as negative control siRNAs were 
synthesized by Integrated DNA Technologies (Coralville, IA, USA), and their sequences 
shown in Supplemental Table II. VSMC were cultured for 4 to 5 days, with the last 16 h 
being free of antibiotics, and then transfected with a mix of 3 pairs of siRNAs of a particular 
gene (each pair at a final concentration of 10 nM), with FuGENE HD X-tremeGENE 
siRNA Transfection Reagent (Roche Applied Science). The transfected VSMC were 
further cultured for 24 to 36 h, and their contractility was measured upon PE 218 stimulation.  
Activated RhoA assay 
GTP-associated activated RhoA levels in mesenteric artery smooth muscles were 
determined by G-LISA RhoA Activation Assay Biochem Kit (Cytoskeleton Inc. Denver, 
CO, USA) according to manufacturer’s instructions.  
Results 
Expression of Ephb6 and its ligands in VSMC 
The mRNA expression of Ephb6 as well as 3 of its major ligands, Efnb1, 2 and 3, in VSMC 
was detectable by RT-qPCR (Fig. 1A). We assessed these 4 molecules in VSMC at the 
protein level by immunofluorescence (Fig. 1B). The expression of Ephb6 and its ligands 
in these cells suggests that Ephb6 might regulate VSMC function. 
Ephb6Δ/KO mice expressed tailless Ephb6 (Ephb6 Δ) on the cell surface. Fig. 1C 
demonstrates the lack of Ephb6 expression in Ephb6 KO VSMC and re-expression of cell 
surface Ephb6 in Ephb6 Δ /KO VSMC.  
Ephb6 null mutation alters blood vessel contraction   
BP is controlled by cardiac output, vessel resistance and blood volume. We did not observe 
any difference in cardiac output between KO and WT mice according to echocardiography 
(data not included). We then examined small artery contractility, a major factor 
contributing to BP in terms of peripheral blood flow resistance. Ex vivo contractility of the 
mesenteric arteries from KO and WT mice was assessed after stimulation with PE. Male 
KO vessels showed lower contractility than male WT vessels (Fig. 2A), while female KO 
vessels presented higher contractility than WT vessels after PE stimulation (Fig. 2B). This 
raised the possibility that Ephb6 might work in concert with sex hormone to regulate 
vasoconstriction. To test whether such is the case, we castrated male Ephb6 KO mice. 
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Indeed, vessels from castrated KO males manifested increased contractility compared to 
castrated WT males (Figs. 2C and 2D). It is to be noted that these observed contractility 
phenotypes remained unchanged in the presence or absence of endothelium (Figs. 2A-2D), 
indicating that the nitric oxide production by the endothelium is not involved in the altered 
contractility in the absence of Ephb6 and male sex hormone.  
Consistent with the contractility results, at the molecular level, freshly isolated mesenteric 
arteries without endothelium from female KO and castrated male KO, but not male KO 
mice presented a constitutive increase of MLC phosphorylation (Fig. 2E), reflecting the 
increased sensitivity of VSMC to vasoconstrictive stimuli.  
As activated RhoA could increase MLC phosphorylation via the RhoA-associated 
kinase/myosin phosphatase pathway33, we assessed the levels of GTP-bound RhoA in 
mesenteric artery smooth muscles. As shown in Fig. 2F, 5 seconds after the activation by 
PE, endotheliumless mesenteric arteries from castrated and female but not uncastrated male 
KO mice had significantly elevated activated RhoA levels, compared to their counterpart 
WT mice. The RhoA activity in KO mice was increased almost 15 folds after castration, 
much more than that of WT males after castration. Such elevation was compatible with the 
augmented MLC phosphorylation and constriction in female and castrated KO vessels.  
Castrated KO mice show increased BP 
We wondered whether heightened vasoconstriction in female and castrated KO mice led 
to elevated BP. The BP of Ephb6 KO and WT mice was measured by radiotelemetry. SP, 
DP, MAP and HR of male and female KO mice presented no significant differences from 
their respective WT controls (Supplemental Fig. 2). However, 3 weeks after castration, KO 
mice manifested increased SP, DP and MAP compared to castrated WT mice, while both 
groups maintained similar HR (Fig. 3A).  
Was the lack of BP elevation in female KO mice due to that estrogens lowered the BP? To 
answer this question, we administered estrogen for 7 days to the castrated KO and WT 
mice. As shown in Fig. 3B, BP of castrated KO did not come down after estrogen 
administration and remained higher compared to the castrated WT males treated with 
estrogen, indicating that the lack of BP elevation in female KO mice was not due to a 
suppressive effect of estrogen.  
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We next tested whether these in vivo findings could be reproduced in a defined in vitro 
culture system. For this purpose, female KO VSMC were cultured in medium containing 
15% strip serum, in which the bovine sex hormones had been removed by active charcoal 
adsorption. In this system, the female KO VSMC contractility in the absence of 
testosterone was significantly higher than that female KO VSMC in the presence of 
testosterone, while testosterone did not affect the contractility of WT female VSMC (Fig. 
3C). On the other hand, an addition of estrogen to the cultured male KO or WT VSMC did 
not alter their contractility (Fig. 3D). The results indicate that Ephb6 and testosterone need 
to be removed simultaneously to elevate VSMC contractility. These in vitro results are 
compatible with the ex vivo vessel contraction and in vivo BP phenotype of castrated KO 
mice, and demonstrate that Ephb6 and testosterone are necessary to maintain normal 
VSMC contractility and BP, both of which will increase only when Ephb6 and testosterone 
are simultaneously missing. 
BP-related hormone levels in Ephb6 KO mice 
We questioned whether some key hormones involved in BP regulation were affected 
directly by or as a compensatory consequence to Ephb6 null mutation. As depicted in 
Supplemental Figs. 3A and 3B, plasma angiotensin II (AngII) and serum aldosterone levels 
in male, female and castrated KO mice were comparable to those in their WT counterparts. 
Twenty-four-h urine catecholamines (i.e., adrenaline, noradrenaline and dopamine) were 
similar in KO females and WT females during fasting (Fig. 4, second column). However, 
24-h urine catecholamines under this condition were significantly lower in KO males than 
in WT males (Fig. 4, first column). After KO males were castrated, their 24-h urine 
catecholamines rose to levels comparable to those in castrated WT mice (Fig. 4, last 
column). This suggests that in male KO mice, there is a compensative reduction of ambient 
catecholamines and such compensation is abolished after castration. 
Ephb6 modulates BP and VSMC contractility through Efnb reverse signaling 
Ephb6 and its major ligands, Efnb1, Efnb2 and Efnb3, are capable of bidirectional 
signaling, i.e., Ephb6 can be stimulated by its ligands and transmit signals into cells, and 
Efnbs can also be stimulated by Ephb6, transmitting signals into cells. We investigated 
which signaling direction was responsible for the effect of Ephb6 in BP control. This was 
first done in primary VSMC culture.  
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Mouse VSMC from the mesenteric arteries and aorta after 4 to 5 days of culture were 
stimulated by PE. About 80% of these cells responded dose-dependently to PE stimulation 
(Figs. 5A and 5B), indicating that they were still mainly of the contractile phenotype at that 
time. We monitored the speed of VSMC contraction in terms of percentages of their 
original length at different time points after PE stimulation. This parameter reflects the 
force of VSMC contraction, which dislodges adherent VSMC from the plastic well surface. 
WT VSMC, whether from males, females or castrated males, were cultured in wells coated 
with goat anti-mouse Ephb6 Ab, so that they would receive forward signaling due to Ephb6 
crosslinking by solid-phase anti-Ephb6 Ab on the wells. The contraction response of these 
VSMC to PE was similar to that of cells cultured in wells coated with control normal goat 
IgG (Fig. 5C), indicating that the forward signaling received by these cells via Ephb6 did 
not have any effect on their contractility. Then, these WT cells were cultured in wells 
coated with Ephb6-Fc (the Fc of recombinant protein is of human origin), which would 
crosslink Efnbs on VSMC and trigger reverse signaling through Efnbs (either single or 
multiple Efnbs, i.e., Efnb1, Efnb2 and/or Efnb3). The contractility of all these VSMC types 
(from WT males, females and castrated males) after PE stimulation was significantly 
decreased relative to those cultured in wells coated with control normal human IgG (Fig. 
5D). The results reveal that reverse signaling from Ephb6 to Efnb(s) downregulates VSMC 
contractility. Possible reasons for the similarly reduced contractility of VSMC from males, 
females and castrated males will be discussed later. The decrease in VSMC contraction in 
Ephb6-Fc-coated wells was not due to Ephb6-Fc’s mechanical binding to Efnbs expressed 
on VSMC, because similarly coated anti-EphB6 Ab did not have any influence on VSMC 
(Fig. 5C), which express Ephb6 on their surface.  
To confirm our in vitro findings in vivo, we measured the BP of male or castrated male 
Ephb6 Δ KO mice, which express Tg tailless Ephb6 in the Ephb6 KO background. Male 
and castrated male Ephb6 Δ KO mice showed no BP increase compared to their WT 
counterparts (Supplemental Figs. 4A and 4B), indicating that the missing intracellular 
Ephb6 tail, which is needed for forward signaling from ligands to Ephb6, is not important 
for its function in BP regulation. In other words, this result suggests that the observed BP 
control phenotype of Ephb6 is the consequence of a lack of reverse signaling from Ephb6 
to Efnbs. 
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Identification of Grip1 as a component of the Efnb reverse signaling pathway related to 
VSMC contraction 
Efnbs have no enzymatic activity, but use adaptor proteins to link Efnb intracellular tails 
to various signaling pathways. To identify molecules in the Efnb reverse signaling pathway 
that regulate VSMC contractility, siRNAs were deployed to knock down the expression of 
Grip1, Disheveled and PDZ-RGS3 that are known to associate with Efnbs34-36. The 
effectiveness of mRNA knockdown was verified by RT-qPCR (Fig. 6A). The solid-phase 
EphB6-Fc-induced hyporesponsiveness of WT VSMC to PE stimulation could be partially 
negated by Grip1 siRNA, but not by Disheveled or PDZ-RGS3 siRNA (Fig. 6B). These 
data indicate that Grip1 is involved in the Ephb6 reverse signaling that dampens VSMC 
contractility.  
Discussion 
This study identified a previously unknown function of Eph and Efn in vasoconstriction 
and BP regulation. We demonstrated that 1) Ephb6 triggered reverse signaling via Efnbs, 
leading to hyporesponsiveness of VSMC, 2) Ephb6, in coordination with testosterone, 
controlled ambient catecholamine secretion, and 3) the absence of both Ephb6 and 
testosterone overtly increased BP. 
A few words are warranted to reconcile the differences in results on VSMC contraction, 
small artery contraction and in vivo BP measurements. Increased vessel contraction (Fig. 
2C), accompanied by augmented constitutive MLC phosphorylation and BP (Figs. 2D and 
3), was observed consistently in castrated Ephb6 KO mice compared to castrated WT mice. 
On the other hand, some of the data related to VSMC contractility, small artery contraction 
and BP were at odds with each other. For example, VSMC, regardless of whether they 
were from males, females or castrated males, were susceptible to Ephb6-Fc-triggered 
reverse signaling, culminating in reduced contractility. However, in intact small artery 
contraction studies, only small arteries from KO females and castrated KO males but not 
males presented increased contraction. Moreover, although female KO arteries 
demonstrated enhanced contractility, female KO mice showed no overt BP elevation. 
Possible explanations are as follows.  
In small arteries, VSMC are in close contact with each other, whereas under cell culture 
conditions, this contact is limited since cells are not confluent. In our experiments, cells 
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were used at about 20% confluence (see Fig. 5A), as it was difficult to conduct contraction 
studies if they were connected to each other. In any case, even at full confluence, VSMC 
were still not packed as tightly as they would be in vessels. Consequently, WT VSMC in 
culture lack sufficient Ephb6 stimulation from neighboring cells, and individual cells exist 
in a state close to Ephb6 KO cells. The lack of sufficient Ephb6 stimulation in cultured 
VSMC was evident from the fact that when cultured WT VSMC from males, females and 
castrated males were exposed to solid-phase Ephb6-Fc, which gave sufficient stimulation 
to Efnbs in VSMC, their response to PE was drastically reduced (Fig. 5D). This suggests 
that the fundamental effect of reverse signaling through Efnbs in VSMC is a diminished 
response to vasoconstrictive stimuli. A lack of such reverse signaling translates into ex 
vivo increased small artery contractility, and augmented constitutive MLC phosphorylation 
at the molecular level, as well as increased RhoA activity in female and castrated KO mice. 
Why then did KO females not show elevated BP? BP is a tightly-controlled physiological 
parameter with many compensatory feedback mechanisms. In KO males, reduced ambient 
catecholamine release seems to be one such mechanism to balance the defect caused by 
Ephb6 deletion. Only when this compensation is also affected by castration, is BP overtly 
elevated. Indeed, we have discovered that Ephb6 is highly expressed in the adrenal 
medulla, the major source of ambient catecholamines (Supplemental Fig. 5). In females, it 
is possible that there is a different in vivo compensatory mechanism irrelevant to 
catecholamines. As a consequence, female KO mice still maintained normal BP. 
A more interesting question is why male VSMC receiving Efnb reverse signaling 
manifested reduced contractility, but this phenotype was not reflected in intact vessels from 
male KO mice. In fact, mesenteric arteries from male Ephb6 KO even showed lower 
contractility than those from WT males (Fig. 2A), and they presented no constitutive 
increase of MLC phosphorylation (Fig. 2D) or increased RhoA activity (Fig. 2F), unlike 
the small arteries from females and castrated male KO mice. One possible explanation is 
that under the influence of testosterone, a compensatory mechanism in VSMC at the 
vascular level (in addition to the systemic change in ambient catecholamine secretion) 
overreaches its goal, resulting in dampened contractility. This overcompensation is not 
operational without testosterone, so vessels from females and castrated males showed 
increased but not decreased contractility. Examples of such overcompensation do exist in 
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biological systems. For example, when ILK – a major signaling molecule in the integrin 
signaling pathway that controls hepatocyte differentiation – is null mutated in the liver, 
overexpression of multiple integrin chains and enzymes involved in the synthesis of 
collagens has a net result of putting ILK null-mutated hepatocytes in an overcompensated 
state37. In our case, such overcompensation only occurs in intact vessels and not in isolated 
VSMC, because in the latter, low cell density limits cell-cell contact, and most cells, 
regardless of whether they are KO or WT, are all in a de facto near-KO phenotype. 
We attempted to elucidate the mechanism by which Ephb6 null mutation affects 
vasoconstriction and BP. We noted that neither Ephb6 null mutation nor castration affects 
the expression of Efnb1, Efnb2, Efnb3 and type 1a α-adrenoreceptor in VSMC at the 
protein level (Supplemental Figure 6A) or altered Efnb1, Efnb2, Efnb3, Ephb6, and Grip1 
expression at the mRNA level (Supplemental Fig. 6B). Since endothelial cells are in close 
contact with VSMC, their Efn and Eph expression might influence the contractility of 
VSMC. We confirmed that neither Ephb6 deletion nor castration altered the expression of 
Efnb1, Efnb2 and Efnb3 expression in the mesenteric artery endothelial cells 
(Supplemental Fig. 6C). We further demonstrated that cultured VSMC in the presence or 
absence of testosterone or estrogen expressed similar levels of Efnb1, Efnb2, Efnb2 and 
Grip1 (Supplemental Figs. 6D and 6E). These data show that the mechanisms of Ephb6 in 
influence VSMC contraction and BP are not via modulating the expression of their ligands 
or Grip1.  
We also examined the histology of small arteries of WT versus KO mice, and uncastrated 
versus castrated KO mice, but no obvious difference was observed (data not shown).  
Our additional mechanistic studies established that reverse signaling from Ephb6 to Efnbs, 
but not forward signaling transduced by Ephb6 intracellular domains, was responsible for 
the observed phenotype, according to in vivo BP measurements in Ephb6Δ/KO mice and 
in vitro VSMC contraction with solid-phase Ephb6-Fc. This conclusion on the critical role 
of Efnb reverse signaling in BP regulation is corroborated by our finding that Efnb1 smooth 
muscle-specific conditional KO mice presented similar although not identical, abnormal 
BP regulation, like Ephb6 KO mice (to be reported elsewhere). 
EphB6 null mutation and Efnb reverse signaling did not modulate Ca++ flux (Supplemental 
Figure 7). Thus, parameters upstream of Ca++ flux regulating VSMC contractility seem to 
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be normal. We discovered that constitutive VSMC MLC phosphorylation, a critical event 
controlling VSMC responsiveness to Ca++ influx, was increased in female KO mice and 
castrated male KO mice. Therefore, although there was no change in Ca++ flux, these 
VSMC became more responsive to Ca++ due to their increased MLC phosphorylation, and 
this translated into increased vessel constriction upon PE stimulation.  
Although Efnbs only have short intracytoplasmic tails with no enzymatic activity, there are 
5 conserved tyrosine phosphorylation sites in the tails in addition to a PDZ-binding motif 
at the C-terminal. The former can dock SH2 domain-containing proteins, such as Tiam137 
and Disheveled33, and the latter, PDZ domain-containing signaling proteins, such as Grip34 
and PDZ-RGS335. We discovered that knocking down Grip1 but not Disheveled or PDZ-
RGS3 expression in VSMC by siRNAs partially reversed the hyporesponsiveness induced 
by solid-phase Ephb6-Fc. Therefore, Grip1 is located in the Efnb reverse signaling pathway 
that leads to the reduced response of VSMC. We also discovered that RhoA activation in 
the form of GTP-associated RhoA was augmented in the mesenteric artery smooth muscles 
of KO females and castrated KO males but not unmanipulated KO males within 5 seconds 
after PE activation, compared to their WT counterparts. Activated RhoA can activate 
RhoA-associated kinase, which phosphorylates myosin phosphatase. The phosphorylation 
of the phosphatase will reduce its activity, which will then prolong the phosphorylation of 
MLC33. This might be a mechanism to increase the responsiveness of MLC to Ca++ flux in 
the VSMC of castrated and female KO small arteries. How the reverse signaling through 
Efnb in VSMC leads to a reduction of RhoA activity is not clear, and we can only speculate 
at this point. Grip1 contains 7 PDZ domains38. It is possible that multiple PDZ domains in 
Grip1 can bridge Efnbs and modulators of RhoA activity, such as GDP dissociation 
inhibitors (GDI) or GDP exchange factors (GEF), and influence the function of these 
modulators, which will in turn regulate RhoA activity. Indeed, Grip1 can associate with a 
Rho-GDI39 and a Ras-GEF40 through its PDZ domains. Validation of such hypotheses is in 
progress. 
Based on our observations described above, we propose the following unified scheme 
regarding the newly discovered functions of Ephb6 and Efnbs in BP regulation. Under 
physiological conditions, Ephb6 on neighboring cells provides VSMC with a negative 
signal to dampen their contractility. Since interactions between Ephb6 and Efnbs are 
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constant, such a dampening effect is not regulated rapidly and likely controls constitutive 
vascular tone rather than fast responses to neuroendocrine stimulation. The dampening 
signal is transmitted reversely through Efnbs into VSMC via an Efnb-associating protein, 
Grip1. Through a so-far unknown signaling pathway which leads to the activation of RhoA, 
the reverse signaling modulates constitutive MLC phosphorylation, which is increased in 
the absence of reverse signaling and results in enhanced contraction responses to Ca++ flux 
in VSMC. Although Efnb reverse signaling can alter VSMC contractility at the cellular 
level regardless of gender or castration, such modulation is not always reflected in BP due 
to various in vivo compensatory mechanisms. In male KO mice, one of these mechanisms 
is a negative feedback loop that decreases ambient catecholamine secretion by the 
nervous/endocrine system. This loop depends on both Ephb6 and testosterone. When both 
are absent, the loop is no longer functional, and catecholamine secretion is no longer 
reduced. In combination with heightened VSMC responsiveness, it leads to overtly 
increased BP. Conceivably, defects in Ephb6 and Efnb interactions or in the Efnb reverse 
signaling pathway, in combination with declining testosterone levels in a subpopulation of 
aging males, might result in elevated BP. 
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FIGURES AND LEGENDS 
Figure 1 Expression of Ephb6 and Efnbs in mouse VSMC 
.  
All experiments were repeated at least twice, and data from a representative experiment 
are reported. 
A. Ephb6, Efnb1, Efnb2 and Efnb3 mRNA expression in mouse VSMC. Ephb6, Efnb1, 
Efnb2 and Efnb3 mRNA expression in VSMC from mesenteric arteries and aorta was 
measured by RT-qPCR with β-actin mRNA as internal control. Means ± SD of Ephb6 or 
Efnb signal/ β -actin signal ratios are shown. 
B. Ephb6 and Efnb expression on VSMC according to immunofluorescence. WT VSMC 
cultured for 4-5 days were stained with FITC-goat anti-α-actin (in pseudo-green color) Ab 
and goat anti-mouse-Ephb6, Efnb1, Efnb2 and Efnb3 Abs, followed by PE-donkey anti-
goat IgG (in pseudo-red color). Cells stained with control isotypic first Ab control (normal 
goat IgG, last column) showed no specific signal.  
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C. VSMC from Ephb6∆/KO mice re-expressed cell surface Ephb6. VSMC from WT (first 
and last columns), Ephb6/KO and Ephb6 KO mice were stained with anti-Ephb6 Ab (first 
3 columns) or isotypic control Ab (last column) and anti-α-actin Ab, as indicated, and 2-
color micrographs are presented. 
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Figure 2 Contractility MLC phosphorylation and RhoA activation of mesenteric arteries 
from Ephb6 KO and WT mice. 
 
A-D: Contractility of mesenteric arteries from EphB6 KO and WT mice following PE 
stimulation.  
Segments (2 mm) of the third-order branch of the mesenteric artery with endothelium or 
with endothelium removed were stimulated with PE. A single cumulative concentration-
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response curve to PE 223 was obtained. The maximal tension (Emax) was determined by 
challenging the vessels with a physiological saline containing 127 mM KCl. Vessel 
contractility is expressed as percentage of the Emax. Data from three mice per group were 
pooled and mean + SE are shown. *: p<0.01 (paired Student’s t test). A: vessel contractility 
of males; B: vessel contractility of females; C: vessel contractility with endothelium of 
castrated males; D: vessel contractility without endothelium of castrated males. 
E. Constitutive MLC phosphorylation in Ephb6 KO arteries.  
Proteins from freshly-isolated mesenteric arteries and aortas of male, castrated male (Male-
Cast) and female WT and Ephb6 KO mice were analyzed for total and phosphorylated 
MLC by immunoblotting. The experiments were repeated 3 times, and data from 
representative immunoblotting are shown. The means ± SD of signal ratios of 
phosphorylated versus total MLC of 3 independent experiments were determined by 
densitometry and illustrated in the bar graph in the lower panel.  
F. Activated RhoA levels in PE-stimulated smooth muscles of mesenteric arteries. 
Mesenteric arteries were isolated from WT and KO mice and the epithelium of the vessels 
was removed. The vessels were subjected to PE stimulation (20 μM) for 5 sec at room 
temperature and then quickly frozen in liquid nitrogen. The vessels were then homogenized 
and the activated RhoA (GTP associated RhoA) levels were determined in duplicate by the 
G-LISA RhoA Activation Assay Biochem Kit. Results of two independent experiments 
were pooled and Means + SD are illustrated. Data were analyzed by paired student t tests, 
and p values are indicated. 
 81 
Figure 3 the effect of sex hormones on BP and VSMC contraction of castrated Ephb6 KO 
mice. 
 
A. Increased BP in castrated Ephb6 KO mice. 
Mice were implanted with telemetry transmitters, and then castrated. After 3 weeks, BP 
and HR were measured for 3 consecutive days.  
B. Administration of estrogen to the castrated Ephb6 KO mice did not lower BP. Male 
mice were castrated one week after transmitter implantation; three weeks after the 
castration, mice were administered with estrogen (240 µg) daily s.c. for 7 days. Their BP 
and HR were measured by telemetry during the last 3 days of estrogen administration. For 
A and B, mouse numbers per group are shown. Values are expressed as means ± SE 24-h 
BP and HR for each day ± SE. SP: systolic pressure; DP: diastolic pressure; MAP: mean 
arterial pressure; HR: heart rate. Data were analyzed by repeated ANOVA, and the p values 
are shown. 
C. Female KO VSMC showed higher contraction in the absence of exogenous testosterone. 
VSMC from WT and KO female mice were cultured in 15% stripped FCS for 4 days in the 
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presence of 10 μg/ml testosterone or vehicle. The cells were then stimulated with 20 μM 
PE.  
D. Estrogen did not affect VSMC contraction in the absence of Ephb6. 
VSMC from WT and KO male mice were cultured in 15% stripped FCS for 4 days in the 
presence of 10 μg/ml estrogen or vehicle. The cells were then stimulated with 20 μM PE. 
For C and D, each point represents the mean + SE of percentage contraction of 10 or more 
cells. All experiments were repeated at least twice, and data from a representative 
experiment are shown. *: significant differences compared to controls (p<0.05; paired 
Student’s t test). 
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Figure 4 Twenty-four-h urine catecholamine levels in Ephb6 KO mice. 
 
Male, female and castrated Ephb6 KO and WT mice were placed in metabolic cages. Urine 
was collected during a 24-h fasting period. Urine catecholamines were measured by 
ELISA, and means + SD of hormones excreted during the 24-h period and mouse number 
per groups (n) are presented.  
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Figure 5 Reverse but not forward signaling between Ephb6 and Efnbs dampens VSMC 
contractility. 
 
 
Data presentation and statistical analysis are the same as described in Fig. 4C and 4D. 
A. Micrographs of VSMC contraction after PE stimulation. VSMC were stimulated with 
20 μM PE and imaged every min. Images at 0, 5, 10 and 15 min are presented. Four arrows 
point to the same 4 cells during the 15-min imaging period, and show their contraction. 
The photos also reveal that about 85% of the cells are capable of contraction, indicating 
the purity of VSMC in such cell preparations.  
B. Dose-dependent response of VSMC contractility to PE stimulation.WT VSMC was 
stimulated with PE at different concentrations for 15 min at 37 degree.  
C. Solid-phase anti-Ephb6 Ab had no effect on VSMC contractility. 
Wells were coated with goat-anti-Ephb6 Ab or normal goat IgG (2 μg/ml during coating). 
VSMC from WT male (left panel), WT female (middle panel) or castrated WT male (right 
panel) mice were cultured in these wells for 4 days and then stimulated with 20 μM PE.  
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D. Solid-phase Ephb6-Fc reduced VSMC contractility. Wells were coated with 
recombinant Ephb6-Fc or normal human IgG (2 μg/ml during coating). VSMC from WT 
male (left panel), WT female (middle panel) or castrated WT mice (right panel) were 
cultured in these wells for 4-5 days and then stimulated with 20 μM PE.  
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Figure 6 Grip1 in the Efnb reverse signaling pathway in VSMC 
 
Experiments in this figure were repeated more than twice, and representative data are 
shown. 
A. Effective mRNA knockdown of Disheveled, PDZ-RGS3 and Grip1 by siRNAs. 
Cultured WT VSMC were transfected with a mixture of siRNAs of a particular gene or 
control siRNAs, as indicated. After additional 24-h culture, the cells were harvested and 
the mRNA expression of each gene was determined by RT-qPCR. The data are expressed 
as means + SD of the ratios of the target gene signal versus the β-actin signal. 
B. Grip1 knockdown by siRNAs partially reversed the inhibitory effect of solid-phase 
Ephb6-Fc.  
VSMC from WT males were cultured in wells coated with Ephb6-Fc (2 μg/ml for coating). 
After 2 days, the cells were transfected with siRNAs targeting Disheveled, PDZ-RGS3 or 
Grip1, or with control siRNA. On day 4 of culture, they were stimulated with PE (20 μM) 
and their percentage contraction was registered. Means ± SD of the percentage are shown. 
The thin line (indicated as Normal Contraction) represents the mean percentage contraction 
of VSMC cultured in wells coated with normal human IgG (2 μg/ml) without siRNA 
transfection (for a better visual effect, the SD of each time point in this control is omitted). 
 87 
*: p< 0.05 according to paired Student’s t test, between Grip1 siRNA- and control siRNA-
transfected VSMC. 
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SUPPLEMENTAL INFORMATION 
Supplemental methods 
Measurement of Ca++ flux 
VMSC were incubated in DMEM containing 2% FBS and 5 µM Fura-2-AM for 30 min. 
The cells were washed in medium warmed for 15 to 20 min to remove extracellular dye. 
They were re-cultured in HBSS with Ca++ (1.26 mM) and placed under a Zeiss microscope 
with environmental controls (37oC and 5% CO2). The cells were stimulated with PE (20 
µM) and were imaged for 5 min at a rate of 6 pictures per min. Excitation wavelengths 
were switched between 340 nm and 380 nm with illumination time of 180 ms, and emission 
wavelength was 510 nm. Signals from more than 15 randomly-selected cells were recorded 
and the results expressed as ratios of fluorescent intensity at 510 nm excited by 340 nm 
versus 380 nm. 
Quantitative immunofluorescemce microscopy for Efnb1, Efnb2, Enb3, type 1a  
adrenoreceptor and angiotensin II receptor Ia 
VSMC were cultured in 24-well plates with cover glass placed at the bottom of the wells. 
After four to five days, the cells were washed twice with PBS and fixed with 
paraformaldehyde (4%) for 15 minutes. For cell surface Ag staining, cells were blocked 
with 10% goat IgG in PBS for 20 minutes and then incubated with various first Abs (2 
µg/ml): goat anti-mouse EFNB1 Ab (R&D System, Minneapolis, MN, USA); goat anti-
mouse EFNB2 Ab (R&D Systems); goat anti-mouse EFNB3 Ab (R&D Systems); rabbit 
anti-mouse type 1a adrenoreceptor (1a -AR) Ab, (Abcam Inc., Cambridge, MA, USA); 
and rabbit anti-mouse AngII receptor Ia (ATR1a) Ab (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) overnight at 4 oC.  
Cells were then reacted with corresponding second Abs (i.e., rhodamine-conjugated 
donkey anti-goat Ab, 0.15 µg/ml, (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA); and FITC-conjugated sheep anti-rabbit IgG, 0.2 µg/ml, (Chemicon 
International, Billerica, MA, USA) for overnight at 4 oC. The stained cells were examined 
under a Zeiss microscope. The total fluorescent intensity of a cell and cell size were 
measured using software AxionVision (Zeiss) and the results are presented as arbitrary 
fluorescent intensity per unit cell area.  
In situ hybridization (ISH) 
 89 
A 1,700-bp  fragment of EphB6 cDNA (positions 859 to 2,559) in the pGEM-3Z vector 
was used to generate sense and antisense riboprobes with SP6 and T7 RNA polymerase for 
both 35S-UTP and 35S-CTP incorporation. Tissues were frozen in -35C isopentane and 
kept at -80C until cut.  ISH was performed on 10-m cryostat sections. ISH microscopy 
was undertaken by photographic emulsion followed by 8-day exposure.  
 90 
Supplemental tables 
Supplemental Table I. Sequ1ences of primers for RT-qPCR. 
 
Supplemental Table II siRNA sequences of Dishevelled, PDZ-RGS3, Grip1 and controls
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Legends to supplemental figures 
Supplemental Figure1 Plasmid construct used to generate β-actin promoter-driven 
Ephb6Ephb6 without its intracellular domain) Tg mice. 
 
 
Ephb6g mice were generated by linearized ClaI/ClaI fragment from plasmid pAC-
Ephb6. The fragment contained the human -actin promoter followed by the Ephb6 
coding sequence with the intracellular domain truncated, and the poly A sequence of -
actin.  
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Supplemental Figure2 BP and HR of male and female Ephb6 KO mice. 
 
BP and HR were measured for 3 days by radiotelemetry, starting at least 7 days after 
transmitter implantation. Mouse numbers per group are shown. Values are expressed as 
mean 24-h BP and HR for each day ± SE. SP: systolic pressure; DP: diastolic pressure; 
MAP: mean arterial pressure; HR: heart rate. Data were analyzed by repeated ANOVA, 
and the p values are reported. A: males; B: females.  
 93 
Supplemental Figure3 Plasma and serum hormone levels in Ephb6 KO mice. 
 
Plasma AngII (A) and serum aldosterone (B) of male, female and castrated EphB6 KO and 
WT mice were measured by ELISA. For castrated mice, samples were collected at more 
than 4 weeks after castration. Mouse numbers per group (n) are indicated. Means + SD of 
hormone concentrations are shown. No statistically significant differences were found 
(Student’s t test).  
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Supplemental Figure4 Castrated Ephb6/KO mice present no BP increase. 
 
BP and HR of male (A) or castrated (B) male Ephb6/KO mice were measured by 
radiotelemetry as described in Fig. 3. Data were analyzed by repeated ANOVA, and the p 
values are reported.   
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Supplemental Figure 5 Ephb6 expression in the adrenal gland medulla according to ISH 
 
Med: medulla; Cx: cortex. Scale: 1 mm. 
A. Adult adrenal gland labeled with anti-sense probe. 
B. Adult adrenal gland labeled with sense probe.  
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Supplemental Figure 6 Expression of EFNBs, Ephb6, AR, AT1, and Grip1 in VSMC and 
endothelial cells 
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A. Normal expression of Efnb1, Efnb2, Efnb3, type 1a-adrenoreceptor (AR) and AngII 
receptor (AT1) in Ephb6 KO VSMC according to immunofluorescence. 
VSMC from male, female and castrated male Ephb6 KO or WT mice were stained with 
Abs against Efnb1, Efnb2, Efnb3, AR or AT1 as indicated. VSMC were identified with 
anti--actin Ab staining. Normal goat IgG served as isotypic control. For each staining, 
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more than 10 -actin-positive cells were randomly selected and their total 
immunofluorescence intensity and cell size were recorded by Zeiss AxioVision software. 
The experiment was repeated at least twice. The means + SD of fluorescence intensity per 
arbitrary unit cell area of all cells examined (more than 10 per experiment) in a 
representative experiment are shown.   
B and C. Efnbs, Ephb6 and Grip1 expression in endothelial cells according to q-PCR. 
Efnb1, Efnb2, Efnb3 Ephb6 and Grip1 mRNA levels in freshly isolated mesenteric arteries 
with endothelium stripped (B) or endothelial cells from mesenteric arteries (C) of males, 
females and castrated males of WT or KO mice were determined by RT-qPCR in triplicate. 
The data are expressed as means + SD of the ratios of the target gene signal versus the -
actin signal. No significant difference between KO samples and their WT counterparts was 
found (Student’s t tests), except Ephb6, which was deleted in KO mice.  
D. Efnbs, Ephb6 and Grip1 expression according to q-PCR in VSMC after sex hormone 
treatment in vitro. 
VSMC from female WT mice were cultured in the presence of testosterone (10 g/ml) for 
4 days. Conversely, VSMC from male WT mice were cultured in the presence of estrogen 
(10 g/ml) for 4 days. The cells were harvested and their mRNA levels of Efnb1, Efnb2, 
Efnb2, Ephb6 and Grip1 were determined by RT-qPCR. The data are expressed as means 
+ SD of the ratios of the target gene signal versus the -actin signal. No significant 
difference between KO samples and their WT counterparts was found (Student’s t tests), 
except Ephb6, which was deleted in KO mice.   
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Supplemental Figure 7 Ca++ flux in PE-stimulated VSMC. 
 
The experiments in this figure were repeated more than twice, and a representative dataset 
is shown. 
A. Ca++ flux in PE-stimulated VSMC from WT and Ephb6 KO mice. 
VSMC from male (left panel), female (middle panel) or castrated male (right panel) WT 
or Ephb6 KO mice were cultured for 4 days and then loaded with Fura2 (5 M). They were 
then placed in HBSS containing 1.26 mM Ca++ at 37oC and stimulated with PE (20 M). 
The ratio of emission at 510 nm triggered by 340 nm versus 380 nm excitation in each cell 
was registered every 10 s for 5 min, and the means + SD of the ratio of more than 15 
randomly-selected VSMC are shown. Arrows indicate the time point when PE was added.  
B. Ca++ flux in PE-stimulated WT VSMC cultured in wells coated with Ephb6-Fc.  
VSMC from WT male, female or castrated male mice were cultured for 4 days in wells 
coated with Ephb6-Fc or NHIgG (2 g/ml during coating). Ca++ flux after PE stimulation 
(20 M) was measured as described above.  
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Article 2. 
A possible role of Efnb1- A lligand of Eph receptor tyrosine kinases in modulating 
blood pressure 
*Zenghui Wu1, *Hongyu Luo1, #Eric Thorin, *Johanne Tremblay, *Junzheng Peng, *Julie 
L. Lavoie, *Yujia Wang, *Shijie Qi, *^Tao Wu, and *+Jiangping Wu 
 
J Biol Chem. 2012 May 4; 287 (19):15557-69. Epub 2012 Mar 5. 
 
Summary: in this paper we showed the elevated blood pressure in Efnb1-/-mice under 
immobilized condition. The phosphorylation of MLC was also increased in knockout mice. 
It was revealed that the Efnb1 reverse signaling was involving in the regulation of blood 
pressure and the function of vascular smooth muscle cells. 
 
Zenghui Wu performed experiments using VSMC and data analysis. Dr. Hongyu Luo 
generated Efnb1 KO mice, measured the aldosterone levels and analyzed data. Drs. 
Johanne Tremblay, Junzheng Peng and Julie Lavoe measured BP. Dr Eric Thorin 
performed vessel constriction experiments in vitro. Dr. Yujia Wang constructed plasmids 
for Grip1 overexpression in VSMC. Dr. Tao Wu initiated VSMC culture technique. Dr. 
Shijie Qi conducted castration, ovariectomy and mouse husbandry. Dr Jiangping Wu and 
Dr Hongyu Luo directed the experimental design and data analysis. 
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Running title: Efnb1 regulates vascular smooth muscle contractility and blood pressure 
 
 
 
 
 
Abstract 
Background: Currently, there is no knowledge about the function of ephrins in vascular 
smooth muscle contraction and blood pressure regulation. Results: Stimulating Efnb1 
reduces vascular smooth muscle cell contraction. Efnb1 null mutation leads to increased 
RhoA activation and heightens blood pressure in mice. Conclusion: Efnb1 can regulate 
vessel tone and blood pressure. Significance: We have identified a new group of molecules 
capable of regulating blood pressure. Eph kinases constitute the largest receptor tyrosine 
kinase family and their ligands, ephrins (Efns), are also cell surface molecules. Efns, 
although being ligands, can transduce signals reversely into cells. We have no prior 
knowledge of the role played by any members of this family of kinases or their ligands in 
blood pressure (BP) regulation. In the present studies, we investigated the role of Efnb1 in 
vascular smooth muscle cell (VSMC) contractility and BP regulation. We revealed that 
reverse signalling through Efnb1 led to a reduction of RhoA activation and VSMC 
contractility in vitro. Consistent with this finding, ex vivo, there was an increase of RhoA 
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activity accompanied by augmented myosin light chain phosphorylation in mesenteric 
arteries from mice with smooth muscle-specific conditional Efnb1 gene knockout (KO). 
Small interfering RNA knockdown of Grip1, a molecule associated with the Efnb1 
intracellular tail, partially eliminated the effect of Efnb1 on VSMC contractility and MLC 
phosphorylation. In supporting of these in vitro and ex vivo results, Efnb1 KO mice on a 
high-salt diet showed statistically significant heightened increment of BP at multiple time 
points during stress, compared to wild type littermates. Our results demonstrate that Efnb1 
is a previously unknown negative regulator of VSMC contractility and BP, and that it exerts 
such effects via reverse signalling through Grip1. 
 
Eph kinases form the largest family of receptor tyrosine kinases. Eph kinases can be 
divided into A and B families based on their sequence homology. There are 9 members in 
the EphA family and 6 members in the EphB family. Each species does not necessarily 
have all the members of each family. In mice, except there are only 5 members in the EphB 
family. The ligands of Eph kinases are also cell surface proteins (2-4), and this dictates that 
interactions between Ephs and ephrins (Efns) are mainly local and are restricted to 
neighboring cells. Efns are divided into A and B families, the former being GPI-anchored 
cell surface proteins, and the latter transmembrane proteins (2-4). Ephs and Efns interact 
promiscuously, but EphAs predominantly bind to EfnAs, and EphBs, mainly to EfnBs (2-
4). Interestingly, EfnBs may also transduce signals into cells upon binding to EphBs, and 
this phenomenon is called reverse signaling (2-4).  
The functions of Eph/Efn molecules in the central nervous system were the first to be 
studied in depth (3,4). In recent years, their functions have been revealed in various other 
tissue and organs. These molecules are involved in immune regulation (5), intestinal and 
urorectal tract development and function (6,7), angiogenesis (8), bone formation (9,10), 
insulin secretion by islet α-cells 225, kidney glumerolar filtration 226, and ionic homeostasis 
of vestibular endolymph fluid in the inner ear 227, to name a few.   
There are a few reports showing that EfnB2 and EfnA1 are expressed in vascular smooth 
muscle cells (VSMC) 228, and VSMC with EfnB2 deletion manifests compromised 
migration 229. One study has shown that EfnA1 could trigger EphA4 signaling and actin 
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stress fiber assembly 230. However, there are no studies to date on the function of Ephs and 
Efns in VSMC contractility and blood pressure (BP) regulation.  
In an unrelated project, our DNA microarray assay showed that some genes controlling BP 
were differentially expressed in Ephb6 gene knockout (KO) versus wild type (WT) 
thymocytes. This prompted us to investigate the roles of Ephs and Efns in BP regulation. 
In this report, we have demonstrated for the first time that Efnb1 regulates VSMC 
contractility and blood pressure in mice with conditional deletion of the Efnb1 gene.  
 
Methods: 
Generation of smooth muscle cell-specific Efnb1 KO mice  
The scheme, procedures and verification of the generation of Efnb1 floxed mice are 
reported recently by us 231. Efnb1 is an X-linked gene. Mice with LoxP sites flanked by the 
1st Efnb1 exon were named Efnb1f/f (loxP insertions in both alleles in females) or Efnb1f 
(loxP insertion in one allele in males). They were backcrossed with C57BL/6 for 5 or 10 
generations and then mated with smooth muscle myocin heavy chain-promoter-driven Cre 
transgenic (Tg) mice in the C57BL/6 background (smMHC-Cre-IRES-eGFP; ref. 19) to 
obtain smooth muscle cell-specific Efnb1 gene KO mice.  
 
Reverse transcription/real-time polymerase chain reaction (RT/qPCR) 
Efnb1, Grip1, Disheveled and PDZ-RGS3 mRNA levels were measured by RT/qPCR. 
Forward and reverse primers and the size of amplified fragments are listed in Table I. Total 
RNA from VSMC or spleen cells was extracted using TRIzol® (Invitrogen, Carlsbad, CA) 
and then reverse-transcribed with Superscript II™ reverse-transcriptase (Invitrogen). The 
PCR condition for the reactions were as follows: 2 min at 50oC, 2 min at 95oC followed by 
45 cycles of 10 s at 94oC, 20 s at 58oC and 20 s at 72oC. β-actin mRNA levels were used 
as internal controls and data were expressed as signal ratios of test gene mRNA/β-actin 
mRNA.  
 
Immunoblotting 
The aorta and mesenteric arteries of WT and KO mice were isolated, washed twice with 
HBSS buffer, and then frozen in liquid nitrogen until their use. The vessels were 
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homogenized for 1 min at room temperature in 0.4 ml radio-immunoprecipiation assay 
buffer, which contained Pho-stop and Protease Inhibitor Cocktail (Roche Applied Science, 
Laval, QC, Canada). The samples were spun at 12,000 rpm for 15 min at 4oC and the 
supernatants were collected. Twenty micrograms of proteins per sample were resolved in 
12% SDS-PAGE. Proteins from the gel were transferred to PVDF membranes (Invitrogen), 
which were incubated in blocking buffer containing 5% (w/v) skimmed milk (for MLC, 
5% BSA was used in the blocking buffer) for 1 h at room temperature, and then hybridized 
overnight at 4oC with goat anti-mouse Efnb1 Ab (R & D Systems, Minneapolis, MN), 
rabbit anti-mouse α-actin Ab, mouse anti-mouse phospho-MLC mAb, or rabbit anti-mouse 
total MLC Ab (all from Cell Signalling Technology, Danvers, MA). The Abs were used at 
the manufactures’ recommended dilutions or at 1:1000. The membranes were washed 3 
times and reacted with corresponding second Abs, i.e., horseradish peroxidise-conjugated 
donkey anti-rabbit IgG Ab (GE healthcare, Baie d’Urfe Quebec, Canada), horseradish 
peroxidise-conjugated sheep anti-mouse IgG Ab (GE Healthcare), or horseradish 
peroxidise-conjugated rabbit anti-goat IgG Ab (R & D Systems), for 90 min. The signals 
were detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, Rockford, IL).  
 
VSMC isolation 
Mouse VSMC isolation was conducted as described by Golovina et al. (20) with 
modifications. Briefly, the mesenteric arteries, including their secondary branches from the 
10- to 15 week-old mice were cleaned of the adventitia with fine forceps and sterile cotton-
tipped applicators under sterile conditions. The isolated blood vessels were cut into small 
pieces 232 and digested at 37oC for 20 min in low-Ca2+ HBSS containing both collagenase 
type II (347 U/ml, Worthington Biochemical Corporation, Lakewood, NJ) and elastase 
type IV (6 U/ml) (Sigma-Aldrich, St. Louis, MO). The digestion mixture was centrifuged 
at 1,500 g for 5 minutes to bring down cells. The dissociated cells were suspended and 
plated on 12-well plates. The cells were cultured at 37oC in Dulbecco’s modified Eagle’s 
medium (Wisent, St. Bruno, QC, Canada) supplemented with 15% fetal bovine serum 
(FBS) for 4 to 5 days before experimentation.  
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Immunofluorescence microscopy 
VSMC were cultured in 24-well plates with cover glass placed at the bottom of the wells. 
After 4 to 5 days, the cells were washed twice with PBS and fixed with paraformaldehyde 
(4%) for 20 min. For cell surface Ag staining, cells were blocked with 10% goat IgG in 
PBS for 20 min and then incubated with various first Abs (2 µg/ml): goat anti-mouse Efnb1 
Ab (R&D System, Minneapolis, MN); rabbit anti-mouse type 1a α adrenoreceptor (α1a-
AR) Ab, (Abcam Inc., Cambridge, MA); and rabbit anti-mouse AngII receptor Ia (ATR1a) 
Ab (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4oC. Cells were then reacted 
with corresponding second Abs (i.e., rhodamine-conjugated donkey anti-goat Ab, 0.15 
µg/ml, Jackson ImmunoResearch Laboratories, West Grove, PA, USA; and FITC-
conjugated sheep anti-rabbit IgG, 0.2 µg/ml, Chemicon International, Billerica, MA) 
overnight at 4oC. For intracellular Ag staining, the cells were permeabilized with 
permeabilization buffer (BD Biosciences, San Jose, CA) for 20 min at 4oC, and then 
incubated with various first Abs: mouse anti-human α-actin mAb (2 µg/ml; Santa Cruz 
Biotechnology); rabbit anti-mouse myosin light chain (MLC, 0.2 µg/ml; Santa Cruz 
Biotechnology); and rabbit anti-mouse phospho-MLC Ab (0.2 μg/ml; Santa Cruz 
Biotechnology) overnight at 4 degree. Cells were then washed and reacted with, 
respectively, second Abs: rhodamine (TRITC)-conjugated AffiniPure F(ab')2 fragment of 
goat anti-mouse IgG (H+L) (0.2 µg/ml; Jackson ImmunoResearch Laboratories); FITC-
conjugated goat anti-mouse IgG (0.2 µg/ml; Bethyl Laboratories, Montgomery, TX); 
FITC-conjugated sheep anti-rabbit IgG (0.2 µg/ml; Chemicon International) at room 
temperature for 2 h, and imbedded with ProLong® Gold anti-fade reagent (Invitrogen). 
The stained cells were examined under a Zeiss microscope. In some experiments, the total 
fluorescent intensity of a cell and cell size were measured using AxioVision software from 
Zeiss; results are then presented as fluorescent intensity per arbitrary unit of cell area 233.  
 
Measurement of VSMC contractility 
Cultured primary VMSC were washed once with Ca++-free HBSS and cultured in the same 
solution. They were placed under a Zeiss microscope with environmental controls (37oC 
and 5% CO2).  The cells were stimulated with PE (20 µM) or Ang II 
234 (both from Sigma-
Aldrich). These concentrations were determined to be optimal according to pilot studies. 
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The cells were photographed continuously for 15 min at a rate of 1 picture per min. Fifteen 
or more cells were randomly selected and their length was measured at each time point 
with Zeiss Axiovision software. The percentage contraction was calculated as follows: 
% contraction = (cell length at time 0 – cell length at time X) / cell length at time 0.  
 
Measurement of Ca++ flux 
VMSC were incubated in 2% FBS DMEM medium containing 5 µM Fura-2-AM for 30 
min. The cells were washed in warmed medium for 15 to 20 min to remove extracellular 
dye. They were re-cultured in HBSS with Ca++ 235 and placed under a Zeiss microscope 
with environmental controls (37oC and 5% CO2). The cells were stimulated with PE (20 
µM) and were imaged for 5 minutes at a rate of 6 pictures per min. The excitation 
wavelengths were switched between 340 nm and 380 nm with illumination time of 180 ms, 
and the emission wavelength was 510 nm. Signals from more than 15 randomly selected 
cells were registered and the results expressed as ratios of fluorescent intensity at 510 nm 
excited by 340 nm versus 380 nm. 
 
Small interfering RNA (siRNA) transfection 
siRNA of Grip1, Dishevelled, PDZ-RGS3 and negative control siRNA were synthesized 
by Integrated DNA Technologies (Coralville, IA); the sequences of these siRNAs are 
shown in Table II. VSMC were cultured for 4 to 5 days with the last 16 hours free of 
antibiotics and then transfected with a mix of 3 pairs of siRNAs of a particular gene (each 
pair at a final concentration of 10 nM), using FuGENE HD X-tremeGENE siRNA 
Transfection Reagent (Roche Applied Science). The transfected VSMC were further 
cultured for 24 to 36 h; contractility was measured upon PE stimulation and MLC 
phosphorylation was measured by immunofluorescence. 
 
Transient Grip1 overexpression in VSMC 
A Grip1 expression plasmid pCEP4-Grip1 was constructed by cloning mouse Grip1 cDNA 
(a NotI/HincII fragment of clone MGC80644 containing Grip1 cDNA from position 1 to 
4064 according to Genbank BC072632 sequence) in the NotI/XhoI sites downstream of 
the CMV promoter in a mammalian cell protein expression vector pCEP4. WT VSMC 
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were cultured for 6 days, and then transfected with pCEP4-Grip1 or the control empty 
vector pCEP4 using 0.2 µg pasmid DNA mixed with FuGENE HD X-tremeGENE siRNA 
Transfection Reagent (Roche Applied Science) for a well VSMC in 6-well plates. Cell 
contraction was conducted 24 h later.  
 
Activated RhoA assay 
GTP-associated activated RhoA levels in mesenteric artery smooth muscles were 
determined by G-LISK RhoA Activation Assay Biochem Kit (Cytoskeleton Inc. Denver, 
CO, USA) according to manufacturer’s instructions.  
Ex vivo vessel constriction 
Vessel constriction was studied ex vivo as described previously (21). Mesenteric artery 
segments (2 mm in length) of third-order branches (exterior diameter 125 to 150 µm) were 
stripped off endothelium and mounted on 20-µm tungsten wires in small vessel myographs, 
stretched to optimal tension and maintained in physiological saline solution (PSS: NaCl, 
130 mM; KCl, 4.7 mM; KH2PO4, 1.18 mM; MgSO4, 1.17 mM; NaHCO3, 1.17 mM; CaCl2, 
1.6 mM; EDTA, 0.023 mM; glucose, 10 mM; aerated with 12% O2/5% CO2/83% N2; pH 
7.4) at 37°C. After a 40-min stabilization period, arterial segments were challenged with 
40-mM KCl PSS (KCl was substituted for an equivalent concentration of NaCl). Single 
cumulative concentration-response curves to the α1-adrenergic receptor agonist 
phenylephrine (PE, 1 nM to 100 µM, Sigma, St. Louis, MO, USA) were charted. At the 
end of the protocol, maximal tension (Emax) was determined by changing the PSS to a 
solution containing 127 mM KCl. The data are expressed as percentages of Emax. 
Student’s t tests were performed to compare concentration-response curves.  
 
BP measurements by radiotelemetry 
Mice were anesthetized with isoflurane and surgically implanted with TA11PA-C10 
radiotelemetry sensors (Data Sciences International, St. Paul, MN, USA) in the left carotid 
artery for direct measurement of arterial pressure and HR as described previously (22). 
Mice were given 7 days to recover. Next, BP and HR in conscious free-moving mice were 
continuously recorded for 3 days using the Dataquest acquisition 3.1 system (Data Sciences 
International). Individual 10-s waveforms of systolic pressure (SP), diastolic pressure 
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(DP), mean arterial pressure (MAP) and heart rate (HR) were sampled every 2 minutes 
throughout the monitoring period. To assess the impact of immobilization stress on BP and 
HR were measured continuously during 30-min immobilization in a restraining device 
(IITC Life Science, Woodland Hills, CA) 236. Raw data were processed by the Dataquest 
A.R.T-Analysis program (24) and then presented as means ± SE. Statistical significance of 
differences between the experimental groups was evaluated by unpaired t test and repeated-
measures ANOVA tests with the Statview program. P<0.05 values were considered to be 
statistically significant. 
 
ELISA for urine catecholamine and plasma AngII measurements 
The 24-h urine catecholamines were assayed by catecholamine ELISA Kit (Rocky 
Mountain Diagnostics, Colorado Springs, CO). The plasma AngII was measured by 
Angiotensin ELISA Kit (Phoenix Pharmaceuticals, Burlingame, CA). The assays were 
conducted according to manufacturers’ instructions. 
 
Results 
Generation of SMC-specific Efnb1 conditional gene KO mice 
Efnb1 null mutation caused embryonic lethality (25). To study their function in VMSC, we 
generated conditional KO mice 237. These mice (Efnb1f/f for females and Efnb1f for males, 
as Efnb1 is an X-linked gene) were crossed with smMHC-Cre-IRES-eGFP Tg mice 238. 
The resulting Efnb1 conditional KO mice were named smMHC-Cre-Efnb1f/f for females 
and smMHC-Cre-Efnb1f for males. For reasons to be elucidated, female smMHC-Cre-
Efnb1f/f mice were embryonic lethal and only male smMHC-Cre-Efnb1f could be 
generated. Therefore, smMHC-Cre-Efnb1f male mice (backcrossed to the C57BL/6 
background for 5 or 10 generations) were used as KO mice throughout this study, while 
age-matched Cre-Efnb1f male mice with the same generation of backcrossing were used 
as controls. These mice were called Efnb1 KO and WT mice hereafter, respectively. 
 
As shown in Fig. 1A, the SMC-specific deletion of exon 1 in the genome resulted in Efnb1 
mRNA deletion in Efnb1 KO VSMC, but not in spleen cells of Efnb1 KO mice, according 
to RT/qPCR. The mRNA deletion in the KO arterial tissue was not complete, probably due 
 111 
to the presence of a small amount of fibroblasts and endothelial cells in the vessel. Efnb1 
deletion in KO VSMC at the protein level was demonstrated by immunoblotting. As shown 
in Fig. 1B, Efnb1 could be detected from lysates of freshly isolated WT but not in Efnb1 
KO arteries.  
 
Efnb1 deletion in VSMC at the protein level was also clearly demonstrated by 
immunofluorescence (Fig. 1C), as WT α-actin-positive (green) VSMC were Efnb1-
positive (red), while α -actin-positive Efnb1 KO VSMC were Efnb1-negative. The result 
proved not only VSMC-specific deletion of Efnb1 in Efnb1 KO mice, but also the 
specificity of anti-Efnb1 Ab. 
 
Efnb1 engagement in VSMC results in their decreased contractility due to Efnb1 reverse 
signalling 
We established a method of intravital microscopy to assess the contractility of KO and WT 
VSMC. Isolated VSMC were cultured for 4-5 days and then stimulated with 
vasoconstricting agents such as phenylephrin (PE) and angiotensin II (AngII). Images of 
the cells were recorded for 15 min and VSMC length was measured digitally at different 
time points. As illustrated in Fig. 2A, the majority of the cells (more than 80%) showed 
drastic contraction upon PE stimulation, and the contraction reached its maximum 15 min 
after the stimulation. This result indicates that after 4-5 days of culture, the isolated VSMC 
retained their contractile phenotype. A few non-contracting cells were likely contaminating 
fibroblasts. By randomly selecting contracting cells and measuring their length at different 
time points, we were able to assess their contractility as a function of cell length and time 
elapsed. 
 
The contractility of Efnb1 KO and WT VSMC was measured on the basis of their responses 
to PE and AngII, but both types of VSMC presented similar contractility (Fig. 2B). A 
possible explanation is that unlike VSMC in vivo where the cells have close contact with 
neighboring VSMC, allowing constant Eph/Efn engagement, the cultured VSMC had 
limited interaction with neighbouring cells hence limited engagement between Efn and 
Eph, especially in our culture conditions, where VSMC were always non-confluent. Under 
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such circumstances, the difference of Efn1 KO and WT in contractility, if there was any, 
was difficult to detect.  
 
We reasoned that if VSMC were cultured on wells coated with anti-Efnb1 or recombinant 
Efnb1, they might receive sufficient reverse or forward signalling, respectively, to mimic 
the in vivo condition. Indeed, when cultured in wells coated with anti-Efnb1 Ab and upon 
PE or AngII stimulation, WT VSMC contraction reduced about 45-70% [(% contraction 
of WT cells in isotypic Ab-coated wells)/(% contraction of WT cells in anti-Efnb1 Ab-
coated wells)] in multiple time points compared to those cultured in wells coated with 
isotypic control Ab (Fig. 2C). For Efnb1 KO VSMC cultured in wells coated with anti-
Efnb1 Ab, their contractility upon PE and AngII stimulation showed no significant 
difference from that of WT VSMC cultured in well coated with isotypic Ab. This is logical, 
as anti-Efnb1 Ab could not react to these cells due to their null mutation of Efnb1. These 
results indicate that the function of Efnb1 in VSMC is to dampen their contractility through 
reverse signaling. As the presence of solid phase anti-Efnb1 Ab dampened the contractility 
of WT VSMC in response to both PE and AngII, the reverse signaling through Efnb1 was 
not specific to adrenoreceptor (AR) or AngII type I receptor (AT1R), but was probably on 
a downstream event after AR and AT1R signalling converges. The effects of solid phase 
anti-Efnb1 Ab in reducing WT VSMC contractility could be brought back to near-normal 
level (the contraction was only about 10% lower than that of the WT cells cultured in 
isotypic Ab-coated wells without soluble Efnb1-Fc) by soluble Efnb1-Fc (Fig. 2D), 
demonstrating the specificity of the interaction between anti-Efnb1Ab and Efnb1-Fc. 
 
When WT VSMC were cultured in wells coated with recombinant Efnb1-Fc, the 
contractility of the cells was no different from that of cells cultured in wells coated with 
normal human IgG (Fc in Efnb1-Fc is of human origin) (Fig. 2E). This proves that forward 
signaling from Efnb1 to its receptors in VSMC is of no consequence in terms of VSMC 
contractility. 
 
Normal expression of AR and AT1R in Efnb1 KO VSMC 
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The reduced contractility of WT VSMC in the presence of Efnb1 engagement in response 
to PE and AngII could be due to modulation of AR or AT1R expression by Efnb1. We 
therefore assessed the expression levels of AR and AT1R on VSMC by 
immunofluorescence microscopy. The staining was quantified using Zeiss AxioVision 
software by measuring the immunofluorescene intensity per arbitrary unit of cell surface 
area 239. Efnb1 KO VSMCs were no different from WT VSMC in their AR and AT1R 
expression when cultured in uncoated wells (Fig. 3A). Although Efnb1 WT VSMC, when 
cultured in wells coated with anti-Efnb1 Ab, showed reduced contractility than KO VSMC, 
their AR and AT1R expression levels did not change (Fig. 3B). In this experiment, WT 
VSMC Efnb1 was stimulated by solid phase anti-Efnb1 Ab, while KO VSMC could not be 
stimulated by the Ab due to a lack of Efnb1. The results indicate that Efnb1 engagement 
or not did not alter AR and AT1R expression.  
 
Effect of Efnb1 reverse signaling on calcium flux of VSMC 
Calcium flux is an essential early signaling event common to both PE and AngII 
stimulation in VSMC, leading to their contraction. We investigated whether the deletion or 
engagement of Efnb1 in VSMC led to increased basal calcium level and/or amplitude of 
calcium flux, which could in turn lead to increased contractility. As shown in Fig. 3C (cells 
cultured in wells coated with isotypic control Abs with no Ca++ in the medium) and in Fig. 
3D (cells cultured in wells coated with anti-Efnb1 Ab with no Ca++ in the medium), Efnb1 
KO and control WT VSMC showed no significant difference in basal and stimulated 
intracellular calcium levels on PE (left panel) and AngII (right panel) stimulation. It is to 
be noted that in Fig. 3D, WT VSMC received stimulation from solid phase anti-EFNB1 
Ab, while KO VSMC could not, due to their lack of EFNB1. In both Fig. 3C and 3D, the 
calcium influx seen in these cells was mobilized from intracellular Ca++ storage in 
sarcoplasmic reticulum. 
 
We next cultured Efnb1 KO and WT VSMC in medium containing Ca++ and stimulated 
them with PE. In this case, the source of increased intracellular calcium in VSMC came 
from both extracellular culture medium and from intracellular sarcoplasmic reticulum.  WT 
and KO VSMC in wells coated with isotypic control Ab (Fig. 3E, left panel) again showed 
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similar basal Ca++ levels and Ca++ flux. In this case, even if EFNB1 in WT VSMC 
received some stimulation from neighbouring cells, while KO VSMC did not, there was 
no difference in their Ca++ levels. We then cultured WT and KO VSMC in wells coated 
with anti-Efnb1 Ab in the presence of calcium in culture medium. In this case, again, WT 
could receive stimulation from solid phase anti-Efnb1 Ab while KO VSMC cannot due to 
their Efnb1 deletion. Yet, their basal Ca++ levels and Ca++ flux presented not difference 
(Fig. 3E, right panel).  
 
The results from this section indicate that Efnb1 null mutation or anti-Efnb1 Ab-triggered 
reverse signaling in VSMC does not affect the function Ca++ ion channels related to Ca++ 
mobilization from either intracellular or extracellular sources. Therefore, the reduced 
VSMC contractility upon Efnb1 reverse signaling is not due to abnormalities of the 
immediate early signaling event Ca++ flux. 
 
Effect of Efnb1 reverse signaling on VSMC MLC phosphorylation and RhoA activation 
Since there was no difference in basal and flux levels of calcium in VSMC with or without 
Efnb1 signaling, we wondered whether Efnb1 reverse signaling altered the sensitivity of 
VSMC to Ca++. We evaluated these cells for their MLC phosphorylation, which is the 
main mechanism regulating VSMC sensitivity to Ca++ (26, 27). Levels of total MLC and 
phosphorylated MLC ex vivo in freshly isolated arteries (with adventitia and endothelium 
removed) were determined by immunoblotting. As shown in Fig. 4A, there was a 
significant increase in levels of constitutive MLC phosphorylation but not total MLC in 
Efnb1 KO vessels, compared to those in WT vessels. We next assessed constitutive MLC 
phosphorylation in cultured VSMC by immunofluorescence microscopy, which was 
employed because the amount of proteins that could possibly be obtained from these 
cultured VSMC was too small for immunoblotting. Consistent with the findings of 
immunoblotting in vessels ex vivo, WT VSMC cultured in anti-Efnb1 Ab-coated wells 
showed reduced levels of constitutive MLC phosphorylation (Fig. 4B, right panel), but not 
total MLC (Fig. 4B, left panel), compared to those without anti-Efnb1 stimulation (cultured 
in wells coated with isotypic control Ab. These results suggest that Efnb1 reverse signaling 
dampens VSMC responsiveness to Ca++ flux by reducing MLC phosphorylation. 
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Consistent findings between immunoblotting and quantitative immunfluorescence 
microscopy validated the latter as an alternative to the former.  
As activated RhoA could increase MLC phosphorylation via the RhoA-associated 
kinase/myosin phosphatase pathway (28), we wondered whether Efnb1 reverse signaling 
in VSMC resulted in RhoA activation. Indeed, when WT VSMC were cultured in wells 
coated with anti-Efnb1 Ab, there was a significant increase of GTP-bound RhoA level, 
compared to cells cultured in wells coated with isotypic control Ab (normal goat IgG) (Fig. 
4C).  
Identification of Grip1 as a component in the Efnb1 reverse signaling pathway in controling 
VSMC contraction 
Since we discovered that reverse signaling is critical for the effect of Efnb1 on VSMC 
contraction, we attempted to identify components of the Efnb1 reverse signaling pathway. 
The intracellular tails of Efnb1 show no direct biological activity, but it has 3 conserved 
tyrosine phosphorylation sites, which are known to interact with SH2-domain-containing 
adaptors, such as Disheveled (29). In addition, the C-terminus of Efnb1 possesses a PDZ-
binding domain (2), which could interact with PDZ-containing proteins such as Grip1 (30) 
or PDZ-RGS3 (31). To test the relevance of these adaptor proteins in mediating Efnb1’s 
reverse signaling in and effect on VSMC, we employed siRNA to knock down the 
expression of Disheveled, Grip1 and PDZ-RGS3 in WT VSMC. The expression and 
knockdown of these genes was confirmed at the mRNA level (Fig. 5A). When Efnb1-
engaged WT VSMC (i.e., VSMC cultured in anti-Efnb1 Ab-coated wells), whose 
contractility was depressed about 40% in multiple time points compared to the controls, 
were transfected with Grip1 but not PDZ-RGS3 or Disheveled siRNA, they regained about 
50% of their lost strength (Fig. 5B). On the other hand, Grip1 siRNA had no effect on 
VSMC without Efnb1 engagement (VSMC cultured in wells without anti-Efnb1 Ab 
coating, Fig. 5C). This shows that the effect of Grip1 siRNA is specific to Efnb1 reverse 
signaling, but does not exert its effect via other pathways by itself. These results indicate 
that diminished Grip1 expression blocks the negative effect of Efnb1 engagement on 
VSMC contraction 
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Conversely, when Grip1 was overexpressed in WT VSMC without anti-Efnb1 stimulation, 
these cells showed about 50% reduced contractility, mimicking the effect of Efnb1 reverse 
signalling (Fig. 5D).  
These data demonstrate that Grip1 is a relevant adaptor protein that mediates Efnb1 reverse 
signaling in VSMC to achieve reduced VSMC contractility. 
We further demonstrated that Grip1 knockdown resulted in an increased level of MLC 
phosphorylation but not total MLC protein in EFNB1-engaged WT VSMC (Fig. 5E); such 
an increase is likely a basis for the increased VSMC contractility that was caused by Grip1 
siRNA transfection. This places Grip1 upstream of MLC phosphorylation in the Efnb1 
reverse signaling pathway. 
Ex vivo findings in mesenteric arteries from Efnb1 KO mice. 
We wondered whether the reduced RhoA activation and contraction of cultured VSMC 
upon Efnb1 activation was reflected in freshly isolated small arteries, which control 
vascular resistance, hence BP. GTP-associated RhoA levels in mesenteric arteries stripped 
of endothelium was first assessed. As shown in Fig. 6A, the arteries from the KO mice 
manifested significantly heightened GTP-associated RhoA levels compared with that from 
WT mice. This is conversely consistent with the findings from anti-Efnb1 Ab stimulated 
VSMC, which had reduced RhoA activation.  
However, ex vivo vessel constriction tests on freshly isolated mesenteric arteries from KO 
and WT mice did not reveal significant difference, with or without endothelium, upon PE 
stimulation (Fig. 6B). Possible reasons for this observation will be discussed later.  
Efnb1 KO mice presented higher increments of BP than WT mice during immobilization 
stress  
The above findings regarding dampening VSMC contractility by Efnb1 engagement 
suggests that smooth muscle cell-specific Efnb1 null mutation might augment BP. Thus, 
we measured the BP of male Efnb1 KO mice by telemetry. On a normal diet alone, (Fig. 
7A), on a normal diet under stress alone (data not shown) or on a high-salt diet alone (Fig. 
7B), Efnb1 mice and control WT mice presented no significant difference in their SP, DP, 
MAP or HR. BP control has multiple compensatory mechanisms. A BP phenotype might 
be manifested only when the compensation is stretched to the limit. Indeed, the role of 
Efnb1 in BP regulation was revealed when the KO mice (average age: 21 week old) were 
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in a condition that combined a high-salt diet and immobilization stress. At several time 
points, Efnb1 KO mice showed significantly higher increments of SP, DP, and MAP (SP, 
DP and MAP, respectively; i.e., the BP during stress minus BP of the resting status of the 
same animal) (Fig. 7C). Such increased BP was a reproducible phenomenon. In a separate 
experiment carried out on 16-week old mice, such a statistically significant phenotype was 
also observed, even with a small sample size (n=3) (Fig. 7D). This is the first time a role 
of any Efn molecules in BP control has been discovered.  
We have also observed (Fig. 7C) that during stress on a high-salt diet, Efnb1 KO mice had 
significantly a higher HR increment (ΔHR) than WT mice. Obviously, the higher ∆HR 
contributed to higher stress BP in these mice, along with increased VSMC contractility, as 
we have proven in vitro. The reason why Efnb1 deletion heightened ΔHR in this particular 
experiment is not clear and is under investigation, but the phenotype does not seem to be 
consistent and reproducible. As seen in Fig. 7D, in a similar experiment, such a heightened 
∆HR increment was not present.  
 
Normal levels of urinary catecholamines and plasma AngII of Efnb1 KO mice 
The Efnb1 KO mice employed in this study had conditional Efnb1 KO in SMC and the 
phenotype of the mice was attributed to the deletion of Efnb1 in SMC. To rule out the 
unlikely possibility that such conditional KO also affects the endocrine system, which in 
turn contributes to the enhanced VSMC contractility and stress BP, we assayed the 24-h 
urine catecholamines right after stress or without stress (Fig. 8A), and plasma AngII (Fig. 
8B) of Efnb1 KO mice. The results showed no significant difference in these parameters 
between Efnb1 KO and control WT mice, ruling out the possible effect of conditional 
Efnb1 deletion on the secretion of these hormones.  
Discussion  
We for the first time discovered that Efnb1 is likely involved in BP control by regulating 
VSMC contractility. Efnb1 engagement in mouse VSMC resulted in their decreased 
contractility in vitro, while EFNB1 null deletion in smooth muscle cells heightened the 
increment of BP during stress in mice on a high-salt diet in vivo. Such regulation depended 
on reverse signaling of Efnb1 into VSMC and this reverse signalling modulated the levels 
of GTP-associated RhoA and MLC phosphorylation in VSMC. An adaptor protein Grip1 
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was in the Efnb1 reverse signaling pathway and it mediated the effect of Efnb1 on VSMC 
contractility and MLC phosphorylation. A few issues are discussed as follows. 
Efnb1 is vital during embryonic development. Complete deletion of Efnb1 leads to lethality 
during the fetal stage (25). Although male Efnb1 KO mice could be obtained, their 
occurrence was below the rate expected according to Mendel’s law. It is known that LoxP-
Cre-mediated deletion is not an all or none event, and there is variation in Cre expression 
even with the same copy number of Cre genes in the Tg genome (32). Leaky Tg Cre 
expression outside the targeted tissue is also frequently encountered. We speculate that 
fetuses with stronger Cre expression might become embryonic lethal, due to either a higher 
degree of Efnb1 deletion in SMC or leaky Cre expression in other tissues. No female 
smMHC-Cre-Efnb1f/f was ever born. This might be a result of essential interaction 
between Efnb1 and certain molecule(s) whose necessity is different in male and female 
fetuses.  
 
Intracellular Ca++ level change in VSMC is a common and early signaling event after AR 
and AngIIR activation. We noticed that the VSMC Ca++ occurred within 1 min after PE 
stimulation, a time frame compatible with that under a physiological condition in vivo, 
under which arteries will constrict quickly upon adrenaline stimulation. However, it took 
about 15 min for cultured VSMC to achieve maximal contraction. This is because that the 
cultured VSMC adhere to the wells, and will need to master enough force to gradually 
dislodge themselves from the plastic well surface to complete the contraction, while VSMC 
in the vessels are free-standing, and can contract without much hindrance.  
The increased intracellular Ca++ in VSMC comes from the influx of Ca++ from 
extracellular milieu via L-type voltage-gated calcium channel on the plasma membrane, 
but is mainly from the mobilization of Ca++ reserve in sarcoplasmic reticulum via 
ryanodine and inositol trisphosphate receptors on the sarcoplasmic reticulum membrane. 
The subsequent ebbing of the intracellular Ca++ depends on large-conductance Ca++-
activated K+ channel on the plasma membrane and the SERCA (Sarco-Endoplasmic 
Reticulum Ca++-ATPase) pump on the sarcoplasmic reticulum membrane (33,34). VSMC 
in the presence or absence of Efnb1 reverse signalling presented similar basal Ca++ levels 
and Ca++ flux after PE and AngII stimulation. This is also true regardless whether there is 
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extracellular Ca++ in the medium.  This indicates that all the signaling components (e.g. 
AR, AngIIR, L-type voltage-gated calcium channels, ryanodine receptors, inositol 
trisphosphate receptors, large-conductance Ca++-activated K+ channels, or SERCA 
pumps) leading to Ca++ flux are not modulated by Efnb1 reverse signaling.  
In addition to intracellular Ca++ level, VSMC contractility is regulated by their sensitivity 
to Ca++, and the sensitivity is regulated by the degree of MLC phosphorylation (26,27). 
We have found that in the absence of Efnb1, the constitutive MLC phosphorylation in 
artery proteins was drastically augmented. The converse is also true: with Efnb1 
engagement, VSMC showed decreased MLC phosphorylation. Conceivably, such 
modulation of MLC phosphorylation leads to altered VSMC Ca++ sensitivity, and 
consequently altered VSMC contractility.  
 
We have tried to identify components in the Efnb1 reverse signaling pathway that regulates 
MLC phosphorylation and VSMC contraction. We discovered that RhoA activation in the 
form of GTP-associated RhoA was reduced in anti-Efnb1 Ab-stimulated VSMC. 
Compatible with such a finding, RhoA activation was augmented in the mesenteric artery 
smooth muscles of KO mice, compared to that in WT mice. Activated RhoA can activate 
RhoA-associated kinase, which phosphorylates myosin phosphatase. The phosphorylation 
of the phosphatase will reduce its activity, which will then prolong the phosphorylation of 
MLC (28). This might be a mechanism to increase the responsiveness of MLC to Ca++ 
flux in the absence of Efnb1 reverse signaling.  
Additional search of the components in the Efnb1 reverse signaling pathway has identified 
Grip1, as its knockdown partially reverses Efnb1’s effect on dampening VSMC 
contractility. Whether and how Grip1 is connected to RhoA activation, which will in turn 
promote MLC phosphorylation, is not clear and we can only speculate at this point. Grip1 
is an adapter protein containing 7 PDZ domains (35), which can associate with the PDZ-
binding domain at the C-termini of Efnbs (28). It is possible that the remaining PDZ 
domains in Grip1 might interact with modulators of RhoA activity, such as GDP 
dissociation inhibitors (GDI) or GDP exchange factors (GEF), and influence their 
functions, which will in turn regulate RhoA activity. Indeed, Grip1 can associate with a 
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Rho-GDI (36) and a Ras-GEF 65 through its PDZ domains. Validation of such hypotheses 
is in progress.   
Consistent with most of the in vitro and ex vivo findings, Efnb1 KO mice manifested an 
augmented increment of SP, DP and MAP during stress, compared to WT mice, when they 
were on a high-salt diet. Although the increase was only statistically significant at several 
time points, this finding is genuine because it was reproducible in 2 independent 
experiments. BP, a vital physiological parameter, is tightly regulated by multiple 
compensatory mechanisms at the levels of vascular tone, blood volume and cardiac output. 
It is not easy to override all these compensatory mechanisms to achieve an overt BP 
phenotype. Any molecule that could cause an overt BP phenotype, even a minimal one, 
has much more than a minimal role in BP regulation. This is especially true for Efnb1, 
which is a member of the Efnb subfamily. The Efnb subfamily has 3 Efnb members which 
have redundant functions and interact promiscuously with Ephs. Such redundancy might 
have further diminished the BP phenotype of Efnb1 KO mice, so that BP upregulation in 
the KO mice is not manifested on a normal diet or under stress while on a normal diet, but 
is only revealed with a combination of a high salt diet plus stress. Under such conditions, 
the compensation mechanisms are finally overwhelmed. It is very likely that other Efnbs 
in addition to Efnb1 and some Ephb members are also involved in VSMC contractility and 
BP control. Our additional study showed that this is indeed the case: we have found that 
Ephb6 KO mice have BP and VSMC contractility phenotypes similar to that of Efnb1 KO 
mice (38).  
 There is some discrepancy among certain findings in our study. Ex vivo, RhoA activation 
and constitutive phosphorylation of MLC in the smooth muscle of the mesenteric arteries 
from KO mice were elevated. This is consistent with augmented BP in KO mice in vivo 
compared with WT mice, when they were under stress and on a high salt diet. This is also 
compatible with the findings in cultured VSMC, in that VSMC contractility was reduced 
upon Efnb1 engagement. However, why don’t we see increased ex vivo contraction of 
mesenteric arteries from KO mice compared to that from WT mice (Fig. 6B), and why 
could the lack of increased contraction in vessels translate into the in vivo phenotype of 
increased BP? It is possible that a subtle and minor increase of vasoconstriction is present 
in the vessel, but our vasoconstriction tests ex vivo are not sensitive enough to reveal it. 
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Such an increase, as it is subtle and minor, neither was revealed in vivo when mice were 
on a normal diet or undergone immobilization stress alone. It only manifested itself when 
the KO mice were assaulted with both high salt diet and immobilization stress, which 
overcome most of the compensation mechanisms in BP regulation. 
Based on our findings, we speculate that under a physiological condition, Efnb1 (or other 
Efnb members) on VSMC interact(s) with Ephs in neighbouring VSMC or endothelial 
cells, and such interactions modulate VSMC contractility. Since the expression of Efnb1 
(or other Efnb members) and its binding partner Ephs is unlikely to change instantly, the 
physiological role of Efnb1 (or other Efnbs) and Ephbs could be basal vascular tone 
regulation. These findings have enhanced our understandings of BP regulation 
mechanisms. 
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FIGURES AND LEGENDS 
Figure 1 Generation of mice with SMC-specific deletion of Efnb1 
 
A. Deletion of Efnb1 at the mRNA level in the artery of male Efnb1 KO mice. mRNA from 
the VSMC and spleen cells of male Efnb1 KO and WT mice was assessed for Efnb1 mRNA 
by RT/qPCR. Means + SD of the ratios of Efnb1 versus β-actin signals are presented.  
B. Deletion of Efnb1 at the protein level in Efnb1 KO arteries according to 
immunoblotting. Proteins extracted from the mesenteric arteries of Efnb1 KO and WT mice 
were subjected to immunoblotting analysis. β-actin levels were used as a loading control. 
The signal ratios of Efnb1 and β-actin (lower panel) were determined by densitometry 
C. VSMC-specific deletion of Efnb1 protein in Efnb1 KO mice according to 
immunofluorescence microscopy. VSMC and non-VSMC from Efnb1 KO and WT mice 
were isolated from mesenteric arteries, and their Efnb1 (red, lower row) and α-actin (green, 
upper row) expression was detected by immunofluorescence microscopy. The experiments 
in this figure were repeated 3 times and representative ones are shown. 
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Figure 2 Decreased contractility of Efnb1-engaged VSMC 
 
A. VSMC contraction after PE stimulation. VSMC were isolated from the mesenteric 
arteries of WT mice, and cultured for 4 days. The cells were stimulated with 20 µM PE 
and imaged every min. Images at 0 min, 5 min, 10 min and 15 min are shown. Four arrows 
point to the same 4 cells during the 15-min imaging period, and show their contraction. 
The photos also reveal that about 85% of the cells are capable of contraction, indicating 
the purity of VSMC in such cell preparations.  
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B. VSMC from Efnb1 KO and WT mice presented similar contractility upon PE and AngII 
stimulation when cultured in uncoated wells. VSMC from Efnb1 KO and WT mice were 
stimulated with 20 µM PE (left column) or 10 µM AngII (right column). The means + SD 
of their percentage contraction are illustrated. Data were analyzed with paired Student’s t 
test, but no significant difference was found. 
C. Solid phase anti-Efnb1 Ab caused decreased contractility in WT but not Efnb1 KO 
VSMC Efnb1 KO or WT VSMC were cultured in wells coated with goat anti-Efnb1 Ab 
(αEfnb1 Ab) or goat IgG-coated wells (2 µg/ml/well for 12-well plates during coating at 
4oC overnight) for 4 days, and then stimulated with PE (20 µM; left panel) or AngII 247. 
Means + SD of percentage contraction of these VSMC are illustrated. αEfbn1 Ab: anti-
Efnb1 antibody. *: significant differences between Efnb1 KO and WT VSMC on αEfnb1 
Ab-coated wells, and between WT VSMC cultured on isotypic Ab-coated wells and WT 
VSMC cultured on wells coated with αEfnb1 Ab (p<0.05; paired Student’s t test). No 
significant difference was found between Efnb1 KO VSMC on αEfnb1 Ab-coated wells 
and WT VSMC on isotypic Ab-coated wells. 
D. Soluble recombinant Efnb1-Fc blocked the effect of solid phase anti-Efnb1 Ab on WT 
VSMC contraction upon PE stimulation. WT VSMC were cultured in α-Efnb1 Ab-coated 
wells, in the presence of soluble Efnb1-Fc or normal human IgG (both at 10 μg/ml). Means 
+ SD of percentage contraction of these VSMC stimulated with PE (20 μM) are illustrated. 
*: significant differences (p<0.05; paired Student’s t test). 
E. Solid phase Efnb1-Fc had no effect on VSMC contraction stimulated by PE. WT 
VSMCs were cultured in Efnb1-Fc- or normal human IgG-coated wells (both at 10 μg/ml 
for coating). Percentage contraction of these VSMC stimulated with PE (20 μM) are 
illustrated. Data were analyzed with paired Student’s t test, but no significant difference 
was found. All experiments in this figure were conducted more than twice and data from 
representative experiments are shown. 
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Figure 3 Early Efnb1-mediated signaling events in VSMC stimulated by PE and AngII 
 
 
A. Normal AR and AT1R expression in Efnb1 KO VSMC. VSMC from male Efnb1 KO 
or WT mice were cultured in uncoated wells for 4 days and then stained with Abs against 
AR or AT1R as indicated. VSMC were identified with anti-α-actin Ab staining. For each 
experiment, more than 15 α-actin-positive cells were randomly selected and their total 
immune fluorescence intensity and cell size were registered. The means + SD of the 
fluorescent intensity per arbitrary cell area unit 248 of all cells examined are shown. Data 
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were analyzed with paired Student’s t test, but no significant difference was found. B. 
Normal AR and AT1R expression in WT VSMC with Efnb1 engagement. VSMC from 
male WT mice were cultured in wells coated with goat αEfnb1 Ab or normal goat IgG 
(2μg/ml during coating) for 4 days and then stained with Abs against AR or AT1R and 
analyzed as described above. Data were analyzed with paired Student’s t test, but no 
significant difference was found. C-E Normal Ca++ flux in VSMC with or without Efnb1 
engagement: VSMC from male Efnb1 KO or WT mice were cultured for four days and 
then loaded with Fura2 (5 µM). The cells were then placed in HBSS with or without 1.26 
mM Ca++ at 37oC and stimulated with PE (20 µM) or AngII 249. The ratio of emissions at 
510 nm triggered by 340 nm versus 380 nm excitation in each cell was registered every 10 
s for a duration of 5 min and the means + SD of the ratio of more than 15 randomly selected 
VSMC are shown. The arrows indicate the time point at which PE was added. C. VSMC 
from male Efnb1 KO or WT mice were cultured in normal goat IgG-coated wells for 4 
days and stimulated with PE (left panel) or AngII (right panel) in Ca++-free buffer D. 
VSMC from male Efnb1 KO or WT mice were cultured in goat αEfnb1 Ab-coated wells 
and stimulated with PE (left panel) or AngII (right panel) in Ca++-free buffer. E. VSMC 
from male Efnb1 KO or WT mice were cultured in goat αEfnb1 Ab-coated or normal goat 
IgG-coated wells and stimulated with PE (left panel) or AngII (fight panel) in Ca++-
containing buffer. All experiments in this figure were conducted more than twice and data 
from representative experiments are shown. 
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Figure 4 MLC phosphorylation and RhoA activation in VSMC  
 
A. Increased constitutive MLC phosphorylation in Efnb1 KO VSMC ex vivo. The 
mesenteric arteries of Efnb1 KO and WT mice were cleared of adventitia and 
homogenized. The proteins of these tissues were analyzed for phosphorylated MLC 
(phospho-MLC) and total MLC expression by immunoblotting, as indicated. Densitometry 
was performed to quantify the signals, and the data are expressed as ratios of phospho-
MLC versus total MLC signals (bar graph, lower panel). B. Reduced MLC phosphorylation 
in Efnb1-engaged WT VSMC: VSMC from male WT mice were cultured in wells coated 
with goat αEfnb1 Ab or normal goat IgG (2 μg/ml during coating) for four days. Total 
MLC (left panel) and phosphor-MLC, right panel) of VSMC were detected by 
immunofluorescence. The means + SD of fluorescent intensity per arbitrary cell area unit 
of more than 15 randomly selected α-actin-positive cells examined are shown in the bar 
graphs. *: significant differences (p<0.05, paired Student’s t test). C. Increased RhoA 
activation in Efnb1-engaged WT VSMC: VSMC from WT mice were cultured in wells 
coated with goat αEfnb1 Ab or normal goat IgG (2 μg/ml during coating) for four days. 
The cells were then harvested and the GTP-accociated RhoA in the cell lysates were 
determined in duplicate. The experiments were repeated twice and the results are consistent. 
A representative set of data are shown. *: significant differences (p<0.05, paired Student’s 
t test). 
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Figure 5 Grip1 in the Efnb1 reverse signling pathway 
 
 
A. Effective knockdown of Grip1, Dishevelled and PDZ-RGS3 mRNA by siRNA: VSMC 
from WT mice were transfected with 30 nM siRNA targeting Grip1, Dishevelled or PDZ-
RGS3, or with control siRNA. After additional 4-h culture, the mRNA levels of these 3 
genes were measured by RT/qPCR, and the data are expressed as the means + SD of signal 
ratios between the test genes and β-actin. B. Grip1 knockdown by siRNA partially reversed 
the inhibitory effect of solid phase αEfnb1 Ab. VSMC from WT males were cultured in 
wells coated with goat αEfnb1 Ab (2 μg/ml for coating). After 2 days, the cells were 
transfected with 30 nM siRNA targeting Grip1, Dishevelled or PDZ-RGS3, or control 
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siRNA. On day 4 of culture, the cells were stimulated with PE (20 μM) and their percentage 
contraction was registered. Means + SD of the percentage are shown. The thin line 
(indicated as Normal Contraction) represents the mean percentage contraction of VSMC 
cultured in wells coated with normal goat IgG (2 μg/ml) without siRNA transfection (for 
better visual effect, the SD of each time point in this control is omitted). C. VSCM cultured 
in uncoated wells are not affected by Grip1 siRNA in their contractility: VSMC from WT 
males were cultured in normal wells for 4 days and then transfected with Grip1 or control 
siRNA. Their contraction in response to 20 μM PE was measured. Means + SD of the 
percentage are shown. No significant statistical difference is found (Student’s t test) 
between VSMC transfected with Grip1 or control siRNA. D. Grip1 overexpression in 
VSMC led to decreased contractility. WT VSMCs were cultured for 6 days and transfected 
with pCEP4-Grip1. Cell contraction stimulated by PE (20 μM) was conducted 24 h later 
and mean ± SD of percentage contraction were shown. E. Grip1 knockdown by siRNA 
resulted in increased MLC phosphorylation in EFNB1-engaged WT VSMC. VSMC from 
WT males were cultured in wells coated with goat αEfnb1 Ab, and transfected with Grip1 
or control siRNA as described in Fig. 5D. The means + SD of fluorescent intensity per 
arbitrary cell area unit of more than 15 cells are shown in the bar graphs. All experiments 
in this figure were conducted more than twice and data from representative experiments 
are shown. *: significant differences (p<0.05, paired Student’s t test). 
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Figure 6 GTP-associated RhoA expression and vasoconstriction of Efnb1 KO mesenteric 
arteries 
 
A. Activated RhoA in Efnb1 mesenteric arteries: The mesenteric arteries of Efnb1 KO and 
WT mice were cleared of adventitia and homogenized. The proteins of these tissues were 
analyzed for GTP-associated RhoA levels in duplicate. The experiment was repeated twice, 
and data of a representative one are shown as Mean + SD of GTP-RhoA concentration per 
µg total protein. *: p< 0.05 according to paired Student’s t test. B. Contractility of 
mesenteric arteries from Efnb1 KO and WT mice following PE stimulation. Segments (2 
mm) of the third-order branch of the mesenteric artery with endothelium or with 
endothelium removed were stimulated with PE. A single cumulative concentration-
response curve to PE 250 was obtained. The maximal tension (Emax) was determined by 
challenging the vessels with a physiological saline containing 127 mM KCl. Vessel 
contractility is expressed as percentage of the Emax. Data from three mice per group were 
pooled and Mean + SE are shown. There is no significant difference between KO and WT 
vessels (paired Student’s t test).  
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Figure 7 Blood pressure and heart rate of Efnb1 KO mice 
 
A and B. Male Efnb1 KO mice in the C57BL/6 background (F10) on a normal diet or high-
salt diet presented normal BP and HR: A. Mice 251 were on a normal diet. B. Mice (21 week 
old) were on a high salt diet for 3 weeks. BP and HR were measured for 3 days by telemetry 
starting at least 7 days after transmitter implantation. For mice on a high-salt diet, BP and 
HR were measured 3 weeks after the initiation of the high-salt diet. Number per group is 
indicated. Values are expressed as mean 24-h BP and HR for each day ± SE. SP: systolic 
pressure; DP: diastolic pressure; MAP: mean arterial pressure; HR: heart rate. C. Male 
Efnb1 KO mice (after 10 generations of backcrossing to the C57BL/6 background) on a 
high-salt diet under immobilization stress presented augmented increment of BP: SP, DP, 
MAP and HR of 21-week-old male Efnb1 KO and WT mice (number per group is indicated) 
were on a high-salt diet for 3 weeks, and their BP and HR were recorded by telemetry 
during 30-min immobilization stress. The data are expressed as means + SE of increments 
(Δ) of SP, DP, ∆MAP, and HR. ∆SP, ∆DP, ∆MAP and ΔHR are calculated as follows: Δ 
= value during stress – value during the resting period. D. Male Efnb1 KO mice (after 5 
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generations of backcrossing to the C57BL/6 background from the 129/sv X C57BL/6 
background) on a high-salt diet under immobilization stress presented augmented 
increment of BP. SP, DP, MAP and HR of 16-week-old male Efnb1 KO and WT mice 
(number per group is indicated) on a high-salt diet for 3 weeks were recorded by telemetry 
during 30-min immobilization stress. ∆SP, ∆DP, ∆MAP and ∆HR are shown. Data in this 
figure were analyzed by unpaired t test and repeated-measures ANOVA, and the p values 
are shown. * indicates p<0.05. 
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Figure 8 Normal urine and plasma hormone levels in Efnb1 KO and WT mice 
 
A. Twenty-four-h urine catecholamine levels after stress in male Efnb1 KO mice. Male Efnb1 
KO and WT mice were placed in metabolic cages without prior stress or immediately after 
immobilization stress. Urine was collected during a 24-h fasting period. Urinary catecholamines 
were measured by ELISA. Mouse number per group and means + SD of the hormones in 24-h 
urine are presented. No statistically significant difference was found (Student’s t test) between 
KO and WT mice. B. Plasma AngII levels in male Efnb1 KO and WT mice. Plasma AngII of 
male Efnb1 KO and WT mice was measured by ELISA. Mouse numbers per group and mean + 
SD of the hormone concentrations are shown. No statistically significant difference was found 
(Student’s t test) between the KO and WT mice.  
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Abstract 
EPH receptor tyrosine kinases and their ligands, ephrins (EFNs), fulfill vital and diverse 
functions in various tissues and organs. In the present study, we reported that Efnb3 plays a 
novel role in controlling vascular tone and blood pressure (BP) through reverse signalling. Efnb3 
gene knockout (KO) in female mice elevated BP and small artery resistance in vivo, enhanced 
small arterial contractility ex vivo, and augmented vascular smooth muscle cell (VSMC) 
contractility in vitro. At the molecular level, VSMC from female KO mice showed heightened 
myosin light chain (MLC) phosphorylation compared to their wild type (WT) counterparts, 
corroborating increased VSMC contractility. MLC kinase and MLC phosphatase 
phosphorylation in female KO VSMC was lower than in WT controls, and such reduction is 
known to enhance MLC phosphorylation. However, all these abnormalities were not observed 
in male KO mice or tissues from male KO mice, suggesting that these phenotypes are sex 
hormone-dependent. When female KO mice were ovariectomized, they lost their hypertensive 
phenotype, whereas estrogen increased VSMC contractility in male KO but not WT mice. These 
results indicate that estrogen promotes VSMC contractility, and hence BP, in the absence of 
Efnb3. Although male KO mice had normal BP, castration led to its significant elevation in KO 
but not in WT mice. However, castration did not increase KO vessel contractility, and 
exogenous testosterone did not decrease it in female KO mice. The results suggest that 
testosterone does not intrinsically repress BP elevation, but needs to work in concert with Efnb3 
deletion to achieve such an effect, and this regulation by Efnb3/testosterone occurs in target 
tissues/organs other than VSMC. 
We further demonstrated that cross-linking VSMC from WT mice with solid-phase anti-Efnb3 
antibody (Ab) reduced their contractility, while solid-phase recombinant Efnb3 had no impact, 
indicating that Efnb3 acts through reverse signalling to dampen VSMC contractility. We also 
discerned that Grip1, an adaptor protein, was critical in mediating Enb3 reverse signalling in 
VSMC.  
To validate the relevance of our findings in humans, we targeted 522 single nucleotide 
polymorphisms (SNPs) within 4 genes in the EPH/EFN signalling system, i.e., EPHB6, 
EFNBb2, EFNB33 and GRIP1, to query the International Blood Pressure Consortium dataset, 
which contains SNP information on 69,395 individuals of European ancestry in 29 general 
population-based cohorts. The minimum p-value (0.000389) for tag SNPs within GRIP1 gene 
 141 
was 0.000389 for its association with diastolic BP. It approaches the critical p-value of 0.000302 
(or 0.000151 based on overly conservative correction). GRIP1 is situated in a node where 
Ephb/Efnb reverse signalling pathways converge, and thus probably carries more weight for the 
detection of association(s) with BP phenotypes. Such a result is quite promising, considering 
that the analysis is not based on stratification of gender and sex hormone levels,  
Our study reveals previously unknown sex hormone-dependent EFNB3 functions in 
hypertension.  
 
Introduction 
Eph kinases are the largest family of receptor tyrosine kinases. They are divided into A and B 
subfamilies according to sequence homology 252. Ephrins (Efns), which are also cell surface 
molecules, are ligands of Ephs. Efns are classified as A and B subfamilies. A subfamily 
members attach to the cell surface through glycosylphosphatidylinositol anchoring, whereas B 
subfamily members attach through transmembrane tails 253-255. Interactions among Ephs and 
Efns are promiscuous but, in general, Epha members interface preferentially with Efna 
members, and Ephb members with Efnb members 254-256. Such redundancy suggests that these 
kinases are crucial in various biological contexts. Efns can stimulate Eph receptors, and this is 
called forward signalling. Interestingly, Ephs are also capable of stimulating Efns which then 
transmit signalling reversely into cells, a phenomenon known as reverse signalling.  
Ephs and Efns are expressed in many tissues and organs. They play important roles in the central 
nervous system 254, 255, immune system 257, 258, digestive system 259, 260, bone metabolism [16,17], 
angiogenesis [18] and other processes 261-263. 
Until recently, few studies assessed the role of Ephs and Efns in vascular smooth muscle cell 
(VSMC) function. VSMC with Efnb2 deletion show compromised migration 264. In cultured rat 
and human VSMC, Efna1 triggers Epha4 signalling and actin stress fiber assembly 265.  Whether 
such signalling elicits changes in VSMC contractility has not been investigated.  
We recently reported that Ephb6, in concert with sex hormones, is crucial in VSMC contraction 
and blood pressure (BP) regulation 266. VSMC are a target tissue through which Ephb6 exerts 
its effect on BP control. Since Ephb6 and all its major ligands of the Efnb family, i.e., Efnb1, 
Efnb2 and Efnb3, are expressed in VSMC [24], there is a molecular framework for their function 
in these cells. We showed that while solid-phase recombinant Ephb6 reduces VSMC contraction 
 142 
in response to phenylephrine (PE) stimulation, solid-phase anti-Ephb6 antibody (Ab) does not 
266, indicating that reverse signalling from Ephb6 to Efnbs but not forward signalling from Efnbs 
to Ephb6 is responsible for dampening VSMC contractility. Corroborating this finding, mice 
expressing tailless Ephb6 (Ephb6 without intracellular domains) were normotensive, and their 
VSMC acted similarly to wild type (WT) VSMC upon exposure to PE [24].  
Unlike males, small arteries freshly isolated from Ephb6 knockout (KO) females show increased 
contraction force upon PE stimulation compared to their WT counterparts. However, small 
arteries from castrated male Ephb6 KO mice become more contractile than those of WT controls 
266, demonstrating that Ephb6 acts in concert with sex hormones to regulate blood vessel tone. 
Despite increased vessel contractility in female Ephb6 KO mice they remain normotensive, 
likely due to compensatory BP control mechanisms. On the other hand, castrated Ephb6 KO 
mice become hypertensive 266, probably owing to loss of male sex hormone-dependent 
compensatory mechanisms. Indeed, 24-h urinary catecholamine levels are diminished in non-
castrated Ephb6 KO males, and such reduction is lost upon castration 266. Thus, adrenal gland 
chromaffin cells are the second target tissue of Ephb6 with regard to its role in BP control. 
Therefore, we identified Ephb6 and, by logical extension, its ligands (Efnbs) as novel BP 
regulatory factors. 
Ephb6 has 3 major ligands, namely, Efnb1, Efnb2 and Efnb3. In the present study, we 
discovered that Efnb3 KO in mice resulted in similar but not identical BP phenotypes as those 
in Ephb6 KO mice, suggesting that at least a part of Ephb6’s observed effect in BP regulation 
occurs via its reverse signalling through Efnb3. We targeted single nucleotide polymorphisms 
(SNPs) from the EPHB/EFNB system to query the International Blood Pressure Consortium 
(IBPC) dataset, which contains SNP information on 69,395 individuals, and found that a SNP 
in the EPHB/EFNB signalling pathway approached statistical significance for association with 
diastolic blood pressure (DP).  
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Materials and Methods 
 
Efnb3 KO mice 
Efnb3 KO mice were produced by Regeneron Pharmaceuticals, as described previously 267, and 
generously provided to us. They had been backcrossed to the C57BL/6 background for more 
than 10 generations. Age- and gender-matched WT littermates or C57BL/6 mice served as 
controls and are referred to as WT mice.  
 
VSMC isolation 
Mouse VSMC were isolated from aortic and mesenteric arteries, including their secondary 
branches as described before 266, 268.  
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
Efnb3 mRNA levels in VSMC were measured by RT-qPCR 266, 268. β-actin mRNA served as 
internal control. Samples were tested in triplicate, and the data expressed as signal ratios of test 
gene mRNA/β-actin mRNA. 
 
Immunofluorescence microscopy 
VSMC surface Efnb3, α1-adrenergic receptor (AR) and intracellular α-actin expression were 
studied by immunofluorescence microscopy 266, 268. Stained cells were examined under a Zeiss 
microscope. AR expression was quantified by ascertaining the fluorescence of more than 15 
cells, and the data were expressed as arbitrary intensity per unit cell surface area (pixel) by Zeiss 
AxioVision software. 
 
BP measurement 
Systolic and diastolic BP (SP and DP) and heart rates (HR) of conscious mice were monitored 
by radiotelemetry 266, 268. Raw data were processed with the Dataquest A.R.T.-Analysis program 
269, and presented as means ± SE. Statistically significant differences between the experimental 
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groups were evaluated by unpaired t test and repeated-measures analysis of variance (ANOVA). 
P<0.05 values were considered to be statistically significant. 
 
Echocardiography 
Transthoracic echocardiography was undertaken in mice lightly anesthetized with isoflurane. 
Their carotid vessels and heart were imaged with a high-resolution ultrasound biomicroscope 
(Vevo770; Visualsonics, Toronto, ON, Canada) equipped with a 100% bandwidth 30-MHz 
central frequency transducer (RMV-707, 12.7 mm focal length, 6 mm aperture). Lateral and 
axial resolutions with this probe are ~115 μm and ~55 μm, respectively 270. Preheated ultrasound 
transmission gel (Aquasonic 100, Parker Laboratories, Orange, NJ, USA) was placed on regions 
of interest to provide acoustic coupling medium between the transducers and animals. The left 
and right common carotid arteries were imaged longitudinally in B mode to guide recordings of 
Doppler time-varying flow velocities for 2 s. Doppler sample volume was positioned 1-2 mm 
prior to the carotid bifurcation at a 60o angle. Acquired angle-corrected Doppler data were 
analyzed to measure the mean Pourcelot index (PI) over 10 consecutive cardiac cycles, 
according to Stoyanova et al. 271. The PI is a dimensionless echographic parameter that 
characterizes vascular hemodynamics downstream of a measurement point, i.e., the 
hemodynamics of vascular brain and facial networks. It depends on both arterial compliance 
and downstream vascular resistance. 
The heart was also imaged in B mode via the parasternal long-axis view to assess aortic 
hemodynamics and cardiac output (CO). The M-mode sampling line was positioned 
perpendicularly to the ascending aorta, 0.5-1.5 mm downstream of the aortic valve, and time-
varying tracings tracked changes in aortic diameter (AoD). Mean AoD was assessed over 5 
consecutive cardiac cycles. Doppler velocity waveforms were then recorded in the ascending 
aorta by positioning sampling volume at the exact same location where M-mode tracings were 
obtained. The envelope of angle-corrected (60o) Doppler tracings was delineated manually to 
compute the velocity time integral (VTI), which was averaged over 10 cardiac cycles. Assuming 
a parabolic velocity profile in the ascending aorta 271, stroke volume (SV) was calculated (in ml) 
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as ½ (AoD / 2)2 × π × VTI, and CO (in ml/min) was estimated as SV  HR, where HR was 
mean HR of the animals. 
Left ventricle (LV) dimensions (in mm) at end-systole and end-diastole were finally assessed to 
quantify fractional shortening, ejection fraction and LV mass. B-mode parasternal long-axis 
viewing guided the capture of M-mode tracings through the anterior and posterior LV walls at 
the level of the papillary muscle. For each mouse, LV end-diastolic diameter (LVEDD), LV 
end-systolic diameter (LVESD), LV end-diastolic posterior wall thickness (LVEDPW) and 
intra-ventricular septum dimension at end-diastole (IVSED) were quantified, and LV mass 
ascertained in mg with the following equation 272, 273: 
LV mass (mg) = 1.055  [(LVEDD + LVEDPW + IVSED) – LVEDD] 
 
Ex vivo vessel constriction 
Vessel constriction was studied ex vivo 266, 268, 274. Briefly, mesenteric artery segments of third-
order branches were stripped off the endothelium and stretched to optimal tension at 37°C. 
Single cumulative concentration-response curves were charted on exposure to the AR agonist 
PE. At the end of the protocol, maximal tension (Emax) was quantified with a solution 
containing 127 mM KCl. The data are expressed as percentages of Emax. Concentration-
response curves were compared by Student’s t test .  
 
VSMC contractility 
VSMC contractility was measured 266, 268 273, 
and photographed continuously for 15 min at a rate of 1 picture per min. Fifteen or more cells 
were randomly selected, and their length was measured at each time point with Zeiss Axiovision 
software. Percentage contraction was calculated as follows: 
% contraction = 100 x (cell length at time 0 – cell length at time X) / cell length at time 0.  
Statistically significant differences were assessed by Student’s t test.  
 
Ca++ flux 
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PE-stimulated Ca++ influx in VMSC was measured by immunofluorescence microscopy 266, 268. 
Briefly, VSMC were loaded with Fura-2-AM, stimu 273 at 37oC and 
imaged for 60 s at a rate of 1 picture per 3 s. Excitation wavelengths were switched between 
340 nm and 380 nm, and emission wavelength was 510 nm. Signals from more than 15 randomly 
selected cells were recorded, and the results expressed as ratios of fluorescence intensity at 510 
nm excited by 340 nm versus 380 nm. 
 
Immoblotting 
VSMC from the aorta and mesenteric arteries of WT and KO mice were isolated and cultured 
for 3-4 days. After , all the VSMC were lysised by RIPA273, 
273 . Phosphorylated myosin light chain (MLC) and total MLC of VSMC were measured by 
immunoblotting as described in our publications 266, 268. Phosphorylated and total MLC kinase  
(MLCK) and MLC phosphatase (MLCP) of the VSMC were similarly measured, using rabbit 
anti-MLCK mAb (clone EP1458Y; Abcam, Cambridge, UK), rabbit anti-phospho-MLCK Ab 
(Invitrogen, Camarillo, CA), rabbit anti-MLCP Ab (#2634; Cell Signalling, Danvers, MA), and 
rabbit anti-phospho-MLCP Ab (#5163; Cell Signalling). For AR detection, VSMC were used 
-AR (ab3462; Abcam) was used for blotting. 
 
Urinary catecholamines 
Twenty four-hour urine under a fasting condition were collected and urinary catecholamines 
were assayed by catecholamine ELISA kit (Rocky Mountain Diagnostics, Colorado Springs, 
CO, USA) according to the manufacturer’s instructions. 
Plasma angiotensin II (AngII) 
Plasma AngII was measured by ELISA (Phoenix Pharmaceuticals, Burlingame, CA, USA) 
according to the manufacturer’s instructions. Samples were in duplicate.   
 
Serum aldosterone 
Mouse serum aldosterone was measured by HPLC in the CHUM Clinical Endocrinology 
Laboratory with certified quality control for human serum aldosterone levels.  
 
Meta-analysis of SNPs in Eph/Efn and related genes associated with BP phenotypes in humans 
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The p-values for association with DP and SP were calculated for a total of 528 SNPs found 
within the regions of 4 genes (EPHB6, EFNB2, EFNB3 and GRIP1) and within 10 kb 5’ and 3’ 
of these genes, employing the LocusZoom genome browser [33] to query the ]IBPC dataset [34], 
which contains SNP information on 69,395 individuals of European ancestry in 29 general 
population-based cohorts. These 528 SNPs represented 166 independent linkage disequilibrium 
(LD) blocks, as determined by the Tagger program [35] on the HapMap website [36]. Table 1A 
lists the genes and regions in which the SNPs are located. Query of 166 independent LD blocks 
resulted in a Bonferroni-corrected critical p-value of 0.0003012 for a given BP phenotype (SP 
or DP). Looking for the best results between DP and SP phenotypes would require a lower 
critical p-value; however, correcting for 2 X 166 tests (p=0.000151) would be overly 
conservative as these 2 measurements are not independent. 
 
Results 
 
Efnb3 KO mice 
RT-qPCR demonstrated that Efnb3 mRNA was virtually absent in endothelium-stripped 
mesenteric arteries from Efnb3 KO mice (Fig. 1A). Efnb3 KO was also confirmed at the protein 
level in isolated Efnb3 KO VSMC by immunofluorescence microscopy (Fig. 1B). 
Efnb3 regulates BP in concert with sex hormones 
Our previous study showed that BP is heightened in castrated Ephb6 KO mice compared to their 
WT counterparts [24]. As in this case Ephb6 acts through Efnb reverse signalling [24], and 
Efnb3 is a ligand of Ephb6, we investigated whether Efnb3 KO mice had abnormal BP 
phenotype(s). The BP of Efnb3 KO and WT mice was measured by radiotelemetry. The SP, DP, 
mean arterial pressure (MAP) and HR of male KO mice showed no significant differences from 
their WT controls (Fig. 2A). However, female KO mice presented significantly elevated SP, DP 
and MAP compared to WT females (Fig. 2B).  
The fact that BP is increased in female but not male KO mice suggests that Efnb3 works in 
concert with sex hormones to achieve its BP-regulating effects. We asked whether estrogen 
enhanced or testosterone reduced BP in the absence of Efnb3. Male mice were castrated, and 
females, ovariectomized, then rested for 3 weeks to wane sex hormone levels. As illustrated in 
Figure 2C, after castration, the BP of male KO mice was significantly higher than that of their 
 148 
WT counterparts, indicating that testosterone was repressing BP up-regulation in the absence of 
Efnb3. On the other hand, Efnb3 KO females became normotensive after ovariectomy (Fig. 2D), 
suggesting that estrogens were promoting BP up-regulation in the absence of Efnb3. It should 
be noted that castration and ovariectomy of WT mice did not affect BP (data not reported). 
Therefore, Efnb3 needs to work in concert with sex hormones to achieve its BP-regulating 
effects.  
In these experiments, the HR of male and female KO mice was always similar to that of their 
WT counterparts, ruling out the possibility that BP anomalies in KO females and castrated males 
derive from differences in CO. This point was further verified by echography (see next section). 
 
Small artery resistance in vivo  
BP is a function of CO, blood volume and blood vessel flow resistance, the latter being mainly 
determined by the tone of small arteries. Echography was employed to examine CO, the PI (a 
parameter reflecting blood flow resistance) of carotid arteries, and LV mass in live KO and WT 
mice. CO in male (Table 2A) and female (Table 2B) KO mice was comparable to that in WT 
controls, indicating that this parameter, which could affect BP, is not under the influence of 
Efnb3 and is not responsible for elevated BP in female KO mice. However, the left carotid PI 
in female KO (Table 2B) but not male KO (Table 2A) mice was significantly boosted 
(p=0.0218), reflecting heightened resistance of these small arteries. LV mass increased 
significantly in female but not in male KO mice (p=0.0397, Table 2B). This hypertrophy might 
be the result of augmented cardiac workload in female KO mice to overcome the heightened 
blood flow resistance of their small arteries. 
 
Increased vessel contractility of female KO mice ex vivo 
The echography results of in vivo studies pointed to vessel flow resistance as an intermediate 
cause of elevated BP in female KO mice. We next attempted to confirm this finding ex vivo and 
further pin-point target cell types (e.g., endothelial cells and VSMC) through which Efnb3 
exerted its effect. The ex vivo contractility of mesenteric arteries from KO and WT mice was 
assessed after stimulation with PE. Female but not male KO vessels showed greater contractility 
than their WT counterparts (Figs. 3A and 3B). This contractility phenotype remained unchanged 
in the presence or absence of endothelium (Figs. 3A and 3B), indicating that VSMC but not the 
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endothelium were the target and that nitric oxide or endothelin produced by the endothelium 
was not required to enhance vessel contractility in the absence of Efnb3. Castration did not 
change vessel contractility in male KO mice, as KO vessels remained similar to their WT 
counterparts in terms of contractility. On the other hand, vessels from ovariectomized female 
KO mice lost their hyper-contractility, becoming similar to those of WT controls. Such a change 
of the contractility of female KO vessels before and after ovariectomy is reminiscent of the BP 
phenotype of KO females. The discrepancy between unchanged vessel contractility and 
increased BP after castration in KO males will be discussed later.  
 
Efnb3 modulates VSMC contractility in concert with sex hormones and through reverse 
signalling  
Data on vasoconstriction in the previous section identified VSMC as the target tissue of Efnb3 
deletion. We tried to confirm this finding in single VSMC. When VSMC were stimulated with 
PE, those derived from female – unlike male – Efnb3 KO mice showed increased contractility 
compared to their WT coiunterparts (Figs. 4A and 4B), confirming that Efnb3 deletion in 
females leads to augmented VSMC contractility.  
Differential contractility between VSMC from female and male KO mice as well as the effect 
of castration and ovariectomy on BP in Efnb3 KO mice prompted us to assess whether they 
were the target tissues of sex hormones in the absence of Efnb3. To answer this question, VSMC 
from male KO and WT mice were cultured in the presence of exogenous estrogen. KO VSMC 
contractility increased in comparison to WT controls (Fig. 4C). On the other hand, male WT 
VSMC contractility remained unchanged in the presence or absence of exogenous estrogen. 
This result corroborates the hypertensive phenotype of female KO mice, and indicates that 
VSMC are a target of concerted Efnb3 and estrogen effects: Efnb3 deletion in the presence of 
estrogen enhances VSMC contractility and, hence, increases vascular tone and BP.  
On the other hand, VSMC contractility in female KO mice was not repressed by exogenous 
testosterone (Fig. 4D). This finding is not compatible with the BP phenotype of castrated KO 
males, in which reduced testosterone levels combined with Efnb3 KO raised BP. Possible 
explanations are given in the Discussion.  
In theory, Efnb3 deletion could affect both forward (from Efnb3 through Ephbs) and reverse 
(from Ephbs through Efnb3) signalling in VSMC. To distinguish these 2 possibilities, we placed 
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VSMC from WT females on wells coated with solid-phase anti-Efnb3 Ab (to trigger reverse 
signalling) and found that their contractility was significantly reduced (Fig. 4C, line with solid 
squares). However, solid-phase Efnb3-Fc (to trigger forward signalling) did not significantly 
affect VSMC contractility (Fig. 4E, line with triangles), suggesting that reverse signalling via 
Efnb3 but not forward signalling from Efnb3 to Ephs decreases VSMC contractility. Solid-phase 
anti-Efnb3 Ab also reduced VSMC contractility in male WT mice (Fig. 4F), although male KO 
and WT had similar values (Fig. 4B). Possible explanations of these findings are presented in 
the Discussion. 
 
Normal AR expression and Ca++ flux in KO VSMC 
We asked whether Efnb3 deletion modulated AR expression or Ca++ flux in VSMC, as both 
these events can affect VSMC contractility. AR expression in KO VSMC from male and female 
mice was similar to that in WT controls (Fig. 5A), according to immunofluorescence 
microscopy and confirmed by immunoblotting (Fig. 5B). PE-stimulated Ca++ flux in KO 
VSMC from males and females was not different from that in WT mice (Fig. 5C). These results 
indicate that Efnb3 does not affect VSMC contractility through modulation of AR expression 
or Ca++ flux-related ion channels. 
 
Efnb3 KO affects signalling pathways related to VSMC contractility 
Since there was no difference in Ca++ flux in VSMC from female KO mice compared to WT 
females, increased contractility of the small arteries and VSMC from female KO mice was likely 
due to heightened Ca++ responsiveness of VSMC, which is regulated by MLC phosphorylation. 
Female KO mice arteries indeed manifested a significantly higher degree of MLC 
phosphorylation than their WT counterparts immediately (3 s) after PE stimulation (Fig. 6A). 
On the other hand, such MLC phosphorylation in male KO arteries was similar to that in WT 
controls, consistent with our findings that female but not male KO small arteries presented 
increased contractility compared to WT. 
MLC is phosphorylated by MLCK which is, in turn, phosphorylated at ser1760 by Ca++/CaM-
dependent protein kinase II or protein kinase A, and such phosphorylation reduces MLCK 
enzymatic activity [37,38] We assessed MLCK phosphorylation at ser1760 and observed that 
VSMC from female but not male KO mice had significantly lower values upon PE stimulation 
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than WT controls (Fig. 6B). This result implies higher MLC phosphorylation in VSMC from 
female KO mice, compatible with the finding that female VSMC presented augmented 
contractility.  MLC phosphorylation is also modulated by MLCP, which dephosphorylates MLC 
and reduces VSMC contractility [39]. MLCP phosphorylation at T695 prevents MLCP binding 
to MLC and thus diminishes the effect on its substrate [40]. We investigated the outcome of 
Efnb3 deletion on MLCP phosphorylation in VSMC. Immediately after PE stimulation (3 s), 
MLCP phosphorylation at T695 in VSMC from both female  and male KO mice was similar to 
that of their WT counterparts (Fig. 6C). This observation suggests that MLCP is not influenced 
by Efnb3 deletion and does not participate in the contractility upregulation of female KO arteries.  
Efnb3 had no enzymatic activity. However, Efns engage adaptor proteins to link their 
intracellular tails to various signalling pathways. Small interference RNAs (siRNAs) were 
deployed to knock down the expression of 3 adaptor proteins, i.e., Grip1, PDZ-RGS3 and 
Disheveled, which are known to associate with Efnbs [41-43]. The effectiveness of mRNA 
knockdown was verified by RT-qPCR (Fig. 7A). VSMC from female WT mice were cultured 
in wells coated with anti-Efnb3 Ab to invoke Efnb3 reverse signalling, dampening VSMC 
contractility. With Grip1 siRNA but not PDZ-RGS3 or Dishevelled siRNA transfection into 
these cells, the inhibitory effect of Efnb3 reverse signalling was released and they showed 
increased contractility compared to those transfected with control siRNA (Fig. 7B). This result 
indicates that Grip1 is involved in Efnb3 reverse signalling which regulates VSMC contractility.  
 
BP-related hormone levels in Efnb3 KO mice 
We questioned whether some key hormones involved in BP regulation were affected by Efnb3 
null mutation directly or as a compensatory consequence. As depicted in Figure 8A, 24-h urinary 
catecholamine (i.e., adrenaline, dopamine and noradrenaline) levels of male and female KO 
mice were similar to those in their WT counterparts during fasting, showing that ambient 
catecholamine secretion in KO mice is not altered. Plasma AngII levels in male and female KO 
mice were also comparable to those in their WT counterparts (Fig. 8B). Thus, these hormones 
are not the cause of increased vessel resistance and BP in female KO mice. The serum 
aldosterone levels of male and female KO mice were all significantly lower than those of WT 
controls (Fig. 8C). Decreased aldosterone levels in female KO are expected, likely a 
compensatory mechanism that enhances sodium excretion to reduce blood volume due to higher 
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BP in these mice. Possible reasons for decreased aldosterone levels in male KO mice are 
discussed later. 
 
SNPs in genes of the EPH/EFN system associated with BP phenotypes 
Our findings in this and previous studies [24,26]. along with some of our unpublished 
observations indicate that molecules in the EphB and EfnB families (e.g., EphB6, EfnB1, EfnB2, 
EfnB3) and a certain adaptor protein (Grip1) in their signalling pathways are novel factors that 
can modulate BP in mice. The relevance of these results in human BP regulation was 
investigated. The IBPC conducted a meta-analysis of genome-wide association scanning 
(GWAS) in 69,395 individuals of European ancestry in 29 cohorts from European and North 
American countries [34]. Two and a half million genotyped or imputed SNPs were tested for 
their association with SP and DP in these individuals. We queried the results of this meta-
analysis for association of 528 SNPs in EPHB6, EFNB2, EFNB3 and GRIP1 genes with DP and 
SP in these individuals. EFNB1 was not included in the analysis because it is an X-linked gene, 
and its SNP information is not included in the IBPC dataset. The p-values of these SNPs for 
their association with SP and DP are illustrated in Supplementary Figure 1 plots. Table 1B 
summarizes the names of SNPs with the most significant association and their p-values. The 
minimum p-value (0.000389) for tag SNPs within GRIP1 gene occurs with SNP rs1495496 for 
its association with DP. This value approaches the critical p-value of 0.000302 (or 0.000151 
based on overly conservative correction considering BP and DP as 2 totally independent 
phenotypes, which they are not). For the other 3 genes analyzed, i.e., EPHB6, EFNB2 and 
EFNB3, the minimum p-values of their SNPs did not approach the critical p-value. The 
implications of these findings are elaborated in the Discussion. 
 
Discussion 
 
Ephs and Efns perform critical functions in many tissues and organs. In our recent studies, a 
novel role for Ephs and Efns in BP regulation was discovered in Ephb6 KO and Efnb1 KO mice 
266, 268. In the current investigation, we provide additional evidence in support of the notion that 
Eph/Efn family members are essential in BP control. We demonstrated that, after Efnb3 deletion, 
small arterial resistance is increased in these mice in vivo, and that VSMC and the small arteries 
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from female Efnb3 KO mice showed heightened responsiveness to vasoconstrictive stimuli ex 
vivo and in vitro. As a result, female Efnb3 KO mice had higher BP than WT females. At the 
molecular level, Efnb3 deletion in female mice decreased MLCK and MLCP phosphorylation 
in VSMC, both of which augmented MLC phosphorylation and, hence, VSMC contractility.  
Our data consistently pointed to hyper-responsiveness of female Efnb3 KO VSMC and small 
arteries, suggesting that they are target tissues for Efnb3 function in BP regulation. However, 
Efnb3 deletion depends on female sex hormones to achieve BP control and VSMC contractility. 
Reduction of female sex hormones by ovariectomy led to disappearance of the BP increase in 
female KO mice and return of their vessel contractility to the WT level ex vivo. The enhancing 
effect of female sex hormones, in this case estrogen, only occurs in the absence of Efnb3 with 
regard to VSMC contractility, in that male KO VSMC showed increased contractility in the 
presence of exogenous estrogen, while estrogen by itself did not affect it in WT males. How 
estrogen influences the Efnb3 reverse signalling pathway in VSMC is currently unknown, and 
is under investigation in our laboratory. 
It has become clear that VSMC in male mice are not a target tissue of Efnb3 in terms of its 
function in BP control. Male KO mice had normal BP and vessel tone in vivo; their small arteries 
showed normal contractility and MLC phosphorylation ex vivo. VSMC from male KO mice 
presented contractility and MLCK phosphorylation similar to values of their WT counterparts. 
This is not due to a suppressive effect of testosterone on Efnb3 function regarding VSMC 
contractility, because adding exogenous testosterone to female KO VSMC did not reduce it. We 
also tested vessel and VSMC contractility in castrated KO mice, but these parameters did not 
increase in comparison to non-castrated animals (Fig. 3C and data not included), ruling out the 
possibility that testosterone inhibits VSMC contractility in the absence of Efnb3. The fact that 
castrated KO mice manifested augmented BP compared to their WT counterparts indicates that 
Efnb3 can indeed act in concert with testosterone to regulate BP, but the target of the duo under 
physiological conditions is outside VSMC. It should be mentioned that VSMC from male WT 
mice still responded to Efnb3 reverse signalling by reducing their contractility when they were 
cross-linked by solid-phase anti-Efnb3 Ab (Fig. 4F). This suggests that male VSMC could still 
be subject to the effect of non-physiologically strong Efnb3 reverse signalling. However, in vivo, 
stimulation from Ephs to Efnb3 on VSMC in vessels is probably not as strong as artificial in 
vitro cross-linking by solid-phase anti-Efnb3 Ab, and that is why we did not observe any 
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phenotype in male KO mice in BP and echographic studies in vivo and vessel contraction ex 
vivo.  
We reported previously that chromaffin cells in the adrenal glands are a second target tissue in 
male Ephb6 KO mice, after VSMC, in terms of Ephb6’s effect on BP regulation. Catecholamine 
synthesis and/or secretion are repressed in Ephb6 KO males. As a result, these male Ephb6 KO 
mice remain normotensive due to the compensatory reduction of catecholamines [24]. Once 
testosterone is reduced by castration, the compensation is lost, catecholamine levels return to 
normal, and the mice become hypertensive 266. As Efnb3 is a ligand of Ephb6, as the latter acts 
through reverse signalling to achieve its BP-regulating effect, and as BP increases similarly in 
Ephb6 and Efnb3 KO males after castration, we wondered whether adrenal gland chromaffin 
cells are another target tissue of Efnb3. However, we did not detect any change in ambient 
catecholamine levels in male Efnb3 KO mice based on their 24-h urinary catecholamine levels, 
indicating that chromaffin cells in the adrenal glands are not a target tissue of Efnb3 and that the 
testosterone-dependent compensation mechanism in catecholamine synthesis/secretion in male 
Ephb6 KO mice is mediated by ligands other than Efnb3.  
We noted a significant decrease in serum aldosterone levels in both male and female Efnb3 KO 
mice, probably a feedback response to cope with increased BP tendency. Reduced aldosterone 
levels in female KO mice are fully understandable, because of their elevated BP. However, 
decreased aldosterone levels in male Efnb3 KO mice, albeit their normal BP, suggest a trend 
towards heightened BP, but it did not change probably because of sufficient compensation by 
mechanisms such as aldosterone reduction, which then diminishes sodium and water re-
absorption from distal tubules and collecting ducts of nephrons into blood. In this case, the 
increased BP tendency in male KO mice is likely caused by so-far uncharacterized Efnb3 target 
tissues/organs other than VSMC, as alluded to earlier in this discussion.  
BP is a vital physiological parameter and, not surprisingly, multiple compensatory mechanisms 
are engaged once fluctuation tends to occur. These compensatory mechanisms have to be 
disabled before the BP phenotype becomes obvious. Previously, we identified catecholamine 
synthesis and/or release as such a mechanism in Ephb6 KO mice. There is also one in male 
Efnb3 KO mice, but its nature has not been revealed. An interesting feature of these 
compensatory mechanisms is that they act in concert with sex hormones, and male hormone 
seems to be essential for them. In other words, male hormone is protective against hypertension; 
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the results in both Ephb6 KO and Efnb3 KO mice are similar although not identical in pointing 
to this conclusion: in both types of KO mice, castration leads to hypertension in males. It is 
known that ageing male humans have higher incidence of hypertension. Our finding points to a 
possibility that in a subpopulation of hypertensive ageing males, the increased BP could be 
caused by the EPH/EFN signalling pathway defects, which only start to have BP manifestation 
once male sex hormone level decreases. On the other hand, estrogen is culpable for elevated BP 
in the absence of Efnb3. Such results suggest that if we decide to assess genes in the EPH/EFN 
family as hypertension risk factors, we need to consider not only gender but also sex hormone 
levels to filter out “noises”.  
As for the Efnb3’s effect on VSMC contractility regulation, we determined that it depends on 
reverse signalling via Efnb3 into cells. Efnb3 intracellular tails have no enzymatic activity, but 
are capable of binding to several adaptor proteins, such as Grip1, PDZ-RGS3 and Dishevelled 
[41-43]. Among these 3 molecules, we found that Grip1 is critically required for Efnb3 function, 
in that Grip1 knockdown by siRNA can reverse the dampening effect of solid-phase anti-Efnb3 
Ab on VSMC contractility. Grip1 has 5 PDZ domains [41] which can associate with signalling 
molecules that contain PDZ-binding domains and thus mediate Efn reverse signalling. This 
molecule, since it can physically bind to Efnb3 [41], seems to be the most proximal in the Efnb3 
reverse signalling pathway. We have also pin-pointed defects in MLC phosphorylation in Efnb3 
KO VSMC, which determines the responsiveness of VSMC to Ca++ flux and, hence, 
contractility. We have identified abnormal MLCK phosphorylation, which controls MLCK 
activity and, subsequently, MLC phosphorylation. The connection between Grip1 or other 
putative proximal molecules with MLCK phosphorylation remains to be further investigated. It 
is not surprising that Grip1 has been found to be critical in controlling VSMC contractility in all 
3 types of KO mice, i.e., Ephb6 [24], Efnb1 [26] and Efnb3 KO (this study) mice, as Ephb6 
regulates BP via reverse signalling, and Efnb1 and Efnb3 are both likely in this reverse 
signalling pathway. Moreover, Efnb1 and Efnb3 intracellular tails have a high degree of 
homology and can bind to Grip1. Therefore, Grip1 is situated in a node of signalling pathways 
emanating from the Ephb/Efnb family of molecules with regard to their roles in BP regulation, 
and carries more weight than each individual Ephb/Efnb member.      
Collectively, we discovered a novel role for a group of genes whose known function is not 
associated with BP and vascular tone. This has opened a new area of knowledge in the 
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pathogenesis of hypertension. Under physiological conditions, Ephb6 on neighboring cells 
probably provides VSMC with a negative signal to dampen their contractility through reverse 
signalling.  We have confirmed, in our previous publications 266, 268 and the current one, that 
Efnb1 and Efnb3 are mediating such reverse signalling. Since the interactions between Ephb6 
and Efnbs are constant, such a dampening effect is not regulated rapidly and likely controls 
constitutive vascular tone rather than fast responses to neuroendocrine stimulation.  
As of today, no genes in the EPHB/EFNB family have been identified as hypertension risk genes 
in several large-scale GWAS 275. There are a couple of possible reasons.  1) The contribution of 
genes in the EPHB/EFNB family to the BP phenotype is relatively small, and the possible 
association is rendered undetectable due to heavy statistical penalties in GWAS. 2) As evidenced 
by our work, the effect of Ephbs and Efnbs on BP phenotypes needs concerted input of sex 
hormones, and is thus not only gender- but also hormone leve-dependent; however, no current 
GWAS study has specifically stratified cohorts based on sex hormone levels. We conducted a 
more focused query of the IBPC dataset and discovered that a SNP, rs1495496, located between 
exons 22 and 23 of GRIP1, had a p-value of 0.000389 for its association with DP, and such a p-
value approached the Bonferroni corrected critical p-value 0.000302 or an overly conservative 
corrected critical p-value of 0.000151. This finding is very promising since the queried cohorts 
were not stratified according to sex hormone levels, and Bonferroni correction by itself was 
deemed to be quite conservative. Considering our observation that Ephb/Efnbs likely influence 
vessel tone in mice, the possible association of this SNP in GRIP1 gene with DP seems logical. 
Why does only a SNP from GRIP1 approach significance and not those from 3 EPHB6/EFNBs 
queried? As discussed above, in mice Grip1 is situated in a node of Ephb6, Efnb1 and Efnb3 
reverse signalling; it thus probably carries more weight than each individual Ephb or Efnb 
member and, hence, is easier to detect for its associations with BP phenotypes. It is possible that 
in a cohort stratified by gender and sex hormone levels, significant association of BP phenotypes 
with SNPs from GRIP1 and EPHB/EFNB family members will be detected in humans, and this 
will fully establish the relevance of our findings from animal models to human hypertension.  
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Tables 
Table I. Association of SNPs in the EPHB6/EFNB system with BP phenotypes in 69,396 human 
subjects 
A. Locations of 4 genes for which 528 SNPs were tested 
 
 Build 36 Build 37 
Gene Location Size (kb) Location size (kb) 
EPHB6 
chr7:                
142,252,914 -
142,288,969               
36.06 
chr 7:                    
142,542,792 - 
142,578,847 
36.06 
EFNB2 
chr13:                 
105,930,097-
105,995,338 
65.24 
chr 13:      
107,132,079-
107,197,388 
65.31 
EFNB3 
chr17:               
7,539,245-
7,565,418 
26.17 
chr 17:                    
7,598,520-
7,624,693 
26.17 
GRIP1 
chr12:   
65,019,066-
65,369,020 
349.95 
chr 12: 
66,731,211-
67,082,925 
351.71 
 
B. Minimum p-values from IBPC meta-analysis among SNPs examined within EPHB6, EFNB2, 
EFNB3 and GRIP1 genes 
Gene 
Number 
of SNPs 
examined 
LD  Blocks 
r2=0.8 
Diastolic Pressure Systolic Pressure 
SNP p-value SNP p-value 
EPHB6 48 4 rs1009848 0.0373 rs2299557 0.404 
EFNB2 54 24 rs2057408 0.077 rs9520087 0.218 
EFNB3 6 6 rs3744258 0.201 rs3744258 0.191 
GRIP1 420 132 rs1495496 0.000389 rs1495496 0.00144 
Total 528 166 Critical p value: 0.05/166 = 0.0003012 
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Table II. Echographic analysis of CO, carotid artery resistance and left ventricle mass of KO 
and WT mice 
BP-related echographic parameters of individual Efnb3 KO and WT mice are reported. Means 
+ SD are shown at the end of each group, and p values (unpaired Student’ t test) are indicated 
at the end of Tables 2A and 2B. PI: Pourcelot index; LV: left ventricle.  
A. Echographic parameters of male Efnb3 KO mice 
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B.  Echographic parameters of female Efnb3 KO mice 
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FIGURES AND LEGENDS 
Figure 1 Efnb3 deletion in vascular cells in Efnb3 KO mice 
 
 
All experiments were repeated at least twice, and data from a representative experiment are 
reported. 
A. Efnb3 mRNA deletion in mesenteric arteries of Efnb3 KO mice 
Efnb3 mRNA expression in mesenteric arteries from WT and Efnb3 KO mice was measured by 
RT-qPCR with -actin mRNA as internal control. Means + SD of Efnb3 signal/-actin signal 
ratios are reported. 
B. Efnb3 deletion in VSMC 
WT and Efnb3 KO VSMC cultured for 4-5 days were stained with FITC-goat anti--actin Ab 
(in pseudo-green color) and goat anti-mouse-Efnb3 Ab, followed by PE-donkey anti-goat IgG 
Ab (in pseudo-red color). Nuclei were identified by DAPI staining.  
 169 
Figure 2 BP and HR of Efnb3 KO mice 
 
BP and HR were measured for 3 days by radiotelemetry starting at least 7 days after transmitter 
implantation. In castrated and ovariectomized mice, telemetry was conducted 3 weeks after 
surgery. Number per group is indicated. Values are expressed as mean 24-h BP and HR for each 
day ± SE. SP: systolic pressure; DP: diastolic pressure; MAP: mean arterial pressure; HR: heart 
rate. The WT and KO data were evaluated statistically by repeated-measures ANOVA. P-values 
are indicated.  
A. BP and HR of males 
B. BP and HR of females 
C. BP and HR of castrated males 
D. BP and HR of ovariectomized females   
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Figure 3 Contractility of mesenteric arteries from Efnb3 KO mice 
Segments of the third-order branch of the mesenteric artery with or without endothelium were 
stimulated with PE. A single cumulative concentration-response curve to PE (1 nM to 100 µM) 
was obtained. Maximal tension (Emax) was determined by challenging the vessels with 
physiological saline containing 127 mM KCl. Vessel contractility is expressed as the percentage 
of Emax. Data from 3 mice per group were pooled, and means + SE are reported. *p<0.01 
(paired Student’s t test).  
A. Vessel contractility in male KO and WT mice  
B. Vessel contractility in female KO and WT mice 
C. Vessel contractility in castrated male KO and WT mice  
D. Vessel contractility in ovariectomized female KO and WT mice  
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Figure 4 VSMC contractility is influenced by Efnb3 deletion and reverse signalling 
 
VSMC were isolated from the mesenteric arteries of WT and KO mice, and cultured for 4 days. 
They were stimulated with 20 M PE at 37oC and imaged every min for 15 min. Means + SD 
of percentage contraction of more than 15 cells are reported. Statistically significant differences 
were assessed by Student’s t test. *p<0.05 (unpaired Student's t test). All experiments were 
conducted more than twice, and data from representative experiments are presented.  
A and B. Increased contractility of VSMC from female but not male Efnb3 KO mice 
VSMC from WT and KO females (A) and males (B) were cultured for 4 days, then stimulated 
with PE.  
C. Estrogen augments contractility of VSMC from male KO but not WT mice 
VSMC from WT and KO males were cultured in wells coated with anti-Efnb3 Ab (2 g/ml 
during coating) for 4 days in the presence (10 g/ml) estrogen, then stimulated with PE. The 
thin line (indicated as WT Vehicle) represents the mean percentage contraction of female WT 
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VSMC cultured in wells coated with anti-Efnb3 Ab in the presence of vehicle in lieu of 
testoterone (for a better visual effect, the SD of each time point in this control is omitted). 
D. Testosterone does not suppress contractility of VSMC from female KO or WT mice 
VSMC from WT and KO females were cultured in wells coated with anti-Efnb3 Ab for 4 days 
in the presence (10 g/ml) of testosterone, then stimulated with PE. The thin line (indicated as 
WT Vehicle) represents the mean percentage contraction of male WT VSMC cultured in wells 
coated with anti-Efnb3 Ab in the presence of vehicle in lieu of estrogen (for a better visual effect, 
the SD of each time point in this control is omitted). 
E and F. Reverse signalling through Efnb3 reduces VSMC contractility 
Wells were coated with goat-anti-Efnb3 Ab, normal goat IgG or Efnb3-Fc (2 g/ml during 
coating). VSMC from WT females (E) and WT males (F) were cultured in these wells for 4 
days, then stimulated with PE.   
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Figure 5 Normal 1-adrenoreceptor (AR) expression and Ca++ flux in Efnb3 KO VSMC 
 
A. Normal AR expression in Efnb3 KO VSMC according to immunofluorescence microscopy 
VSMC from male (right panel) and female (left panel) Efnb3 KO or WT mice were cultured for 
4 days, then stained with Ab against AR, as indicated. They were identified by anti--actin Ab 
staining. For each experiment, more than 15 -actin-positive cells were randomly selected, and 
their total immunofluorescence intensity and cell size were recorded. Means + SD of 
fluorescence intensity per unit of arbitrary cell area (pixel) of all cells in a group examined are 
reported.  
B. Normal AR expression in Efnb3 KO VSMC according to immunoblotting 
VSMC from male (right panel) and female (left panel) Efnb3 KO and WT mice were cultured 
for 4 days, then harvested. Cell lysates were analyzed for AR expression by immunoblotting. A 
representative immunoblotting is shown. Densitometry data from two independent experiments 
were pooled and presented as bar graphs in the lower panel. 
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C. Normal Ca++ flux in VSMC from Efnb3 KO mice 
VSMC from male (right panel) and female (left panel) Efnb3 KO or WT mice were cultured for 
4 days and loaded with Fura2. They were then placed in HBSS with or without 1.26 mM Ca++ 
at 37oC and stimulated with PE. The ratio of emissions at 510 nm triggered by 340 nm versus 
380 nm excitation in each cell was registered every 3 s for 1 min. Means + SD of the ratio of 
more than 15 randomly-selected VSMC are reported. Arrows indicate the time points at which 
PE was added.  
All experiments were conducted more than twice, and data from representative experiments are 
reported. They were analyzed by paired Student’s t test, but no significant difference was found.   
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Figure 6 MLC, MLCK and MLCP phosphorylation of small arteries and VSMC from WT and 
KO mice  
 
VSMC from female and male KO and WT mice were cultured for 4 days, then stimulated with 
20 M PE for 3 s and immediately lysed. Total and phosphorylated MLC, MLCK and MLCP 
were analyzed by immunoblotting. Immoblotting images from representative experiments are 
illustrated. The signal ratios of phosphorylated versus total MLC, MLCK and MLCP were 
quantified by densitometry. Densitometry data from two or more independent experiments (as 
indicated) were pooled and presented as bar graphs in the panels below the immunoblotting 
images. Paired Student’s t tests were employed to examine statistical significant differences. “*” 
indicates p<0.05. 
A. Increased MLC phosphorylation in VSMC from female but not male Efnb3 KO mice  
B. Reduced MLCK phosphorylation in VSMC from female but not male Efnb3 KO mice 
C. Reduced MLCP phosphorylation in VSMC from female but not male Efnb3 KO mice.  
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Figure 7 Grip1 in the Efnb reverse signalling pathway in VSMC 
 
Experiments in this figure were repeated more than twice, and representative data are reported. 
A. Effective mRNA knockdown of Dishevelled, PDZ-RGS3 and Grip1 by siRNA 
Cultured WT VSMC were transfected with a mixture of siRNAs of a particular gene or control 
siRNA, as indicated. After 24-h culture, the cells were harvested and the mRNA expression of 
each gene was determined by RT-qPCR. The data are expressed as means + SD of the ratios of 
the target gene signal versus the -actin signal. 
B. Grip1 knockdown by siRNAs partially reverses the inhibitory effect of solid-phase Ephb6-Fc  
VSMC from WT males were cultured in wells coated with goat anti-mouse Efnb3 Ab (2 g/ml). 
After 2 days, they were transfected with siRNAs targeting Dishevelled, PDZ-RGS3 or Grip1, or 
with control siRNA. On day 4 of culture, they were stimulated with PE (20 M), and their 
percentage contraction was recorded. Means + SD of the percentage are reported. The thin lines 
(indicated as “coated with normal goat IgG”) represent the mean percentage contraction of 
VSMC cultured in wells coated with normal goat IgG (2 g/ml) without siRNA transfection 
(for a better visual effect, the SD of each time point in this control is omitted). *p< 0.05 
according to paired Student’s t test, between Grip1 siRNA- and control siRNA-transfected 
VSMC.  
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Figure 8 BP-related hormone levels in Efnb3 KO mice 
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A. Twenty-four-h urinary catecholamine levels in Efnb3 KO mice 
Male and female Efnb3 KO and WT mice were placed in metabolic cages. Urine was collected 
during a 24-h fasting period. Urinary catecholamines were measured by ELISA, and means + 
SD of hormones excreted during the 24-h period and mouse number per group (n) are presented. 
No statistically significant differences were found (unpaired Student’s t test). 
B and C. Plasma AngII and serum aldosterone levels in Efnb3 KO mice 
Plasma Ang II (B) and serum aldosterone (C) in male and female Efnb3 KO and WT mice were 
measured by ELISA. Mouse numbers per group (n) are indicated. Means + SD of hormone 
concentrations are reported.  P-values are presented. *Significantly different (p<0.05, unpaired 
Student’s t test).  
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Supplementary figure1. LocusZoom plots of –log10  p-values (left hand vertical axis) from 
IBPC meta-analysis for specific queried genes  
Supplementary Figure 1. LocusZoom plots of -log10  p-values (left hand vertical axis) from IBPC 
meta-analysis of specific queried genes  
The positions of all SNPs in the query are indicated at the top of the plot as short, thin vertical 
lines, and as diamonds and circles in the plots. Diamonds represent reference SNPs with the 
highest -log10 p-value in the region, and their names are indicated above the diamonds. R
2 refers 
to LD between the reference SNP and respective SNPs within the region. Blue lines refer to 
recombination rates (right hand vertical axis) in centimorgans/megabase at each position. Thus, 
peaks in blue lines indicate low LD regions of high recombination rates or recombination 
hotspots. 
Efnb2 region for diastolic BP 
 
Efnb2 region for systolic BP 
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Efnb3 region for diastolic BP 
 
Efnb3 region for systolic BP 
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Ephb6 region for diastolic BP 
    
Ephb6 region for systolic BP 
 182 
 
Grip1 region for diastolic BP 
 
 Grip1 region for systolic BP 
 183 
 
 
  
 
 
 
184 
 
 
 
 
 
 
 
 
III. Discussion  
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The etiology of essential hypertension remains unclear. Several models have been built for 
studying the mechanism of hypertension. The VSMC tone plays a basic role in regulating blood 
pressure1,2. 
Eph/Efnb family is the largest tyrosine kinase family, which plays many functions in 
physiological and pathological processes in cells3 such as the cell migration, cancer 
pathogenesis, synapse development et al4-6. However, little work has been done in studying their 
roles in blood pressure control7,8. Thanks to the availability of different Ephs/Efnbs knockout 
mouse models, our studies could explore how Ephs and Efnbs influence the function of VSMCs 
with regard to blood pressure regulation7,8. 
Our study for the first time shows that certain Eph and Efnbs are involved in blood pressure by 
affecting the VSMC contractility7,8. We demonstrate that 1) the reverse signaling pathways from 
Ephb6 to Efnb1 and Efnb3 lead to the hyporesponsiveness of VSMC; 2) Ephb6 and Efnb3 act 
in concert with sex hormones to regulate blood ambient catecholamine levels, which are related 
to small artery vessel tone control; 3) Grip1 is the downstream signaling molecule of 
Ephb6/Efnb1/Efnb3 in regulating of VSMC contractility. A discussion is conducted below in 
an attempt to reconcile some seemingly controversial results, and to explain the overall 
physiological relevance necessity of the Eph/Efn system in the BP regulation. 
1. Signaling pathways to regulate VSMC contractility 
It is known that the contractility of VSMC is regulated by many signaling events9. The following 
diagram is based on available literature, our results and some reasoned speculations. 
 
Figure 1 the contractile signaling pathway of VSMC 
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The diagram shows general signaling pathways, which are involved in the regulation of VSMCs 
contractility. Our results add two major new components to the known literature: the first is the 
reverse signaling pathway through Efnbs, which interact with Grip1 to regulate phosphorylation 
of MLC; the second is testosterone, which can regulate the expression of RhoA and Rho kinase. 
As the membrane-anchored protein, Efnb contains phosphorylation site10 and PDZ-binding 
motif at its intracellular carboxyl terminus4, which could interact with downstream proteins, 
such as Grb4, Dishevelled, DPZ-RGS3 and Grip111,12. As an adapter protein, Grb4 associates 
Dock180, FAK through SH domains11,13,14. Cell migration is related to phosphorylated FAK 
through p130CAS/Dock180/Rac1 signaling pathway15, in which Dock180 serves as nucleotide 
exchange factors (GEFs) for Rho GTPase activation. RhoA takes the initial step of FAK, 
Dock18016 to regulate cytoskeletal reorganization, actin polymerization and force generation in 
smooth muscle17. G-protein18 is also essential in regulation of VSMC contractility19,20. 
Receptors couple with the Gq-G11 and G12-G13 to stimulate phosphorylated MLC via 
Ca2+/MLCK and Rho/ROCK respectively21. Gq-G11 stimulates cAMP production and PKA 
activation to maintain basal BP22; G12-G13 promotes activated RhoA to enhance phosphorylation 
level of MLCP to regulate VSMC23.  
2. The hypotheses of how Eph/Efnb in concert with testosterone regulate VSMC 
functions 
Under physiological conditions, the function of VSMC is tightly regulated24,25. The major 
function of VSMC is to generate tension to regulate blood circulation.  The tension state of 
VSMC is mainly related to the phosphorylated MLC. The elevated phosphorylation level of 
MLC directly enhances the VSMC contractility. Our hypothesis is that EphB6 triggered-reverse 
signaling of Efnbs governs the VSMC contractility by regulating the phosphorylated MLC 
through RhoA-ROCK-MLCP signaling pathway; and Grip1 is the downstream protein in this 
process.  
We also found that the effects of Ephb6 and Efnb3 deletion on males and females and on males 
and castrated males are different in terms of VSMC function and BP. Based on these findings 
and some literature, we come to the second hypothesis that the effect of testosterone is via its 
regulatory function on ROCK synthesis and activity26, and consequently the RhoA activity to 
influence Phosphorylated MLC through RhoA-ROCK-MLCP signaling pathway.  
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3. Evidences supporting the hypothesis that the reverse signaling regulates the 
contractile phenotype 
In EphB6 knockout mouse model, we found that the vasoconstriction, activated RhoA, and 
phosphorylated MLC were elevated in EphB6 female KO mice and castrated male KO mice, 
but no difference was observed in male KO mice. The EphB6-FC binds to all three Efnb ligands 
to active reverse signaling pathway, and the α-EphB6 induces the EphB6 forward signaling. In 
order to study each Eph/Efnb effects, α-EphB6 Ab, EphB6-FC and α-Efnb Abs were used in 
vitro. α-Ephb6 Ab or Ephb6-Fc were used for exploring the consequences of forward and 
reverse signaling. We demonstrated that 1) the Ephb6-Fc can significantly reduce the 
contraction of VSMC. 2) α-Ephb6 Ab stiumlation did not affect the contraction of VSMC. 
In Efnb1, 3 KO mouse models, the vasoconstriction, activated RhoA and phosphorylated MLC 
were increased in Efnb3 female KO mice and Efnb1 castrated male KO mice (the female 
Efnb1KO mice die at embryonic stage27); the activated RhoA and phosphorylated MLC were 
increased in Efnb1 male KO mice. The α-Efnb1 Ab, α-Efnb3 Ab reduce the activated RhoA and 
VSMC contractility. These results demonstrate: 1) deletion of EphB6 causes the malfunction of 
VSMC; 2) the reverse signaling, but nor forward signaling, plays the dominant role in regulation 
of VSMC contractility28 and RhoA promotes phosphorylation of MLC 7,8; 3) there is gender 
difference.  
4. Efnbs regulate RhoA-ROCK-MLCP signaling pathway 
The vascular tone is generated by the phosphorylation of MLC, which conducts the myosin to 
interact with actin. Generally the MLC phosphorylation can be increased by two signaling 
pathways: 1) the activation of MLC kinase through the Ca2+ and calmodulin-dependent 
pathway29; 2) the inhibition of MLCP via the RhoA/ROCK pathway30. 
To address the role of MLCK and MLCP-mediated signaling pathways in regulation of vascular 
tone in Eph/Efnb KO mice, we examined the Ca2+ flux of EphB6, Efnb1 and Efnb3 KO VSMC. 
Our data showed that Ca2+ flux had not changed in EphB/Efnbs KO VSMC, suggesting the Ca2+ 
signaling was unaltered.  
The phosphorylation of MYPT1 by RhoA/ROCK is well established. ROCK phosphorylates the 
MYPT1 at threonine 696, serine 854 and threonine 853 to inhibit MLCP activity30. In Efnb1, 
Efnb3 knockout mouse models, we found that activated RhoA and phosphorylated MLC were 
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elevated in male Efnb1 KO and female Efnb3 KO VSMC; phosphorylated MYPT1 was 
increased in Efnb3 KO mice. The α-Efnb1, α-Efnb3 stimulation showed the reduction of 
activated RhoA, phosphorylated MYPT1 and contractility in VSMCs. The work demonstrates 
that Efnb1, 3 reduce activated RhoA, which influences phosphorylation level of MLCP, leading 
to the reduction of phosphorylated MLC.  
To conclude, these results support our hypothesis that reverse signaling of Efnb1, 3 governs the 
VSMC contractility by regulating the phosphorylated MLC through RhoA-ROCK-MLCP 
signaling pathway. 
5. The effect of Grip1 in VSMC  
To validate the relevance of Grip1 in humans, we targeted single nucleotide polymorphisms 
(SNPs) with grip1 gene to compare the international blood pressure consortium dataset, showing 
that the p-value of Grip1 gene (p=0.000389) reaches to critical point (p=0.000302), suggesting 
that Grip1 is related to the BP. To address whether Grip1 influences VSMC contraction, we 
examined the VSMC treated with Grip1 siRNA. We found that cell contraction, activated RhoA, 
phosphorylated MLC and phosphorylated MLCP was elevated, suggesting that Grip1 is 
involved in regulation of VSMC. However, how Grip1 interacts with Efnbs to regulate VMSC 
is unclear. The Efnb contains PDZ-binding motif at its intracellular carboxyl terminus, which is 
the function domain to interact with Grip1. As a cytoplasmic scaffolding protein containing of 
seven PDZ domains, the Grip1 interacts with PDZ-binding motif of Efnbs to contribute Efnb 
clustering and trafficking10. The deletion of Grip1 weakens the reverse signaling of Efnbs, 
augments phosphorylated MLC and hence VSMC contractility10. 
6. The role of EphB forward signaling in VSMC  
The effect of forward signaling is unclear in regulation of vasoconstriction. We found that 
EphB6 female KO mice show the elevated BP; EphB6Δ KO mice (lack forward signaling 
function of EphB6) show normal BP, suggesting that forward signaling of EphB6 does not alter 
the BP. However the EphB4 KO mice showed decreased BP and vasoconstriction (data 
unpublished), suggesting that forward signaling of EphB4 promotes the BP. We also 
demonstrated that α-Ephb6 Ab did not change VSMC contractility and α-Ephb4 Ab reduced 
VSMC constrictility. The EphB4 inhibitor suppresses VSMC contractility and phoshporylated 
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MLC in vitro (unpublished). Data indicates that EphBs exhibit different functions in VSMC. 
Further study will explore the different functions between EphBs. 
7. The hypothesis that the effect of testosterone on VSMC is via its regulatory function 
on RhoA synthesis and activity 
We confirmed that sex hormone is crucial in EphB/Efnb KO mice in regulation of BP that 
phenotypes are different between male, female and castrated male KO mice7,8. As mentioned 
before, the castrated EphB6 KO male, Efnb3 KO female mice showed elevation of BP, 
vasoconstriction, phosphorylated MLC and activated RhoA. However Efnb3 KO male and 
Efnb1 KO male mice showed normal BP, even EphB6 KO male mice showed lower BP 
comparing with WT control mice. The following table presents the phenotypes in accordance 
with differnet gender. 
 EphB6 KO  Efnb3 KO  Efnb1 KO 
 Male Female Castrated-male  Male Female  Male Castrated-male 
Blood pressure - - +  - +  - - 
Vasoconstriction  + +  - +  - + 
Phosphorylated MLC - + +  - +  + + 
Activated RhoA - + +  - +  + + 
    Decrease - Normal + Increase 
 
In EphB6 KO mice, only castrated males have high blood pressure, indicating that sex hormones 
act in concert with Ephb6 to regulate blood pressure. Why do only EphB6 KO castrated male 
mice show increased BP? In theory, the deletion of EphB6 receptor will enhance the VSMC 
contractile phenotype and result in increased BP in EphB6 KO mice. However, BP is a tightly-
controlled physiological parameter with many compensatory feedback mechanisms. In EphB6 
KO female mice, there might be some in vivo compensatory mechanisms to maintain the normal 
BP. In EphB6 KO male mice, we found that the ambient catecholamine release by the adrenal 
glands is reduced after Ephb6 deletion. This is at least one of the reasons why the EphB6 KO 
male mice does not show increased  phosphorylated-MLC, vessel constriction and avtivated 
RhoA. In Efnb1, 3 KO mice, the elevated BP was found only in female Efnb3 KO mice (the 
female Efnb1 KO is embryonic lethal), suggesting that testosterone play the important role in 
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regulation of BP28. We also demonstrate that  EphB6, Efnb3 KO VSMC shows significant less 
contraction in the presence of exogenous testosterone but not estrgen. 
Previous data confirms that the EphB6, Efnb1, Efnb3 KO mice model are associated with an 
upregulation of RhoA/ROCK/MLCP signaling. In diabete mouse model, testosterone showed 
the suppression of activated RhoA and expression of ROCK. We speculate that testosterone 
plays the similar function in Eph/Efnb KO mice to maintain the normal BP. However much 
work should be done to explore the role of testosterone in VSMC how the deletion of Eph/Efnb 
influence the testosteone function? What is the exact signaling pathway between Eph/Efnb and 
testosterone ?  
8. An attempt to reconcile some controversial findings in our study 
In our studies, VSMC from Efnb1 KO but not EphB6 male mice show elevated MLC 
phosphorylation; in spite that testosterone should have the same effect on these KO male mice 
in terms of maintaining MLC phosphorylation and RhoA activity. There could be 2 possible 
explanations. Firstly, the Enfb1 plays a dominant role in regulating VSMC among three different 
Efnbs. We demonstrated that VSMC respond differently depending on antibodies against 
different Efnbs. The α-Efnb1 Ab is more potent than α-Efnb3 Ab in reducing the contractility 
of VSMC. In EphB6 KO male mice, a reduced reverse signaling through Efnb1 could be 
compensated by other EphBs. So, the BP phenotype is not overt. In the Efnb1 KO male mice, 
the major reverse signaling is affected; hence the elevated BP. Secondly, the reverse but nor 
forward signaling is important in regulating contractile of VSMC. The deletion of Efpb6 causes 
the removal of forward signaling (through EphB6) but still retains the reverse signaling caused 
by other EphBs. On the contrary, the deletion of Efnb1 leads to the removal of reverse signaling 
through Efnb1 but remains the forward signaling caused by other Efnbs.  So, without the 
suppressive effect of Efnb1 via reverse signaling in Efnb1 KO VSMC, MLC phosphorylation 
and RhoA activation are elevated in Efnb1 KO VSMC, which leads to increased BP. 
VSMC show elevated contractility after Grip1 knock down. The exact signaling pathway 
remains to be defined. A possible mechanism is that Grip1 interacts with Efnb1, 3 by its PDZ 
domain. The interaction leads to the enhanced phosphorylation of Efnb1, 3 and causes the 
redistribution on cell membrane. The phosphorylation and redistribution of Efnb1, 3 could form 
larger clusters, which could produce stronger reverse signaling to downstream proteins31-33. 
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Therefore, the silence of Grip1 equals to blocking the reverse signaling pathway and enhances 
the VSMC contractility phenotype. 
9. A brief summary 
Hypertension is a complex, multifactorial and polygenic disease. Over last decade many genetic 
determinants have been dissected. However the understanding of mechanism still needs further 
exploration. This study identified a new function of Eph/Efn in vasoconstriction and BP 
regulation.  The successful disclosure of the relationship between Eph/Efnb and testosterone 
enhances the understanding of BP regulation mechanisms. 
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10. Contribution to sciences and future research directions 
The major contributions to sciences from my Ph.D. program are as follows: 
 
1. For the first time we revealed that in EphB/Efnb can regulate blood pressue.  
2. We demonstrated that Eph/Efnb reverse signaling is dominant in the regulation of vascular 
smooth muscle cell contractility. The phosphorylation of MLC is increased in the absent of 
Ephb6 or Efnb1 in vivo. The Grip1 is involved in this process. 
 
Some interesting questions remain to be further investigated.  
 
1. Can antagonists of Eph/Efnb be employed to treat or prevent hypertension? 
2. What are the downstream target proteins, which directly link Efn to MLC phosphorylation? 
3. Does testosterone involve signaling pathways other than ROCK/RhoA-MLCP-MLC and act 
in concert with Eph/Efn to regulate blood pressure?  
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